var title_f5_51_5936="Xray of distal clavicle fracture Type I";
var content_f5_51_5936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Xray of distal clavicle fracture Type I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 310px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE2AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCR/MBZSAAB61TlcpkNG2e3Xmt+UK7fIMCq8sbqMRgEH15oAw2SZl+77jNNCS4y3H0FatyrhPmIBPpWcyEIcks2cigDI1qAmGMru3FuaxzbSsD5bnPpmt28DSTAM3A96qrEWLEEH6GgDBm8xeGY59M1WZ3wMsRW9qdqTbiSNPu9awzyMjpQBA7sf42/Oqd08u3G44q6y8E9qrTpvXj60AYsrOvRmwKpySuS2GNaNym3Hoaouh3GgCjO7lSNx61TZ5Ao5rQlXiqEoO3NAELMTzTCxyMUvXNJigBHZscHvUTO2epqRhkVHIuDxzQAm9vU02nbab3oAKSlpKAA0lLSUAFFFFABSikooAKXNFJQAuaM0UlAC5ozSUUALmjNJRQAuaMnsaSigBcn1pdx9TTaKAHbj6mjcfU02igB24+po3H1NNooAduPqaNx9TTaKAHbj6mjeabRQA7eaUOQc0yigCTzWo8wnqSPoajooAk3/wC0350eaw/iNR0UAfWks92XJY4x2ApRcuVOQxYD0rDF/eR9WOPpSprVwrYwGPegDUa4baxKD2zVKWaSQZ2gY/ujtRHrKNF+9hxnNSW1zZ3JKowUt6nH6UAUDEGweenHFRNF8zZ2qfUZFbv2RSAYWV/bHSmSW7PkMoTPrQBlpgxEMFf2A61zus6Z9ll82Hc0DHJPofSuumtWijILD8OKBEkiGKX5kYYwRQB548YySG4PtVeRW2nFdDrWlPYTEhSUboe1ZLw5HyHPrQBhz27OuDj61m3EbISAOfWulmjATbxWRdQfMeTQBiS5NUpVO3pWrOgA4AH4VQmXj0oAzWjwfxprDmrLrUEq45oAiYdMUZB6dqd9aMDsBQBE33jTcCpWHPSkI4PFAERAAPFNqTrTWU8cYoAbSYp2CKQ9aAG0UtFACUUtJQAtFJRQAUtJRQAtJRS0AJRRRQAUUUUAFFFFABS0lLQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfTKr5kY2DcPpxUclv5fUZB9Otdm+jGJRwAfTpVK4sowrZkjBHbNAHJSW4wcMQx6Z7VVSJhMV/iHPHWukks4UPzyK/c4rN+0xrdFlVNo6/SgCC1uruKTKhiK6Gx1SG5+SZNn1FZdtrFu0u3CAdsitSGa0udhk2BvVaALstuHXdGwce/OKzpAY2PmAY9q3rOz2gBJMoOAR/Wpr7SpShPlk564oAxBDFco0Uygoy4Geori9a0s6fMyrzD/CRXbMjxvsbhh09aL2xj1CweGRcPj5SexoA8tljXBIPFUZ4FYnJ4roLuyaBjHKPnBxg1nywnPC0AcrdwlHPvWXPECCM11N3CGJ+Xmse6tiE6CgDCkiK9qhePPXp61qSxHHSqrp2C8mgDOZOTxxUbADkVekiYckVA8foKAK4ORmlPII9aeFxxtpuxuuKAGbAvIpj5OMVMR7UbR6UAVjkdaQ8nJqwyAn7tMKc/doAh49aKn8r/ZpNg/u0AQ0VNtX+7THUA8A0AR0Yp2Palx7UANpMU4c9BS4P900AMxS07H+yaVVyfu0AR4pak2H+6aCmB0oAjowKeF/2cD1NPWB3OEQkevagCCkq41tt681EUGM7WoAgoqRl46U0j2oAbS0YooAKSlpKACiiigAooooAKKKKACiiigD68uWuJBukkcg9hVTyYsnzZFXPXNczf8AiC7nJImVeOwrCn1GeXcPMc56mgDu74wJE/lTRE4x1rkp4mTfIjhic/d61yl7cEF8zOD6ZNZw1O4iUiKVtvuaAOqSZ0kBeJiP6U6C+dNwjk2845rkU1y/RiVnJ9mxipU8QS5/exRtn0GKAPS9D8RSwShZJWdT6GvTvDmuJexhZTz6EZzXztba7aDb5kZRumRniu28L63b/aYzFfqCcDYeKAPaL6xtbhCTGM9cgc1lHSdh/cydezDNWdOupnhBB8xevBFXo7mJ324KuOOeKAPP/GWhuqJOkWDn5j2rip7VWzgZB75r3ySJZIGhlXzFIxzg1xWpeHLSaZvJJhcdAelAHkM9m65HBHvWfeWbBORxXo97os1uWWWMsvZlHBrJlsFAw68elAHm9zaHuQPTArPmtwGPU4r0+XToiuAilsfxVXXSIWOZEUevFAHlzp/s/rULR/7Jr1B9Kth/yxQ/hUUmlW38MK5+lAHlrRfNyOvtSiB3yFUt9BXo8uloGGyDn021VfT51J22j/hHigDhFsZ2HEZB9xUg02Q/ewPwrszpl7IfltZs+ymopdF1E4C2sgye4oA5E6eQfvKfbvTTb7CV9K7BfDWqyDm32j6UweENQZzxj6igDj2gA7cVE0HUYxXbnwVqJ6kD8DUc3gnUQAVOD7rQBw7RkY4pjJg8119x4P1QNgKMDrwaqSeF9RyD5ZwPQUAcyV9qTb7V0P8AwjGpFz+5JFPXwnqJHCgHtnigDmwgHalC+wrpf+ES1EDlVB+tPj8K3i9SuT1waAOZVCT0qzDbbhnvXSp4Vue+KtW/hmdGIllCr6AZoA5H7OoOPvP6CrEGiXlyw8uIgHu3SuqOix25JWVi57lRmg2blCv2iUd8AYzQBiLodtZ/NfSB2H8IPeoLplOViQRp2PrWhc6XIcsznA7HtVBoWRsYLLQBRMO5gCQBUTWzBfmABrW8vIGYx7c1FNAVPTLduaAMgwFiRjpUMkTL94D24rVdGzjZ831qrNG3UjigCgFOOgpNlWQPmwOlPWJzQBT2H0o8s+laxs/3eCMMe9QvbEcBskdaAM0oQcUhU9cVddCDTArFeeaAKlJVgxHJ4H51EyMO1ADKKKKACiiigD2Ga9IlYRxjH+1VOW4naNhu2+wXiuqmliI+aFdv+7TEnt/KZWt09jigDg7uGR2ztbOO/eq4tpscRv8A0rt7ma0Rh+4wcetUZp4WORGAPrQByZsZ2JJjyakGl3JI+UAetdGrRuOFA/GrSPEsakqv40AcyujXDsBnAxzWha+Hp3YYJHPat0XJUoUVRnqcVpabczTTjacAei0AdV4X0++s7ZRFdzBsD5eoNdvYTSIEF8ocHr61yGnXEvlEEnP1xWk07siAMeB60AeiafBazf6t+o+6T0pb/QLd3D/MD7GvP7e7nhkDI7A47V0tn4okgiQXQDJjn1oAtPoSbSpJZfRqy7zwVaTZeFXVu654rsLO4g1GATWcikkZKE8io5PMQ4OcnrQB57J4MsxJ+837l560/wD4RSzTI8oMO/NdxPaC6GCcPjqKyJ7SVCyuvHTIPWgDAHhqwXH7pFPvUo0SxTjYin271om1IUA5J9etMeHBwAc+9AFI6XaKeFWo306yG4kKKuNaSHlvl9zxUb25+4oJB6saAKT21iinBXpVK6WzULgj6YrVazjHJBOPeoLmw81cquPbGaAMZ7ixjBEgPTsKqi9tn/1UO/3rTbSHfICEnHpVZ9Bmb/VQY9T0oAqG8CKcxKAe57VDJdK3DgBT3FX/AOx76NCAoPswqlcaNPks0Tqx7gZFAFK48zPyOXX+VZ9wsvTywM9ycVs2llfJIV8ssh9VqxNYNtO1cZ6hsUAcbLFMr/JLjcPXpVdo59w3EnPGetdXLbbVKMq7vXbVOeyJfdJIQg6DbxQBzwQuxXeD9DSrbqJGLNjj1rXMW1ydxAHZFxn61XuEyrFIkOO7Ek/lQBUQGNAwLH8M05stEVU7ifzoYtJGSzAFeoIxxUSxOQR0HbbQAyY7FCbASO/X9az7k3OP3YRfetJrdsZUkg9sdai+zlgQyEc96AMM2ks4JefJ9MYzVZtNcjoBj9a6lrWNYuRzjk+lUpWijOGOcdqAOca0KDJBPv2FQSxgKWPQd62bnUoYiUiiBOeSaxru8aQ/dUZ9BxQBTdU4Iyao3AGTz0q1KS5yxA+nSqrRHPc0AVBHjvg1oabb+YPMPKjioTEDt4Oc4rctbRo7aNFQqWOT9aAK0qgjhRt+tVZEABJHHr61ry27EEnbj0FVpIwUx27ZFAGRInA4qtIgA44rXli3Pg9cZGKpyRqSTk0AZ+PamMnzDPNW9gycdqaUBIPagDPmTbjGKiq5PHkcVUYYOKAG0Up4pKAPoG5gYQk7s8dKyJJAuc1rXTMFlBJyOAKwppEwO7dCTQBBPLvfgcHiq7KMNmpJMB/lxtPPWkSJpQQD83pQBXg56ggdqsBW2jJz6CpIYjGxAHPTg1NIyIygkH1xQBGm8kDseK7TQLcW0SglWO3Nc7pVstw5kbhB0zXUWuDIFj2hcYoA1fMOVxxViEtuz0UcZrPB2tgn5R7VatXbkg4X6daALoYiXO49OlWZFaSDJ2gBe/NZ8MjeaxRcj0xUl7Iyx7Txu9KALWiXc9i6ywSlCp7HivSNF1yHU0EdxtjuOzDo1eTWrDdgLg+/etqxvTGVAATHfPNAHqM0Lwt8wG3+8KhkiW4VkYGsjQPEkY2w3rh0PAyeldIURo/OtmDoey0AYclkLcYbcR2Iqv5AZvkx+NbRu4TlJDkHj6VjalcG1O4DdGeh9KAIpbYu58wnjpTGtYhnfIBisa710I2AxI9qxrzXpjvwD19aAOsdLRDlnqrcanp1up3TLx1Fef6hqt3IDtO3oOtc9qHnSkl5GPrigD0a88b6NZEguXIHRRWHdfEzTVY+Xa3DcY6YzXnc8QYsrdetZ8sRBwCOO9AHoM3xOgABFnNj/aJNM/4WXbzYzGFHoc15yyfLgKMfzqvJAcggCgD0t/iBCRhFTPqCeKgbxnHKxyygEeleeeWoYcAg+1PjjBJIXHagDvP+EnhfAMigCp/7es3UbpIyw7DtXn3lf7NKI+TgDJ6nFAHeT6vaD7skY78VQl1u1UlsxFh1rkPKy2D81KYF7rQB0EniOxOQyAg9cDiom8R2gXCRkL24rn3hUdsn2qNoGxwCB9aAN6TxYRIQISR6VCfFXB/0RDnuTzWN9kPOSPzqKSDb1waANSXxCjgjydo9FqpNqEUg4Xr61ReJmGM8emKb5DdxQAy4kMkhwAFB4qB1yKtiD1OKcIemcZ+lAGcyYHSmOvI4P51pyxnbhQN2enrW7oXhia8dJbhQsXXGMmgDG0fTRkz3A+Vfuqe9bLQ7gSAQf0rvbLwj5iArAQOxfjNaUXhKzRSLpVYn0PFAHk08Kop/vdsVXNo/ljK8+h/nXrM/hnT3BSFUjCHHHNZN14WnVS4WOSIHsfmoA8suYmjcArhscfSqksG3sOa9DvdKSL92YdpY9GFYd5pcByqjYQeooA4+WDOc44quYzvGOBXQ3unyRJuJDL2wOayZFAGCRuHUUAZ0sfBrOuFw3FbMgOw8VlMCGYGgCseabUzDHQDFREc0AfT1z4fV2kZi4C+p5JrDGiQCRw28qDnFeh+UJYXCAkk8k1jXEMaBwVAXqSfWgDBh0i1kOxbdVXafcmorrTdNs4MsxRsdA1R6try27NDFGy4GFYVxWoXcspcyyMSeeaALd15W92huMj0z0qikN27ZH3c5JHU1TtztJLgHPNaomBhGF2j2NAE63dzCipHG3HGemaki126ikUiNgBTYZzgkn5WqRTCT8yr/AMCoAtnxLcbsiIAY7VPD4mnOAsWB7ms028U4Ow7GHpVb7HMsmQ24Y6d6AOki8STxAFMKx/vVnz+Jb2aZ23KuDjArDmdo2w2QO9NjfI5BH1oA6CHXr0hh5gqwNYu225lNc8rfLjue1Womx82c0AdLZ6ndZz5hz7Gu08J+Lrywn2PI0kfdWPQV5lbyfMprWsbja3/16APoWCWz1y382zcLPjJUd6rGMgmC4TKnjBrzPw9rctlNGyOQOv0Ner6ZfQa/ZgPtjvAMhs/eoA4zWdIa2kMkeWi+nSudmgJyT+eK9SltpFZ4blcrjmuQ1nSTbOZIl/cMefagDj7m3+Xvz3xWZdR5bGDx7da6eaNT8rIcAVQu4F2rkACgDjbqEhjsH4EVQeL1GD6V1d1bLg4A/E1lT23zH0NAGA8AC5Lc03yckZDfgK05Ygo+XmoCp3ADINAFFrfa4wPlHamiPDk5xmtIwMSd1RCDac96AKaJnvmn+USoz8vPpVxIjk4A+lTLbkjkgigCgLZ3kWOFdzt0x3NdDpXhCa72+ex5OMLW94Y0JUgW8uV/eOflHTAru9Ps1tohPKMOfuKOw9aAOGk+HVp5QXz5ElPfNZOp+Ant4i1td78DOGHX8a9HmmaR2IzweuafahXcqwIHUg0AeC3WnS2r4bcRjB3VTeMZ5FeseMvDpTz5bRAyEZ8vPSvM/s5LFWzkDnPb2oAzigwcDB9TTgnA61caLkgdaasXbPPpQBTkiJ9KBbvK+2MMx6ZxW1Z6RLcnJG1cda6TRdKhikjQp170AVvCngwytHcXvL5yIz0H1r0m1srawU+UitIRjOOBT9Nt2jtMBSO+ainLb/kD8cY9aAGzXMnG5lKgHaM1ly3D5K7WIPJ9qszooyXGGPYc7ahd3ACxojfLyaAGLJwVixuIyCetK8yHCEkArlh3NImCh3ZB9AOlQorRRNLIM7unc/SgBSkFyAXx/dyR3rDv9JUyMVKAHsR1+lajWsu0O52n8j+VZV5cNggIQR/GaAOX1G0Kzt5oxtHyrXOalZJM7MilZO/vXbXTrInz8yfwn0+tYl3FuLY7igDgp0Zcqw2npWVNH8xJrq9YhjZQmcN3JrnJI9uVP0zQBQkBxxUTqRzVySPAqCQEgjt0oA+q7vxLb2asNgcg5wprjr/xTb3LkNGyAnpWTeOVmZ8YJPOTWFqboY8gDdmgC7quoad5+ZZJFbr8ozWdNLp82Ck8gbpyMVi3QLOTkA8dqjKnCjPH0oA3o4YHfDTKR9cVpJbo0G3htvRhXIkAtk9qljdoiAjuPo1AHXR2w24IJ/Cm3MckeNowO+RXL/aLgHKTOp+tW11i82hXcMB60AasTGNtxByfSrEl3IkWFxuPf0rKh1xU5mgH1Bqb+1rO62mQOh7EDpQBPG6yH5h174qw9lE4BXO48dKSC1SdBJbyg57ZxVg280D/ALwMcjAxzQBWawkhQMvzH86jTdGSHBH1FW43fJCvgA96uJKkiYmQEnvQBTtzkVoW0m1euDnjNNSzidQ0bFSeAKclvLCcOufegDb0+YY4ODmu78NX7WphZHPHJrzqwbn0PXBNdXpMw2hT/Dz9aAPaoJV1OzV1xvx+dUpbdXR45UDKRjBqh4RuD9nAPG08V0c4DtuAy3oaAPPdY0X7LK3lktC3I/wrAuLJlIO04NepXVsskTRN0PTjoa5S4szG7RuDkHj3FAHC3VtyQxWsya13Oflz7g13d3paStnaASetY93pJQt5ZI4oA42a0wCQAce1VGtk+8QQfTFdXPYyoBvQ49jmqU9mQCSvBoA594jn7pNRm33DhefWtSSFlUqQ34GmQ2zdADQBli3KEEqcjqTVq3iB28fxDrV17UnhifxoSPymBZeAQeKAPSra2y1uiYCJGDx9KtzuzvtHQAjFU9Gu0nsYZYW3MvysK15drx7ljwfagDFYKFI6HvVmxUyzJhz6AY61HLayTPhAwx2HetfR9N/s6J5bqZDN1UZoAytVJSZ0ccjjp2rg9U0i0upWd4gHB+8vFdprF2jF5Gyeema58QGZmeNeCeTQBxs3h1snySMHpkVcsvDEgGZAhY8gYrsoLQR/e+bIq5HAdqlc+lAHOJotztURKoGOnrW14e0Cf7Yr3EQRUHJ7fSt7TtLlutgGdueT6V2NtZxwQi3RcKOT3oA5ua3VEIQbU9PWsq9QKxZlKqO2OtdHqyrA2AM8np2rEmDSo6kE56E0Ac3cAK0pRCOMZJqa3tZZ8NjAwORWsmnIziSUHb6VT1jV4NPi2Jx7CgAmitbZN08nI6isK+8QW8IKWkKSEdCaxdRvZ72XfIx8s/dFUlhyCiDt+NAFy/16/u4gAyRc4wBzWJc3l2yt+8JXpjFX/s4YlWBA6A571XubdmgyhO5flzjtQBk3E0zqP3hGOtU5nZTndkEdMVoSxbVAByM46VSmUGRu3933oAwtThwFkz1rDvId4JGCQPpXT3uGg2kZOcZrFlG3dkZFAHOTKQcY6VXbvWlcIBI2OmMiqMgBzQB6Fe3DMeHO/wBKz5yTGd/Q9xU5UEln/OkheP5txB4xQBkyKzMdpBTvkc05l/dgZp11KA5CAKPQVWDgp1yc+tAEzrsUEfNUO85B4qZZRLCEbkgce1VDJt4oAsrICuWIBz6Ujv0yKrI+The/WnnqPpQArPzwcU9F3qckjIxxURUFuR6VPCNqZNAFi2eSJflY8e9bem65PCQjlpFHY1g/NnAJqRiVwAxBFAHYW1/YXjt5sZic/wAQNX0sNw3wSLMvscEVwlrIQxAX5cVoWl86NuWQgjoM9KAOsSORGGU2qOma0bL5CPNXnPINc7ZeILhUXzgsqZ/i61uWOrWtzJmQ7XPGG/pQBuQW0E5LfKCPwq3aWcizAq25TxgVTtep2HcueorpNDgfzEmnGMfdHb60AdroY+zwJuyp9RXTxyh+R1Irn7N1kQBwOla1sCGyp3LigCy/cD9KzNViUoJSPmHB961D9cVUuE3wuCM+9AGC6ow5XHcVWeCMk/4VbePGRhtxOKjaPHK8fjQBnS2SspBAqhc2C7cY4+lbeSMZ5NI+GGKAOTm0yMsSYxtqEWMQ4Kba6SaAcnnH8qrvbhjuJBNAGA+nBicAY7VFLpeV+VQGxXQGII3PPtSeTl89iO1AGJoq3Wm3QwN8JIDD0HrXocttutlmhbcuM8VzSQqD/FmtPSL02c21lLQtwVP86AIjO8c2ASAe1QTyNJuV88jj1rc1GyjkAmtxvjPTHas8WTA/ODlefqKAMBrVp8EnbGOvFXFtVjUKoOB+taxi6gAEe9KsG5+MBvegDKFuCxIHPoBWvpWnsfndfpmpTb7QMj5zxgVtWMGyNVKHaOv1oAntLZYkHG3PpSu7CQKCOcgmrThlXsB2zVKdXUqMZz3oAq30K9hvftWWIAu5pTgjnHrXRFAq+a/y1yXijURafcG9m4xQBj+IdZS3jKwgeaAeK4u4eS4m3zfOfT0q9MPOZpW+Zm65qNIGllAH3sdKAM54SF+U5UdqIYfmyQ2CcA1sNbgDALE9xURjGDjIUD0oAz/s42knpnOc1Vu/mchW2qB371seQrR/ISQPUdPxqlc2ziPdgHHTBzQBgSBcjeefbpWfdIfP+UDHuK2blCGYnd0qhLGxK7fmNAGBcKUZwRx6npWJcL87YOe9dLeLkuTxg4xWDeqRKRjAz2oAwb9ThWAAwMGsyRTyR0rbu0zA9ZDqdpz6UAdXcSjByAB3A6VUWQ8jotbs2iKiktcAfRabHo1mThrhyx44FAHOXLDPoR61WEgJOeuK6K80izg4PmNjvnNRR6VYqAzbgD60AYsXBy/fpUU5ABAIIPpW7cWFoZMLI4A44PFVJ9KVkysvTnigDNTAPJwPWpSuduOT6VKbAkACXGDS/Z5Ijw27PSgCMON/KkmpYcEnHr09KZJE4bcB2p8TgLnYR6mgB8Yw5qTgkc0xSMZ7VJCmTtoAQDBODTiNrZ6fzpzYX5cUqMgQ55x0NAFi3mYKBn7vT3rQtZix4ALVTtIXlVd3yg+ta9tAsKDbjPqaAOi8Pz3FqUZ5Rt67T0Nd9pmtQzqqSjYcY9q8vhnwRj9a1LO5EbccE+poA9v0ecvENh3kenNbkE237p2+teW+FdYeGfyxKGDD1rtrLVIbh9pIRvegDsbcpMgVhn0NV7pGQMGGPeqVrctGQO1bMckdxDg4LdPegDnJU3MT+VQtGOhB561sXNo0QLKDge1UGznr+lAGeYQT8p6dRUMsYwegH1rR8vLHjFV50AB4oAzguUNRyRjjt71aZMLmonGDjJP0oAqsuGJGSfWmIDj7vFWWx05z61GfcFcdsUAIEDDG0D3p6WpcjaTke3SnxQFyCTxWlCgTaCORQBY0s/ZjsblW6irV1AGZniX5COahRMkAVp6csh3IQPLPc9qAMUWzOcKGyeBxTpoxaxHK75Ox9K6C5tvJjIt0JZh1qvbaTPK2+VSq980AZ9naNKyM3Q8mt5I1QDBxgdacYBGAIR071MiHHJGaAKcxJ+7/APrqJoxsDSA4PQZ4q/5QZuQOKoajcpbxMzZ2jsKAKWrXojhIwC3Rea5K/t1u0lZ8mQj5T6Vpl2ui8j7uDwM9KrvCSzZZhgdjQBxzadIrHHygfeNKlqIW4BLHvit+9TCEoTjHJIrFmZm57DrigCnKAFPdehqs0meNoA9zVmUEhsdM5qrkjaz88elAAjlVIUnJ9ahmfO0KMc9akhCkMQ+0CoZACAPQ9aAK1wsLs25SWHpWbLEAAyspAO0YH41osFZnDLls8c1RnIQqQowCeAO9AHOXa5nbv81Y+rRlpPlIBz19q6WeJVLSt26Cuc1Nd0hbOOc8UAc/cIBG4HFY0iYBJ7VvXagRnHJOaxZuetAHqUsSyozbeg6ZrCOxJ9wDEn34Fag1eyh8wNIxDDH3awpbuFvM2OQueCV4oAvvLbuGG4k45yKoM5WNoztK8kVAlzCqFZpOO1SNeWLQ7SshP94UAVUUSI4Bwc8VY8phZAKMvnOfSqsVxbJPnc4QdsVIdRs14WSQfUcUAQAEP8ykt1qQODj29qs+faSBfLYnI5OaazRbjggAUATWgjlG2QDB71LNpkLACMHPrmookE3+qI46irsEMixFgvPqTQBSk0z90NpAPuOlUJVeJ9qoxYcHArZSOXzQZHyO4rWtjH8y7FIAxQBycNvKylnIVc5wTzV2CK2CMVG5+oJ6D8K22tre4XO3acHGaP7EIjDR5ANAGfCXfYcDj04q/JjK+hHSqz28lsQpBJqbcFOWILEDigC7b+VtG4VYhIMvHK1RVyyZ29uamRsjjgUAbdhIY7mE/dO7Ax6V2cUrEgxn8c15/azrGVY8kdz2rp7K9DrGqk8d6AO103X2tionbePTuK7XSL+K4AkgYHPOPSvJkQ4Lk5zWzpF5JbOrRMRjqM9aAPXiBIgYd+tZt9ZAfNHnntUfh/V47yJQMbscqa3HjxyMMDQBywT7x5yO1QyR5ycVv3lmGy8RB7nAqkbfIIB+agDEeI9AOKjltiFLbO9bJtHJGOKsrpuQDK21fegDlXhBGCD+FTxWDucuDx2NdTHb2dvuOzzG/DmlWeJxiOEEnjg0AYAtzGoG0UohYkBckn2roxHGWBlVVFJNeWsA+WNeO9AFCytXR8TDI+la62mU+U7F9axZtXkdT5Q2L7DmorfUZfNUStlCfXFAHUWTRRfIx3vnvUk07EEnAX0FY+87o2h5PX61oCTzYiB1HXFACGdfuqegzUtvtmABIyfSsyYHeefxq1pxYc44HegC3dgRJ/dAHWuU1GQ3UhYAhB0B710esTg2gBOSeOK5mUM7fQY5oAigULMwx97r71XuICqvgHn0NaUCA4BIBHTimXMTRqT0B60Ac5dJtjCgdetYV5GUkYAYBHSunu0JHyjnPX2rHvYwyOc5weDigDnioHO0c/pVcj58YIAHBFaVyoPAUD3qooZyVUhW96AKgJ2sQg9yRTZxukyvKkZ55qz5ZIZM/d6mo5NqkYXBxQBRRcuTIMGlttPa9uNvARDl27AVN3Gea0dWjXSPC7biPPun4x1AoA4HxJcwtcyxWijy1+XIPX3rlrsMxw3GeK17leu04A6+9Y14+csT8o9fWgDIvCAQufqfSsqYDJx2rQnIJOMgGqEoG0lutAGpKeNjHr0rPmleBtnJzyDUjyzSLkqMVXcFhyDigCKRpC+5jinoVdvmYgelCocHbwaWOFxw2SfWgBZI8A7OR6UyOPJGavLFmPABzUjLhS3agCiyBV+ViuKmilwA0gyBxmmHDY70jJ5jKD17e9AGpa3Bjj+ST73atS0vJNgQ5PasHZsQJ09+9TwXBjj2jn60AdFAcv8AvARitCOBS4MTAZOcd65GG9KyHnZ7CrUeotHyrkMaAOoZHiY/NweoFNJdRhpGx6ZrFh1ZwQZGDLWil9BcYDgKR2NAGhFKnHm7TxgdyasxRWl0xBUgjjgVnxKrj5SCMdj0qWM+XgqAw6UAWbvS28ktA+R6VnlJLcHehwOgFXjdylMbhtHY1JDcZYbkDDp83agDLjkLuM5Ht6V0WiS4XY8mMdjRHaWlx8qqque60LpNxbSmWNhJH3zQB1FnIHiAUdOM1oW4yeQTiuYtZnjwj5Htjit60nDKg4z2oA6Wwmkt5EkjyPU16LoGqJcxiKY/P0OO9eZWMgDfNtPoK6DTpXEitHhMc0AehNGVfB+72NUbuII28ElWq3pN0t9blJCN6jg1KYCUeN8bT60AYrOwGAeKiLsxXhiSce1XZLRUYidwuOnPUVBJdRRD92MEcZ70AMSAgAzce9LJcRQoEiAHuRzWfPduxO1jmqMztn5iCMdaALd3qW3JHJ6Z61lXE++UbsnuQabNjqePSqsuc8CgC4jgk+lOHK8fXnpVKFsdeP51PHIVJI5zQBuWtydqFic4rQtZgkxGcBqwYX+VT7VcilImBxQBtzBckbSfp2pVdY4yc4GPwpw/eRKSuTis6+kz8qFt3cd6AIXu9zkMNwJ4qBxnO1uCarSs+dqKABzzT7V0VzHIcoeaAHoSRuX14q1cETWoDcNn86rmMxs+DlScirUGJIjGRgnvQBiXUQ285wPSse7jG4ou7B6V0FwjRkqTuA7VnXNuBmRSMHqO4oA5W6XBCEHOcZNVXgIlywzgda072P8AfZALLVGXKyE527eRQBTkGWBJBGcYqO4jJOSCTnirkoO8kHI9c1DOmG9+tAENnbNNeRxBSCXAyas/Epgk0NoFP7tOfQcVu+B9P+16sJCvyRjeT6GuB+JOsR3Ov3a2x4Vthfs2KAOLv5I1yqAHA5PpXO3b7lbH3R+taN425SAvBrPmPzYHQDAoAzJQWFVLjB7Dir8i88/lVGfowoAluSFchQdo7VDG20nJxn0q3qMMyuWKHHcYql5MxG4RnA9TigBrMwcEkkHpTg/PANL5Uh2nZn1pzxygAKvNAFu2bPB4x1zV+SESQbx0A6Cs63SZgA0R44yK07EupYbWXjgY4oAypkQBV5BHtT4YwmSzc/SrV3C/m7mXOR6dKozyYG0HGe+aAGtJ5jfICMHvUicAsemaitoy5JBXH86fKw27c4I649aAIlfEgbtVhTwGJ4qoOmaVdxPXp6mgC5u5AJNTLcSKcZzntVQodoOTn6UqKwwT0HegDSgvZVb5XbrWzp+oM6sZlJx3rnEyWGOPetITGKFQOSeuKAOogu4dqhiMnpV/yi6b1UYHoa423kAACk5HJycVpW2oSwn5GIB4NAHR2u+N2+Xr3zWpZXToGQMcYzyKw9P1dJX2zLwO4NbcISdf9HIJoA34WguYU86EcgDcBVk6fsYfZmymMgVk2jyLHscEkdfQVsWMsgkVV5HvQBe04eVKBIuM810Ng653Mpx3qpaCN0HnJk9j0qx5EkWWQ/J+dAHUaTdrEyFeD/Ourlk8yBJ0PUV5tZzBWABORXf6O+/TkV8En1PSgCvqaebEs4BDdGrFmxjHOa6KRCQ8TcofQ1gzRhGK8nacUAZ8g4OOtQSBWycYHvVuUdc1XkRieRQBSnUnpyKqSdTWjOnQY71SkU7yDwKAIUbBPFSKQOSpx600KR0U4p6jggggUAW4Gyq7fWr8ZLMpBzis6M7UUgd6vwHC5Bz60AdHB89sOcAjHHUVl3a4I64HermmSA2rZyMGqszBw+Og9f8ACgDKnfO4D5c/xVXSRyA3GF5+tWboEqAVNU5Fw21VIYevSgDbhxLbrIDzjBFT24O4gnNZ2lS/vPLboa1IPlkwy9aAM7UUIbOPrWTOOX64PNdBqK9s8YzyKxLwrGTgYz3oAxb2ONgNoYMOvNZs0eJNysemOlaN0dsoZjz046VTZfnIPAOTjNAGfcKpwAxNPjtHmmVVPy/xE1ZCIDkpxV20O9iFA2HigDfsxb6B4Vv7uAHzDESWJ9BXzTdyvPPJNJgs5LH8/wD69fQnjqRrHwHcgfxREfnXz0yMAvpjmgClMCR7VQnUKfcjPFaUyPglSvuM1QnRsglccUAZtwenqap3CgKc1oyIMN69uKpzrlSMdKAOy1S2Zlk3Bd3QYFYEdmQpMkmAT06112uxPHJJgAYPQ1yEkrI33iGzjg0ASqsKDacECo7nygqlAAM9+tVJGzJkcYpxcMVHVvQ0AaVsECblcknHHp7VbguAjbmUflWciyZCqGJIzwatyxytAAUcepC80AbKzxXdnIjIoIUkHFc4ukW773eQ4zgA+tbOn28sNrIWOQV4yOazboN8wPAHOKAM6409FXajBcfnWZPZTL91s/hWtIN+cfKT6VEBIh9aAMny54xyhz646VNCygHzAQ2O4rejXDYb5sr3qX7FBcZLDZxzQBgAk4yOMetSKvIHrWo2iq4/cuBjrmq8lnPBkiMOB3FADI4WD5OMelWEV2Q7elRRgjl2GfT0p6vuJAPSgBygqwyCeaug4UYBP1NQQyfLzzj1qVcswIJwe1AFlSFIOzGa0rG+MORGzE47dqouSijgH0zTY2+fI+UkUAdxomsRv+6nJ57966y0A8sSQtuOeBXk9tKysp5xnrmuu0O8kQgpICc8g0AejWEjFQG69s1r2s2FAPTNc7p93FJtIIVx1HvWtbmSSUKoBzQBsw2YnkDQcN3xXXWJ2xBcEYAHNYejoYYiWOZDx9K37ZS4UfxYoAsNtLAjpxWPqShbl8dDzWsQyDDDB9Ky7/5pycDGKAMiYHJqE9eauTqcEnrVOXnOOvagCCbLD6VUZSzcDrVqTkgg4IqF+u8igCvsZjgg4FPRdvUZB9akUBCW7GgKSAQcn3oARFbaPmGB7VZh4B7+5qmCV4zzViJtzAA8560AdHZoUsM5OTyarn5ixJxjirHKosY6AVVuOjEgnoMUAV7lFUNvOWz6VRlGSCTk1buH+c5JJ757VSdSDQA0OUljIOMcV0lud2xx3rmZASufTmt7RpBJbpuzQBJquBknoRiuTu3DyMG7dK6jWzuiDKCVHpXMXGNxKjrQBlTj5xyaryFgcgAj1NW5s4BwM561Vl59iecD0oAhJfHXirtgrAgDuaqhTg8E89c1oaYh+2RDsxFAEfxamMPhHyskkhVwOOK8MZhheOcV7L8ZZP8AiTIhznzAK8ZlyAB6igCrL5eSdo21SlK4yOlXJk4qhcdgAePyoArzKC/A6elUpwKuTg7jz+VVJe+aAPUvGhsVmZ40cA9h0rzfVJo1K/L8p9K9U8V2QvLeTA+dMlTXjeuQTQzFXBBB6+1ADjeQIoDRFienOMU6K8hCk+UMZyAeawwwznGTT0nKHoM0Adbb66Io90cCZ7DbTpfENy2cKgHoF4rDsJfMyGAzUkuApKA/SgDesfEs8UbLLGj5/wBnHFQ32vW8sLK1sFkP3WXtWLv3R5GB2x3qpL25B+lAGtbTW08gLMyt6k1ppHCgBSRXzz1rkGbH3Rg+tSR3DKBkmgDrfLRTubDKeq+lSB1+9swOgrloL2ZDlWJUdc1pw6iSi+ZGPqKANQF3UruBGcjPanRu3HI46gd6prcpIBhsNU6DCnDZXt6UAXBFZXEex4cMTywqrLo5WQtbEOv909qnhRGA3k1ctxtkDRMSvvQBgvG6zeXLHtPfI4xVgRIpVgx4GOtb7PFNlJ0DZ/iA5FUrnSAVJtJ94/ukUAVEkXPSnhxknaOtRm3nt9nnxFeeoHFPjKkkDO7sMUAWopgyjaAAK2dGk/eKBnJPGKyrOzklyWJUHtXY6FYRwxqyoGbuTQBbtIbhpgSfLHUMK77QbxIgkcnzM3V+hrk1Yh8Lgc9Kv2rvvDE/L6EdaAPS7LDDevI9a3LFh8oz3rh9Fv8AylAPI6YJrr7NgVDocg44oA3JFDo3qORXPz5eViRhs8itx5MwgDv+lZ9/AChkTOR1oAyJlGTnj6VSfCscY5FX5QDyKpSDDgnjFAFdxlCeeKrEgAluDVqTOSc5zVaRcvz0oAFO7FPKjBA7cio41w2c8ehp75z8uKAIZOmTjHvU+lxq18D2HOO1VZzkYbn3rT0OMASS888CgDWkb5vWqUzfePeppHJY4B4qnI2SwPFAFaXlSe9NY/MpHAI596FJyST0pSh2bhwTQBUkJzjOOeKuaZe+XN5HQnv7VRnk8kM7AYA6msbS7tjrWWGA3TmgD0LUVJtgQCeK5e7BwVwBjnjvXXTjzLHP+zXK3oG7jr3oAypk7jgHqKqPg5buOlX5BnnAJFVG+bKlaAIdgxwQcdK19GizdxYJ981QRRtwuM9K2NNyJkIGe1AHKfGXP2GIBht8yvIJQCOtex/Foo1lGGBzv6V5JIsTDdgjtigDMcenNUrgc5x2rTliXJKmqdzE204GfegDKkOG54J61TuVA+6av3CY5IJ+lZ87ZXoaAPatekba6IcE8DFeca/amaNnx86+vpXqWrwbnkKkYHNcZqFmSJCRx0oA8pmgYu20c96g+yyAZAyAa6bWtPaCQyoMIeuBVS2wCRj5W9aAK1tG0fJ71JO5VG28mtK1hEruDnI9qr6jbmEYA+Y9KAM2CKQtleM9aV4MMRnAHer9sACwI+ark0S+UN+B6cUAcxIQH4yQO+KftGzdnmriQwksFfBzwCKrzoUU9/XFAEG4jDLUiykgbycelQBiSOakH3hQBaVxj5Sasw3TxkYY8djWazEZxxipVBLZoA6Gz1bH+sGT9K6W1ntzF5mQrYztrhLAMpPmdzxWirSGQszdKAOsMmc71A78VHE0pO6MHYT1FU7O8jVlVmzxWzp91bryp+b0oAmtsuqpd/NHnABq+NEtZ9rWX7uQ+h4NWIGhaHaFBY88irVn8iBolGOevSgDGk0y7spsSxMy9d69K6HTDmJU3D/gPar9vOx4k2sMY2npVu3tba4J8oeTKOMgcUAV4oxuBwPrVy2JVs46dqins7i3PzrlR/EOlSWj/vPm6HvQBsWzYdW7kc10+g6kY2AkbKnjBrkIpTvOOKurPucIjbfcCgD1W1ZZkLLyp70pXacdRXN+E9S2FYJj+7Jxk+tdXNHtOe3Y0AYV5AYmIA+U9Ky7gYGeAfSumvIjNARjkDP4Vz043McrzigCg+SOlQsO9WOvGMGoZOhHT+tABGqls9Tihz83Smo208fjTZHwT+lAFd1JfBHPtXQWUey3VR35rGtFMlwM81tE4CgdhQAyZ9gYg8mqPzMWJ+72NWLpxgiqnLYAzigAQB/l2n3NOl4UY7U4p8uOfwqtqM/kQ5JGSML7mgDE1u4LuY1PB61jW7kXkRH8JzVq5JO5yeTVEfK5Ze3NAHsNtmXSkI4yorlb0HeeO5rqdDYy6RCc5BT+lc7qCnzWz05xQBiSEgkHrVeQ9CT1q1ODniqh5PsKAFU4I9629JUFt7dBwKw1/wBZit3SXAIU5OT0xQBxfxZP+jxZI+/3NeTSHIxjjPavV/ixzbRnA++T0ryg9TQBA/GcDmq08jAHAxVxgcc4qncjrmgDPnkO2s6dsA5FX5wMCs6f7revagD6M1HTJy7fuHx61hXOlSNFIGhZXPfpXp9wpkdugWsy8tAW+YcUAeIa3ok6BlddydT7VyZ06WCYFoGK+pNe76rpnmqyplSfauF1TSriG6xI24Z6kUAckYxDHvWI5YZOKxtQuCZRuTgevNel29vbmJo5jnJ646VzniDTYmYtAihQKAOJa5Xfnds9xV6eeRrZWGCuPSj7AkzOxTGPT1rfj0+BtKjYEbue9AHErcKC3yZb9KrSSMSV5yTnrV+fTplmmKqOtUDbyiToePagBuB6VIgz0AzTvLAQnOO3NSQNgjeBt6BgO9AAY48ZY8+lLH874+76YqVLcyPkMPar1vAVYnK/L0zQBHFEYlBY5471JGzvwRwepqYwO4Jbp1pw2hAANooAIYwXXLbfetKDZDICznB7jtVKKLfwBz2PpVlbVwjZbt1oA6TT9VCKoJ80Zwc9hXSW19BONvRfQdq4C1j43Ifzq7Bc+XsK5GOuKAPRbdVXDBn2mr1jNiQhc8nmuT0fVlZwk2XBGBW7a6pb+bshRmJ4+lAHVwyDysON4I6GmXNlGY/Nt+W/551nW8m6M+YWB7Zq7auUcfM3NAFPzJd5HzJ6itC0xvGTV+S1guYxuG2T+8tVFtZLWT94MrnhqANrTmIbjsc16Hot0Ly12P8A6xRivObAjj611mhXBinU9icUAdCqkMVP8XGK56/iMUzrzxXS3KETJIozjrWTriATo45DrmgDmZejZOKrMcr1JPvVu/XEhPOOmKoyNt49aADJ3dzUdwckYpQflGT3prLvl+916YoAv6ZFxu7npV4nI+Tt1JqK2RYrbiglUXk8GgCCXezMMcUioQckYP1qXBJH6U5lIPHUDrQAz7ozXN6rP507AfdWtnVJvLhYZ+bGQRXNnJGQc5oAqz528dKi2AuSeDt4xxViYc5PUdKaD0JxmgD0vwm+/RrfB/hrJ1gbJ2X7rEn8qv8AgY79MWMdm6mmeILdhdMRjk5oA5mbljnp0rPPys2D+Fa88TZJJGKzJomDYODk0AQjJkHJFdBowO8EEgg9axVt2Rgeh+tdHpUMiRksAeM+9AHDfFPmzUjkeZ1ryVlIz25r134oYNgSOzZNeTzfNgjpmgCs4xyDiqN0QfXOKvyAZ6ZNUbhMKeQSKAM6Vdy89azrhcDNasnbNZdwDQB9jeQeGGePWmywqWBYCtdo4ypwy5HoapyKhcKSpoAwryNfm2rz7CuC8WCaBRIVzGxwa9WFrG6sHkA/CuV8U6RDPYTIZlHGRQB5aBhvkUN9ajmj+0Z3Jt29alj+zwybWvV3qSGAqee6sQgxdIznggUAcnqNs0A87GFz2FZzXMVxMsf8PXAOBXXasLWezKRTJnHTNclHYxrICske/OCM0AVdSjSAkxOQOvPNQw3OyPc6Bl7bhWpJafvdki719RziqV1bRRK5QFWHYjigCvALe4BR4lDZzjFOOjwHJjmKsedo6UkblWYlASO4qRpQ7jy8g9MmgChPpV7GwZYiyf3lpEleIsjqVwP4hW3bNPG3Mxx14NTSXcdwjLcQCQ9n6UAc8J2bOCePanRzuTwMVomytpUbYWik54J4qnNZXEOCqb0PcUASJM+RtP51ajuHY7W+6D26VmqW4HAPcHqKnUuvBHB/WgDWN020hQoB6YqFblupG49OaprKM7SQAKehWQbBnNAGgszmTqcY6CtjStQe2lG3luuc1iRAgEI2DjvViJdoG7r6g0Aeo6RqK3EQD8N3PaugjCl1x1xXmOj3RhQByzLjjHFdppGqo5QTAtH0BPWgDq7aRk+UDI9O9aUW2XakvRuKzIWUrvjIIrQtnztyoyORigB/2RraXIGYx0IrYsHYMrdhimWrF1IkGVNSw27RzpwcORgjtQB2ynfboT1IHNZ2sIDaK2OVOKvjiBFznAHNVtRXdaSjv1oA4+8By3v6VnOmNxcHHY962Jx3PX0rNuCTnP4CgCk+QpIzt96ks133AHp3pjnOBggDsat6co3DtgUAaDECPkZB/MVXk+9jBOKmYgr7VA7dTQA+M7nAqSTqajiI6jg0yeTCsT0xQBh6tOWcqM8dazj0z0qWVi0zsRxkioX/AM46UAQSE8e9IAeSM4xzSOmCMHpTY5PmPHQUAeg+AXBtHCkYBzjtWh4hH74EDHy5rG8AOGWYE4+ldBrwOyM49jQByNyR8xbp2FZ4AYg5q5f5YNjjnpWdEu7GARjigCdAzuQDmuisQQg+mK5+MYc554re05gYvccigDhfiYu7TZeOhz+teT4Yq2cHngCvYPiIm7S7j1C/1ryB+vPTFAFWUbGxn8qoT878DFaEzHd04qlcfKGx35oAzZu1Z04OK0ZyQRgcVQueFb2oA+uI5XUEhjj0qGW/eM5GNw9qW4PlgAce1Z91+9cbBwOtAGh/aAuIwyKd3QiqOoTAxn5f4SOal0mDL8knHUU7VIQI22pwRQB4N44t/smpySwBhG/zYHQHvXLpOwnLMQR2r0zxxZJNayJnLqMivLYoyJjHJg89qANK0lbJaTjuKzL5TLcM68YNaUsYiiAUjkcCsoly5DnjtzQBFHLPC4ZJXUL1wauwaiZWbz/nzxk4qjLHh9u/AIzzUCyMqnYQeeaAOgdYSgYZX/az/SmM8TygBkIHeslbsGIgY/DtVNZ98hIkAI7YxQB1du8S+YVYHA6Ed6k8oKodwoHoK5ZLx0cfvBWlDqqHKyHcMcUAbflQOQCw5FOklSydUT5hjJ71mxmG4TfBL8/93NSOH2Kj8kd/X8aAHXVzaXj/ADQhW/vDjNV2s3CbrZiw67TyaVFi6Njd2+tX7cIi5JIkxxzQBip8rkSqQf8AaFWYXQjp0reRIJYytzECCOuOagk8Pq6GWykzx/qyaAKCKJCccZ61YjRl6Z4/WoJIJbY7JAUaprOQl8M2RQBs2O7IAPB6itizmZJVUkn0FY9nJsLfKDWzbOFlQqvOO9AHZ6JqZt8+YSy9GB7V11ttkj8+3O5GHT0rzWORSWck8cdetdB4d1lrWYK2WhY4K0Aeg2rZRfUVv6SglZd3OOnFc9bsjRrJC26Nuh/pXVaWvlxx46kZoA01U7QOwqve/wCokPcqc1bYEx8H5qp3ZxbS85oA5q4GV49azZAS54FaU4ylZ84YP8o7flQBSZTvABIJq7bR7Mk1FGjM+SRV1vlQ+tAEbnCkHFV3IxgdTTDMrqfmJ/hzSA7nXIHFAFqIYXGOnWq+osFt2PrVofdHPNZerOQNoJ+lAGQVJQZ9KhcHYFxhqskgx9agfBAAJ4/X8aAK8ihiACQarn5WIIxgdu9W2Gec+2KgK4LZoA6vwBIBNIo/Cuzv7Nr3yokbDMSST/DXB+BW237gEcmvTLUfv1PXANAHF+IdEl06FJfOV1dtuAOc1hYO3GBwa9A8aZ/syMgdJBz+Brg5sbj70ARRjDE+tbenL8oIODWJtbGR0FbWm8p1wQOtAHOeOYw2n3Oecoa8Xk4O08+9e3eNedNuOOx/lXh8pwwHrnmgCtNwTjNZ9wThs4q+55OTVC6GFOBQBRl5C5rOm5Rs1oTHis2Y8HmgD7JubZWAVwpJ4HpVF9NTdljge1FFAFuzs0VlIApdWsl8s4OMiiigDzjXtF87eBIB+FeVa9oIsdT++GDcAdMUUUAZj2bM5JfG0dqqTWWUzv5NFFAFG6tGVM+Zk1muso4RgO3SiigCxb2m9SGbDHpiqMtqY5Tl8jNFFADQCHOTmpki3MpziiigC5CWjOEbBrRt7xwQH+YLkUUUAXbcCQhgBz61qw2u6IOpGB1z1oooAtrEy8gip4964w2D7UUUAW7e3F0GFwFYAelZ93oYijaW3kAUckN1oooALRSEOcYxWvYthsDv0PpRRQBrwT4RiUG3OMVcVguxgMd6KKAO78B3ckl2IJDuhYZIPb6V6ZbDa6D0oooA1AcBR61naphImH95u1FFAHPSttX8aozL8wOetFFAEeBvAHU96e7ERH+960UUAY6OdzheBmrVudzgUUUAaBPyEntWBqTM0mSePaiigCgR8opHJDbT1PpRRQBE4woIqEjzAR0xRRQB0Pg+MR32R1Nem2I53e1FFAGd4wP/ABLox6yD+Rrh5ACw+lFFACICUfGK0LNcHPfAoooAyPGSj+z5/wDdP8q8HkPBHoT/ADoooArTdTkVQujtznkEUUUAZ9x2rPm5yPWiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain radiograph shows a type I fracture of the distal clavicle with mild angulation. Intact ligaments hold the proximal fragment in normal position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5936=[""].join("\n");
var outline_f5_51_5936=null;
var title_f5_51_5937="Epiglottitis visualization";
var content_f5_51_5937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epiglottitis: Direct visualization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A swollen, cherry-red epiglottis with an endotracheal tube passing posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5937=[""].join("\n");
var outline_f5_51_5937=null;
var title_f5_51_5938="Contents: HIV infection";
var content_f5_51_5938=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       HIV infection",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			HIV infection",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/55/20345\">",
"           Diagnostic assays for HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/20/16712\">",
"           Screening laboratory tests in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/34/10793\">",
"           Serologic screening for HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/44/39623\">",
"           Techniques and interpretation of HIV-1 RNA quantitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21320\">",
"           Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug resistance",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/46/3814\">",
"           Clinical trials of HIV drug resistance testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32424\">",
"           Drug resistance testing in the clinical management of HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4873\">",
"           Overview of HIV drug resistance testing assays",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34218\">",
"           Primer on interpretation of HIV drug resistance testing",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13030\">",
"           Clinical manifestations and diagnosis of HIV-2 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12249\">",
"           Dementia and delirium in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12504\">",
"           Depression, mania, and schizophrenia in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39332\">",
"           Electrolyte disturbances with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38343\">",
"           Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/61/24538\">",
"           Fever and rash in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/44/26313\">",
"           HIV and the older patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37273\">",
"           Immunizations in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/34/5674\">",
"           Immunology of HIV-1 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42584\">",
"           Management of tissue wasting in patients with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/44/5831\">",
"           Overview of the neuropsychiatric aspects of HIV infection and AIDS",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11047\">",
"           Pneumococcal immunization in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26474\">",
"           Primary care of HIV-infected adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33450\">",
"           Primary prevention of opportunistic infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15321\">",
"           Solid organ transplantation in HIV-infected individuals",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/31/2551\">",
"           Substance abuse and addiction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42456\">",
"           Surgical issues in HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/5/26713\">",
"           Treatment of HIV-2 infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV and malignancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12103\">",
"           AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/37/18009\">",
"           AIDS-related Kaposi sarcoma: Staging and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/4/7242\">",
"           AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20042\">",
"           AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7321\">",
"           AIDS-related lymphomas: Primary central nervous system lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30969\">",
"           AIDS-related lymphomas: Primary effusion lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38346\">",
"           AIDS-related lymphomas: Treatment of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27206\">",
"           HIV infection and malignancy: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/14/18665\">",
"           Preinvasive and invasive cervical neoplasia in HIV-infected women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/7/21623\">",
"           Pulmonary involvement in AIDS-related Kaposi sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9750\">",
"           Pulmonary manifestations of HIV-associated lymphoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV and specific organisms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/62/22504\">",
"           AIDS-related cytomegalovirus gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7623\">",
"           AIDS-related cytomegalovirus neurologic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/5/15449\">",
"           Bacterial pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38568\">",
"           Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19093\">",
"           Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/58/11178\">",
"           Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39924\">",
"           Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/28/35270\">",
"           Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18649\">",
"           Epidemiology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/61/40919\">",
"           Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/55/7033\">",
"           Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/8/3209\">",
"           HIV and malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38777\">",
"           Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/9/15512\">",
"           Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36310\">",
"           Parasitic pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/51/37688\">",
"           Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33129\">",
"           Toxoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/1/13337\">",
"           Treatment of AIDS-related cytomegalovirus retinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/23/23929\">",
"           Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22261\">",
"           Tuberculous pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV and specific organs/tissues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26069\">",
"           AIDS cholangiopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/10/41128\">",
"           Approach to HIV-infected patients with central nervous system lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/35/32313\">",
"           Bone and calcium disorders in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25226\">",
"           Cardiac involvement in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38536\">",
"           Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/12/27848\">",
"           Diagnosis, treatment and prognosis of HIV-associated neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/44/37575\">",
"           Emphysema-like disease in HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/1/26650\">",
"           Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/43/26298\">",
"           Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/56/29577\">",
"           Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30218\">",
"           Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/1/35864\">",
"           Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/3/63\">",
"           Evaluation of abdominal pain in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11670\">",
"           Evaluation of the HIV-infected patient with anorectal symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11848\">",
"           Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38551\">",
"           Evaluation of the HIV-infected patient with diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21480\">",
"           Evaluation of the HIV-infected patient with hepatobiliary complaints",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4707\">",
"           Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24359\">",
"           HIV-associated eosinophilic folliculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3098\">",
"           Hematologic manifestations of HIV infection: Anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44039\">",
"           Hematologic manifestations of HIV infection: Neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14522\">",
"           Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34344\">",
"           Human immunodeficiency virus and dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30120\">",
"           Hypogonadism in HIV-infected males",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/3/49\">",
"           Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/31/36345\">",
"           Monitoring the HIV-infected patient taking hepatitis C therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4695\">",
"           Muscle disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40392\">",
"           Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/50/22312\">",
"           Pituitary and adrenal gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23993\">",
"           Pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/58/40870\">",
"           Predictors of response to hepatitis C treatment in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/36/44617\">",
"           Treatment of HIV-associated lipodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/38/18026\">",
"           Treatment of hepatitis C virus infection in the HIV-infected patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Natural history and epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/39/24186\">",
"           Factors affecting HIV progression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/35/16954\">",
"           HIV and women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/44/1737\">",
"           The adolescent with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/2/21546\">",
"           The global human immunodeficiency virus pandemic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13353\">",
"           The stages and natural history of HIV infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29016\">",
"           Effect of herpes simplex virus on HIV infection: Implications for HIV prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/12/28872\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/24/19848\">",
"           HIV treatment as prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13384\">",
"           Non-antiretroviral interventions to reduce perinatal HIV transmission in the developing world",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/50/26410\">",
"           Nonoccupational exposure to HIV in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34041\">",
"           Pre-exposure prophylaxis against HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/23/29050\">",
"           Prevention of HIV transmission during breastfeeding in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/14/34024\">",
"           Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41799\">",
"           Treatment of genital herpes simplex virus type 2 in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/7/43129\">",
"           Acute and early HIV infection: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18151\">",
"           Acute and early HIV infection: Pathogenesis and epidemiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22808\">",
"           Acute and early HIV infection: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transmission",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42456\">",
"           Surgical issues in HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/28/31175\">",
"           Transfusion transmitted HIV infection and AIDS",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/34/10794\">",
"           Adverse effects of antiretroviral therapy in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24037\">",
"           Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16328\">",
"           Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42841\">",
"           Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18825\">",
"           Antiretroviral medications in pregnancy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/13/31956\">",
"           Clinical trials of HIV antiretroviral therapy: Agents in advanced stages of development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37173\">",
"           Clinical trials of HIV antiretroviral therapy: Boosted protease inhibitor monotherapy studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32918\">",
"           Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11286\">",
"           Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7720\">",
"           Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9287\">",
"           Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17672\">",
"           Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14774\">",
"           Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33682\">",
"           Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10325\">",
"           Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/46/3814\">",
"           Clinical trials of HIV drug resistance testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/18/3370\">",
"           Considerations prior to initiating antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/986\">",
"           Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12759\">",
"           Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32424\">",
"           Drug resistance testing in the clinical management of HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40458\">",
"           HIV protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23098\">",
"           Immune reconstitution inflammatory syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/40/30345\">",
"           Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/26/36265\">",
"           Modifying HIV antiretroviral therapy regimens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4873\">",
"           Overview of HIV drug resistance testing assays",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/17/38167\">",
"           Patient monitoring during HIV antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/56/11144\">",
"           Pharmacology of integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/18/37162\">",
"           Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/4/15433\">",
"           Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36234\">",
"           Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/51/10039\">",
"           Structured treatment interruptions in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39018\">",
"           The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/12/29898\">",
"           The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/45/33494\">",
"           Treatment and prevention of mitochondrial toxicity in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/5/26713\">",
"           Treatment of HIV-2 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/39/37495\">",
"           Treatment of HIV-infected adults who have trouble swallowing pills: Liquid, chewable, and crushable formulations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25290\">",
"           Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9786\">",
"           When to initiate antiretroviral therapy in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-84A2A9C29F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_51_5938=[""].join("\n");
var outline_f5_51_5938=null;
var title_f5_51_5939="Tafluprost: Drug information";
var content_f5_51_5939=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tafluprost: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41684?source=see_link\">",
"    see \"Tafluprost: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13913593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zioptan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13803924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Prostaglandin, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13854571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP-lowering effect",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13854572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13854584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zioptan&trade;: 0.0015% (30s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13854528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13854573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic use only. Wash hands before use. Avoid touching the tip of the single-use container to eye or other surfaces. Each single-use container has adequate solution to treat both eyes (if applicable); discard immediately after use. If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13803925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13854536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: Conjunctival hyperemia (4% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Stinging/irritation (7%), conjunctivitis (5%), cataract (3%), dry eye (3%), ocular pain (3%), eyelash darkening (2%), eyelash growth (2%), vision blurred (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Common cold (4%), cough (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening; as reported with prostaglandin analog use): Macular edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13854532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s prescribing information.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13854533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular effects: May permanently change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes. In addition, may increase the length and/or number of eyelashes (may vary between eyes); changes occur slowly and may not be noticeable for months or years. Long-term consequences and potential injury to eye are not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular disease: Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Use in pediatric patients is not recommended due to possible safety issues of increased pigmentation following long-term chronic use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13929423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13929421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13854529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13854530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies following I.V. administration. Effective contraception during treatment is recommended for women of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13854531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zioptan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.0015% (30): $116.40",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14190120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Saflutan (AT, AU, BR, CH, FR, GB, IE, IL, NL, PT);",
"     </li>",
"     <li>",
"      Taflotan (CZ, DE, DK, EE, FI, HK, ID, NO, PL, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13854543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tafluprost acid is a fluorinated prostaglandin F",
"     <sub>",
"      2",
"     </sub>",
"     -alpha analog believed to reduce intraocular pressure by increasing outflow of aqueous humor via the uveoscleral pathway; exact mechanism by which it reduces IOP is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13854545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Reduction of intraocular pressure (IOP): 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: Maximum reduction of IOP: ~12  hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Through the cornea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Ester prodrug (tafluprost) is hydrolyzed to the biologically-active acid metabolite (tafluprost acid); tafluprost acid metabolized further via fatty acid beta oxidation and phase II conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~10 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Pozarowska D, \"Safety and Tolerability of Tafluprost in Treatment of Elevated Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension,\"",
"      <i>",
"       Clin Ophthalmol",
"      </i>",
"      , 2010, 4:1229-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/51/5939/abstract-text/21060677/pubmed\" id=\"21060677\" target=\"_blank\">",
"        21060677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83329 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5939=[""].join("\n");
var outline_f5_51_5939=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13913593\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13803924\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854571\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854572\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854584\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854528\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854573\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13803925\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854536\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854532\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854533\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929423\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929421\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854529\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854530\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854531\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322934\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190120\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854543\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854545\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83329|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"UTD.htm?42/28/43457?source=related_link\">",
"      Tafluprost: International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41684?source=related_link\">",
"      Tafluprost: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_51_5940="Nitisinone: Patient drug information";
var content_f5_51_5940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nitisinone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/43/24244?source=see_link\">",
"     see \"Nitisinone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/10/5284?source=see_link\">",
"     see \"Nitisinone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orfadin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700425",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nitisinone must be used with a special diet that is low in tyrosine and phenylalanine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hereditary tyrosinemia type 1 (HT-1).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nitisinone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low platelet and white blood cell counts may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in skin on hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Capsules may be opened and contents mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694866",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10911 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5940=[""].join("\n");
var outline_f5_51_5940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016883\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016885\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016884\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016889\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016890\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016892\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016887\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016888\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016893\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016894\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/43/24244?source=related_link\">",
"      Nitisinone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/10/5284?source=related_link\">",
"      Nitisinone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_51_5941="Dexamethasone (ophthalmic): Pediatric drug information";
var content_f5_51_5941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexamethasone (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/62/997?source=see_link\">",
"    see \"Dexamethasone (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17172?source=see_link\">",
"    see \"Dexamethasone (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8015642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxidex&reg;;",
"     </li>",
"     <li>",
"      Ozurdex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8015643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diodex&reg;;",
"     </li>",
"     <li>",
"      Maxidex&reg;;",
"     </li>",
"     <li>",
"      Ozurdex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/997?source=see_link\">",
"      see \"Dexamethasone (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Anti-inflammatory:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: Limited data available: Ophthalmic: Instill 1-2 drops into conjunctival sac every hour during the day and every other hour during the night; gradually reduce dose to every 3-4 hours, then to 3-4 times/day (Cassidy, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: Limited data available: Ophthalmic: Instill 1-2 drops into conjunctival sac up to 4-6 times per day; may use hourly in severe disease in older children; taper prior to discontinuation; others have used 2-4 times/day dosing in children following strabismus surgery; in one study twice daily eye drops controlled inflammation equally well as 4 times daily dosing, but with less increase in IOP (Lam, 2005; Ng, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ocular inflammation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution: Ophthalmic: Instill 1-2 drops into conjunctival sac every hour during the day and every other hour during the night; gradually reduce dose to every 4 hours, then to 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suspension: Ophthalmic: Instill 1-2 drops into conjunctival sac up to 4-6 times per day; may use hourly in severe disease; taper prior to discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Macular edema (following BRVO or CRVO):",
"     </b>",
"     Ophthalmic intravitreal implant (Ozurdex&reg;): Intravitreal: 0.7 mg implant injected in affected eye",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Noninfective uveitis:",
"     </b>",
"     Ophthalmic intravitreal implant (Ozurdex&reg;): Intravitreal: 0.7 mg implant injected in affected eye",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Otic inflammation:",
"     </b>",
"     Ophthalmic solution: Initial: Instill 3-4 drops into the aural canal 2-3 times a day; reduce dose gradually once a favorable response is obtained. Alternately, may pack the aural canal with a gauze wick saturated with the solution; remove from the ear after 12-24 hours. Repeat as necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8016302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, intravitreal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ozurdex&reg;: 0.7 mg (1s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as phosphate [drops]: 0.1% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxidex&reg;: 0.1% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8015645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Ophthalmic solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Avoid contact of container tip with skin or eye; remove soft contact lenses prior to using solutions containing benzalkonium chloride. Shake suspension well prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intravitreal injection (Ozurdex&reg;): Administer under controlled aseptic conditions (eg, sterile gloves, sterile drape, sterile eyelid speculum). Adequate anesthesia and a broad-spectrum bactericidal agent should be administered prior to injection. In sterile field, open foil pouch, remove applicator, and pull the safety tab straight off of the applicator (do not twist or flex the tab). See package insert for further administration details. If administration is required in the second eye, a new applicator should be used and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution and suspension: Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: May use ophthalmic solution otically. Prior to use, clean the aural canal thoroughly and sponge dry.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11422164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic ointment/suspension: Store at 8&deg;C to 27&deg;C (46&deg;F to 80&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic solution, ocular implant: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11422104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic: Management of steroid responsive inflammatory conditions such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, or select infective conjunctivitis when benefit of reduced edema and inflammation exceeds steroid use risks (FDA approved in adults); symptomatic treatment of corneal injury from chemical, radiation, or thermal burns, or from penetration of foreign bodies (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Ophthalmic intravitreal implant (Ozurdex&reg;): Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) (FDA approved in adults); noninfective uveitis of the posterior segment of the eye  (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Otic (using ophthalmic solution): Management of steroid responsive inflammatory conditions such as allergic otitis externa and select infective purulent and nonpurulent otitis externa when benefit of reduced edema and inflammation exceeds steroid use risks (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8015641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexamethasone may be confused with desoximetasone, dextroamphetamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Maxidex&reg; may be confused with Maxzide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F10118946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Intravitreal implant (Ozurdex&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Cataract, conjunctival hemorrhage, conjunctival hyperemia, pain,  hypertension, intraocular pressure increased, vitreous detachment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rare but important or life-threatening: Corneal edema, device dislocation, endophthalmitis, hypotony, implant misplacement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Ophthalmic solution/suspension:",
"     </b>",
"     Ocular: Burning, cataract formation, filtering blebs, glaucoma (with optic nerve damage), perforation of globe, secondary ocular infections, stinging, visual acuity defects, visual field defects",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexamethasone or any component; active untreated periocular infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension/solution: Viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis, vaccinia, varicella); mycobacterial or fungal infection of the eye; otic use (solution): Perforation of the eardrum membrane",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravitreal implant: Advanced glaucoma; active or suspected ocular or periocular infections; anterior chamber intraocular lens (ACIOL) and aphakic eyes with rupture of posterior lens capsule",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use, consider routine eye exams in chronic users. Avoid prolonged use of ophthalmic corticosteroids, which may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Monitor intraocular pressure if ophthalmic solution/suspension used for 10 days or longer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Following intravitreal injection of the ocular implant formulation, endophthalmitis, ocular inflammation, increased intraocular pressure, and retinal detachments may occur. Intraocular pressure elevations usually peak 60 days following intravitreal injection and return to baseline by day 180; prolonged monitoring of intraocular pressure may be required. A risk of implant migration into the anterior chamber may be present if the posterior capsule of the lens is absent or torn. Temporary blurring may occur following intravitreal injections; patients should not drive or perform other high-risk activities until this resolves.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Prolonged use of ophthalmic corticosteroids may increase the risk of secondary ocular infections, including persistent fungal infections or bacterial keratitis. Avoid wearing contact lenses during therapy; ophthalmic solution and suspension may contain benzalkonium chloride which may be absorbed by contact lenses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11422144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment). Increased IOP may occur especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Ophthalmic solution (drops) may contain sulfites, which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8015662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8083888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9890216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies following use of ophthalmic dexamethasone.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11426204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic, topical: Intraocular pressure (Lam, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic intravitreal implant: Following intravitreal injection, monitor for increased IOP and endophthalmitis; check for perfusion of optic nerve head immediately after injection, tonometry within 30 minutes, biomicroscopy between 2-7 days after injection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10512758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses normal immune response",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F11422167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17172?source=see_link\">",
"      see \"Dexamethasone (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by prescriber. Take exactly as directed, do not increase dose or discontinue abruptly without consulting prescriber.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ophthalmic: For use in eyes only. Wash hands before using. Lie down or tilt your head back and look upward. Put drops of suspension or solution inside lower eyelid. Close eye and roll eyeball in all directions. Do not blink for 30 seconds. Apply gentle pressure to inner corner of eye for 30 seconds. Do not use any other eye preparation for at least 10 minutes. Do not let tip of applicator touch eye; do not contaminate tip of applicator (may cause eye infection, eye damage, or vision loss). Do not share medication with anyone else. Wear sunglasses when in sunlight; you may be more sensitive to bright light. Inform prescriber if condition worsens, fails to improve, or if you experience eye pain, disturbances of vision, or other adverse eye response.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/51/5941/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cassidy L, Rahi J, Nischal K, et al, \"Outcome of Lens Aspiration and Intraocular Lens Implantation in Children Aged 5 Years and Under,\"",
"      <i>",
"       Br J Ophthalmol",
"      </i>",
"      , 2001, 85(5):540-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/51/5941/abstract-text/11316711/pubmed\" id=\"11316711\" target=\"_blank\">",
"        11316711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam DS, Fan DS, Ng JS, et al, \"Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,\"",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2005, 33(3):252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/51/5941/abstract-text/15932528/pubmed\" id=\"15932528\" target=\"_blank\">",
"        15932528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng JS, Fan DS, Young AL, et al, \"Ocular Hypertensive Response to Topical Dexamethasone in Children: A Dose-Dependent Phenomenon,\"",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2000, 107(11):2097-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/51/5941/abstract-text/11054340/pubmed\" id=\"11054340\" target=\"_blank\">",
"        11054340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15965 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-E05BAE8337-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5941=[""].join("\n");
var outline_f5_51_5941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015642\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015643\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512752\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512759\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016302\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015645\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512760\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422164\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422104\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015641\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118946\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512755\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512756\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422144\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299141\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015662\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083888\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9890216\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426204\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512758\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11422167\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/997?source=related_link\">",
"      Dexamethasone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17172?source=related_link\">",
"      Dexamethasone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14042?source=related_link\">",
"      Dexamethasone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=related_link\">",
"      Dexamethasone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/18/6442?source=related_link\">",
"      Dexamethasone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_51_5942="Evaluation of nonacute scrotal pathology in adult men";
var content_f5_51_5942=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of nonacute scrotal pathology in adult men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5942/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5942/contributors\">",
"     Robert C Eyre, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5942/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5942/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5942/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5942/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/51/5942/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of conditions that affect the scrotum and its contents ranges from incidental findings that merely require explanation and patient reassurance to acute pathologic events that require expeditious diagnosis and treatment. This topic reviews the conditions that a physician is likely to encounter on routine physical examination. Acute scrotal pain in adults and testicular and scrotal disorders in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=see_link\">",
"     \"Evaluation of the acute scrotum in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2663?source=see_link\">",
"     \"Evaluation of scrotal pain or swelling in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tunica vaginalis and the epididymis are two important landmarks for the scrotal examination (",
"    <a class=\"graphic graphic_figure graphicRef75672 \" href=\"UTD.htm?32/1/32786\">",
"     figure 1",
"    </a>",
"    ). The tunica vaginalis is a potential space that encompasses the anterior two-thirds of the testicle and is where fluid from a variety of sources may accumulate. The epididymis usually is positioned posterolaterally to the testicle and must be differentiated from an abnormal mass. The spermatic cord, which consists of the testicular vessels and the vas deferens, is connected to the base of the epididymis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CRYPTORCHIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptorchidism is failure of descent of the testes into the scrotum during fetal development. The defect may result in the testes being located within the abdomen, inguinal canal, or some other ectopic location. Both unilateral and bilateral cryptorchidism are associated with impaired spermatogenesis and an increased risk of testicular tumors; testes that remain in an intra-abdominal location are believed to have up to a 40-fold increased risk of developing testicular carcinoma (making the risk 1 per 1000 to 2500) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5942/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 30 percent of premature and 5 percent of full-term males will have an undescended testicle (UDT) noted during the first year of life. Most of these subsequently descend into the scrotum so that cryptorchidism is present in approximately 1 percent of boys at age one year.",
"   </p>",
"   <p>",
"    Cryptorchidism in children and adolescents is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryptorchid testes cannot be manipulated manually to a scrotal position; testes that can be manipulated manually into the scrotum are called retractile. Examination of adults with a suspected UDT should be done in both the supine and standing positions with adequate cremasteric relaxation to differentiate true UDT or ectopic testes from retractile testes.",
"   </p>",
"   <p>",
"    In the past it was thought that all cryptorchid testes in adults should be surgically removed because of the increased risk of malignancy. However, our ability to locate and evaluate them with computed tomography (CT) scan has gradually shifted the paradigm toward a more conservative observational approach (eg, baseline CT scan at the time of diagnosis and then every five years). Based upon our clinical experience, we favor this approach and use CT scan monitoring to help determine need for surgical excision. One exception may be in a man with a palpable testis in the inguinal canal. These testes are at increased risk for blunt traumatic injury from compression against the pubic bone, thus, surgical excision may be advisable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VARICOCELE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A varicocele is caused by dilatation of the pampiniform plexus of spermatic veins (",
"    <a class=\"graphic graphic_figure graphicRef73206 \" href=\"UTD.htm?7/57/8080\">",
"     figure 2",
"    </a>",
"    ). It is present in 15 to 20 percent of post-pubertal males, occurring in the left hemiscrotum in the vast majority of cases. The reason for the left-sided predominance may be explained anatomically. The left spermatic (gonadal) vein is one of the longest veins in the body, entering the left renal vein at a perpendicular angle. The intravascular pressure in the left renal vein is higher than on the right because it is compressed between the aorta and the superior mesenteric artery coming off the aorta above the renal vein, thereby producing a \"nutcracker effect.\" This phenomenon causes increased pressure in the left gonadal vein, which can dilate and cause incompetence of the valve leaflets, leading to retrograde flow of blood toward the testis in the erect position. The venous complex in the scrotum dilates and produces anything from minimal fullness on Valsalva maneuver to a large soft scrotal mass (\"bag of worms\") that decompresses and disappears in the recumbent position. Varicoceles are graded I, II, or III, according to size (",
"    <a class=\"graphic graphic_table graphicRef51251 \" href=\"UTD.htm?2/43/2747\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bilateral varicoceles occur in 33 percent of patients. Unilateral right varicoceles are very rare and should alert the clinician to possible underlying pathology causing inferior vena caval obstruction (renal cell carcinoma with IVC thrombus, right renal vein thrombosis with clot propagation down the IVC, etc), since the right gonadal vein directly empties into the IVC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicoceles may be asymptomatic or present with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dull, aching, left scrotal pain, typically noticeable when standing and relieved by recumbency",
"     </li>",
"     <li>",
"      Testicular atrophy, believed to be secondary to loss of germ cell mass by induction of apoptosis (programmed cell death) initiated by the associated slightly increased scrotal temperature",
"     </li>",
"     <li>",
"      Decreased fertility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A large number of infertile men are found to have a varicocele on examination. In a World Health Organization (WHO) study of over 9000 men who were partners in an infertile couple, a varicocele was much more common in men with abnormal semen (25.4 percent versus 11.7 percent with normal semen) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5942/abstract/2\">",
"     2",
"    </a>",
"    ]. On the other hand, men with varicoceles may have normal semen parameters and normal fertility. Thus, the precise relationship between varicocele and infertility is unknown, partly because teenage boys may not feel comfortable providing a semen specimen for analysis and partly because many infertility problems are multifactorial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of primary hypogonadism in males\", section on 'Varicocele'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clear guidelines or solid evidence established for treatment, by surgical ligation or venous embolization, of a varicocele. If treatment is necessary, surgical treatment involves ligating the gonadal vein so that retrograde blood flow can no longer reach the plexus of veins in the scrotum. Approaches include inguinal, subinguinal, lumbar, and laparoscopic. Some urologists favor a microsurgical approach, citing a lower recurrence rate. Treatment with gonadal vein embolization is an alternative, but there have been some reports of embolization coils migrating to the lungs and other organs, and surgical ligation is generally the preferred first-line treatment.",
"   </p>",
"   <p>",
"    Treatment is indicated for boys who demonstrate retarded growth of the left testis and in young men who develop testicular atrophy. There are data to suggest that catch-up growth of the atrophic testis is possible in some cases after surgery and that return of testicular size postoperatively directly correlates with normal fertility potential [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5942/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conservative treatment with scrotal support and NSAIDs may suffice for an older man who has completed his family and who presents with minor scrotal discomfort as his only symptom. The management of varicocele in younger infertile men or men with reduced semen parameters is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5942/abstract/4\">",
"     4",
"    </a>",
"    ]. Many series have reported an improvement in semen qualities following varicocele ligation, but these studies were uncontrolled; controlled trials generally have",
"    <strong>",
"     not",
"    </strong>",
"    demonstrated improvement in sperm count or fertility after varicocele correction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5942/abstract/5\">",
"     5",
"    </a>",
"    ]. Nevertheless, in the younger infertile man with a clinically apparent varicocele, it seems reasonable to recommend surgical ligation despite the lack of clear data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subclinical varicoceles are often discovered as part of an infertility evaluation by demonstrating retrograde flow to the scrotum by Color Doppler ultrasonography. The role of surgical ligation for subclinical varicoceles associated with subfertility is not clear.",
"   </p>",
"   <p>",
"    There are no evidenced-based guidelines for management of young men with varicoceles and normal semen parameters. The management of patients under the age of 20 with a clinically obvious varicocele is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of painless scrotal swelling in children and adolescents\", section on 'Varicocele'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For older men with normal semen parameters, we typically follow up with a semen analysis every two years as long as they desire continued fertility; once their family is complete, follow-up is no longer necessary. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CYSTIC SCROTAL MASSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Epididymal cysts and spermatoceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epididymal cysts are usually palpated in the head (caput) of the epididymis and are generally asymptomatic. They occur with increased frequency in male offspring of mothers who used diethylstilbestrol during pregnancy. In addition, epididymal cystadenomas are seen in more than one-half of patients with Von Hippel-Lindau disease and are often bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5942/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\", section on 'Papillary cystadenomas of the epididymis and broad ligament'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These are usually not mistaken for other scrotal pathology, and they can be diagnosed by scrotal ultrasonography if the clinical examination is equivocal. No treatment is required.",
"   </p>",
"   <p>",
"    The distinction between a spermatocele and an epididymal cyst is mainly one of size; epididymal cystic masses that are larger than 2 cm are called spermatoceles. Spermatoceles are always located superior to the testis and are palpated as distinct from the testis, which differentiates them from hydroceles. Spermatoceles generally range in size from 2 to 5 cm and rarely cause symptoms. Occasional patients require surgical excision for chronic pain related to a spermatocele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hydroceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hydrocele is a collection of peritoneal fluid between the parietal and visceral layers of the tunica vaginalis, the investing layer that directly surrounds the testis and spermatic cord (",
"    <a class=\"graphic graphic_figure graphicRef58679 \" href=\"UTD.htm?1/17/1299\">",
"     figure 3",
"    </a>",
"    ). It is the same layer that forms the peritoneal lining of the abdomen. Hydroceles are believed to arise from an imbalance of secretion and reabsorption of fluid from the tunica vaginalis.",
"   </p>",
"   <p>",
"    Hydroceles range in size from small, soft collections that still allow palpation of the scrotal contents to massive, tense collections of several liters that make examination impossible. Symptoms of pain and disability generally increase with the size of the mass. Hydrocele fluid in the scrotal sac transilluminates well, which differentiates the process from a possible hematocele, hernia, or solid mass. A scrotal ultrasound should be considered if the diagnosis is in question since a reactive hydrocele can occur in the presence of a testicular neoplasm or with acute inflammatory scrotal conditions.",
"   </p>",
"   <p>",
"    Idiopathic hydroceles usually arise over a long period of time and are the most common type of hydrocele. Inflammatory conditions of the scrotal contents (epididymitis, torsion, appendiceal torsion) can produce an acute reactive hydrocele, which often resolves with treatment of the underlying condition.",
"   </p>",
"   <p>",
"    Idiopathic hydroceles are often asymptomatic, despite considerable scrotal enlargement. Thus, treatment is necessary only patients who are symptomatic (pain, pressure) or for the rare situation when scrotal skin integrity is compromised from chronic irritation.",
"   </p>",
"   <p>",
"    The most common treatment is surgical excision of the hydrocele sac. Simple aspiration is generally unsuccessful due to rapid reaccumulation of fluid. On the other hand, percutaneous aspiration of the hydrocele fluid may be successful if combined with instillation of a sclerosing agent into the sac. The potential risks of the latter approach are a low incidence of reactive",
"    <span class=\"nowrap\">",
"     orchitis/epididymitis",
"    </span>",
"    and a higher rate of recurrence, which may then make open surgery more difficult because of the development of inflammatory adhesions between the hydrocele sac and the scrotal contents.",
"   </p>",
"   <p>",
"    Hydroceles discovered in infancy are usually \"communicating,\" since they are associated with a patent processus vaginalis, which allows flow of peritoneal fluid into the scrotal sac. They usually disappear in the recumbent position and are often associated with herniation of abdominal contents (indirect hernia) through the processus vaginalis. Surgical repair is advised in these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TESTICULAR CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer is relatively rare, but it is the most common solid tumor in men between the ages of 18 and 40. It usually presents as a painless mass discovered by the patient or physician on physical examination, although rapidly growing germ cell tumors may cause acute scrotal pain secondary to hemorrhage and infarction. On examination, intrascrotal malignancies are usually firm, nontender masses that do not transilluminate, although a reactive hydrocele may be evident with transillumination. Some patients may have accompanying gynecomastia.",
"   </p>",
"   <p>",
"    Scrotal ultrasound is the initial test of choice to diagnose testicular cancer (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    ). However, several conditions may mimic neoplasia on ultrasound, including inflammation, hematoma, infarct, fibrosis, and tubular ectasia. In cases in which the ultrasound is inconclusive, MRI may help differentiate benign from malignant lesions. This was illustrated in a study of 622 patients who underwent ultrasound examination to evaluate a variety of scrotal diseases, of whom 17 had a lesion suspicious for cancer but an inconclusive ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5942/abstract/7\">",
"     7",
"    </a>",
"    ]. No lesion defined as benign by MRI proved to be malignant (negative predictive value 100 percent), while two benign inflammatory lesions were mistakenly thought to be malignant (positive predictive value 71 percent). These findings suggest that ultrasound is sufficient in the vast majority of patients with suspected malignancy on examination, but MRI is a useful adjunct when the ultrasound result is equivocal or shows microcalcification within the testis but no obvious mass. Small, benign calcifications on the surface of the testis are relatively commonly detected on physical examination and ultrasound and do not require further evaluation.",
"   </p>",
"   <p>",
"    Any patient suspected of having a testis cancer should also have blood levels of alpha fetoprotein (AFP) and the beta subunit of human chorionic gonadotropin (beta-hCG) measured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/29/17873?source=see_link\">",
"       \"Patient information: Hydrocele (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=see_link\">",
"       \"Patient information: Varicocele (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spectrum of conditions that affect the scrotum and its contents, which a physician is likely to encounter on routine physical examination, include cryptorchidism, varicocele, epididymal cysts, hydroceles, and testicular cancer. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptorchidism is failure of descent of the testes into the scrotum during fetal development. Both unilateral and bilateral cryptorchidism are associated with impaired spermatogenesis and an increased risk of testicular tumors. Patients with cryptorchidism can be followed with CT scan to help determine need for surgical excision. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cryptorchidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A varicocele is caused by dilatation of the pampiniform plexus of spermatic veins. Varicoceles are common and can be asymptomatic or present with left scrotal pain, testicular atrophy, or decreased fertility. They do not usually require treatment. Although there is no solid evidence to support surgical ligation or venous embolization, they can be considered in the following situations (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Varicocele'",
"      </a>",
"      above): &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Varicoceles that produce significant pain",
"     </li>",
"     <li>",
"      Men with infertility or decreased sperm quality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older men with varicoceles who have normal semen parameters can be followed with semen analysis every two years until fertility is no longer desired. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Varicocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unilateral right varicoceles are very rare and should alert the clinician to possible underlying pathology causing inferior vena caval obstruction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Varicocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A hydrocele is a collection of peritoneal fluid between the parietal and visceral layers of the tunica vaginalis, the layer that directly surrounds the testis and spermatic cord (",
"      <a class=\"graphic graphic_figure graphicRef58679 \" href=\"UTD.htm?1/17/1299\">",
"       figure 3",
"      </a>",
"      ). Hydroceles range in size from small, soft collections that still allow palpation of the scrotal contents to massive, tense collections of several liters that make examination impossible. Symptoms of pain and disability generally increase with the size of the mass. Treatment for hydroceles is needed only for patients who are symptomatic (pain, pressure) or for the rare situation of compromised scrotal skin integrity from chronic irritation. The most common treatment is surgical excision of the hydrocele sac. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hydroceles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epididymal cysts and spermatoceles are palpated in the head of the epididymis and are usually asymptomatic. Epididymal cysts occur with increased frequency in sons of mothers who used diethylstilbestrol during pregnancy. Diagnosis of epididymal cysts and spermatoceles is confirmed by ultrasound, when needed. Epididymal cysts and spermatoceles usually do not require further evaluation or treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Epididymal cysts and spermatoceles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testicular cancer presents as a painless mass discovered by the patient or physician on physical examination. Testicular masses can generally be distinguished from other scrotal masses (hydrocele, spermatocele, epididymal cyst) on physical examination because they are firm, nontender masses that do not transilluminate. Individuals with testicular masses should undergo ultrasonographic diagnostic imaging. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Testicular cancer'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5942/abstract/1\">",
"      Tasian GE, Copp HL, Baskin LS. Diagnostic imaging in cryptorchidism: utility, indications, and effectiveness. J Pediatr Surg 2011; 46:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5942/abstract/2\">",
"      The influence of varicocele on parameters of fertility in a large group of men presenting to infertility clinics. World Health Organization. Fertil Steril 1992; 57:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5942/abstract/3\">",
"      Hadziselimovic F, Herzog B, Jenny P. The chance for fertility in adolescent boys after corrective surgery for varicocele. J Urol 1995; 154:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5942/abstract/4\">",
"      Sandlow J. Pathogenesis and treatment of varicoceles. BMJ 2004; 328:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5942/abstract/5\">",
"      Evers JL, Collins JA, Vandekerckhove P. Surgery or embolisation for varicocele in subfertile men. Cochrane Database Syst Rev 2001; :CD000479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5942/abstract/6\">",
"      Choyke PL, Glenn GM, Wagner JP, et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997; 49:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5942/abstract/7\">",
"      Muglia V, Tucci S Jr, Elias J Jr, et al. Magnetic resonance imaging of scrotal diseases: when it makes the difference. Urology 2002; 59:419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6885 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5942=[""].join("\n");
var outline_f5_51_5942=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CRYPTORCHIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VARICOCELE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CYSTIC SCROTAL MASSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Epididymal cysts and spermatoceles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hydroceles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TESTICULAR CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6885|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/1/32786\" title=\"figure 1\">",
"      Scrotal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/57/8080\" title=\"figure 2\">",
"      Varicocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/17/1299\" title=\"figure 3\">",
"      Hydrocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2747\" title=\"table 1\">",
"      Varicocele grading",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=related_link\">",
"      Causes of painless scrotal swelling in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2663?source=related_link\">",
"      Evaluation of scrotal pain or swelling in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=related_link\">",
"      Evaluation of the acute scrotum in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/29/17873?source=related_link\">",
"      Patient information: Hydrocele (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=related_link\">",
"      Patient information: Varicocele (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_51_5943="Stage I palliative repair for HLHS";
var content_f5_51_5943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Stage I palliative repair for HLHS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 271px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEPAlUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P8T6+NBXTlXTr7UrnULr7JBb2ZiDs4iklJJldFACxP8AxelZ/wDwlGr/APQieJP+/wDp3/yVR4y/5GPwJ/2GpP8A03XlZLHUtQ1nxjcXHi7VdI07SLxYUitYbQxxxCyt5mYmSB2J3SuevTHFAGt/wlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXFfC7xBH8SdMvLzQfHHjCEWkwhlhu7XTEkGVyrYW3YbTzjn+E8V3/wAPdQutX8A+GtS1CXzr280y2uJ5NoXfI8SsxwAAMkngACgCr/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlV1VFAHK/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVdVRQByv/CUav/0IniT/AL/6d/8AJVH/AAlGr/8AQieJP+/+nf8AyVXVVBfXlvYWzXF5MkEC/edzgCgDnP8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5Kq7D4w8NTSCOLxBpLSHon2yPd+Wc1uKwdQykMpGQQeCKAOW/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kqn+I9eudJ8X+FbEIjWGrSXFrKx6pKsRljI+oRx+Iq1431tvDfhi81hYvNSz2SSr/0y3qHP4KWP4UAUv+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5Krqdy7N24bcZz2xTLeeO5t454JFkhkUOjqchlPIIPpQBzP/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVdVRQByv/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVdVRQByv/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVdVRQByv/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVdVRQBytv4uuP7X0yw1Lwxremf2jM1vBPcvaPH5ixSS4PlTuwysT87cZqXVvFMtnr82kWHh/V9WuYLWK7laza2VI0leVUBM00ZJJhfoD29ai8Zf8jH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+gA/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kqvOY/EeqWnh/wHLqHibxjfax4ps45obfTbbSgok8lJHGZYVCj5+MselaGk69eap4U0/wATaL4t8STQHWLOxls9StbBQQ97FBKjeXAD912wVfrjmgDtv+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5KrqqKAOV/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kquqooA5X/hKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+Sq6qigDlf+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5Krqq5zVfGWk6SXOpjULWNW2+Y+nzlCfZghFAEH/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVLpnxC8Iak2y08R6WZc48qS4WKT/vhsH9K1PE8l7/wi+qyaJKF1H7HK1pIAGAl2EocHgjOKAMr/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+Sq0fBesf8JD4P0TWCArX9lDcso/hZ0DEfgSR+FVPBWsz6n/AG3aXzbrzS9Sms3JABZOJImwOn7uRPyNAEP/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVW/b6ha3GoXdlDKGurUIZkH8G8Ern6gGrdAHK/8ACUav/wBCJ4k/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVdVRQByv/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVXVUUAcr/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lV1VFAHK/8ACUav/wBCJ4k/7/6d/wDJVVNW8cXukaVe6lqHgnxJDZWcL3E8nm2DbI0UsxwLok4APABNdrXK/Fj/AJJZ4y/7At7/AOiHoA0PE+vjQV05V06+1K51C6+yQW9mYg7OIpJSSZXRQAsT/wAXpWf/AMJRq/8A0IniT/v/AKd/8lUeMv8AkY/An/Yak/8ATdeVzeu6pdW0njnWNU8XaxpOkaHdpCkFjb2bAJ9jtpePNgdizPMw5bHIHFAHSf8ACUav/wBCJ4k/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVc54aGta5Mivrvj7TYpYBcwT3lppXlzIcdDHA+1sEHa+1sduDjrfh7qF1q/gHw1qWoS+de3mmW1xPJtC75HiVmOAABkk8AAUAVf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KrqqKAOV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kquqooA5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+Sq6qigDlf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KrqqKAOV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kquqooA5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+Sq6qigDlf8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KrqqKAOV/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kquqooA5X/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+Sq6qigDlf8AhKNX/wChE8Sf9/8ATv8A5Kqpq3ji90jSr3UtQ8E+JIbKzhe4nk82wbZGilmOBdEnAB4AJrta5X4sf8ks8Zf9gW9/9EPQB1VFFFAHK+Mv+Rj8Cf8AYak/9N15XH+KNB1nxRovxN0Pw7cWlrd3+sQwSTXLMqrCbCy8zG1SSSuRj3PNdh4y/wCRj8Cf9hqT/wBN15VrVPBXhXV7+W+1Xw1ol9ey48y4ubCKWR8AAZZlJOAAPoBQBxXgT4Zah4H+IUupaVqi3fh+70yKzuorrYk4lhAWJlWKNUKhAF555JOa6v4T/wDJLPBv/YFsv/RCUf8ACuPA/wD0Jvhv/wAFcH/xNdLaW0FnaQ2tnDFBbQoscUUSBUjQDAVQOAAAAAKAJaKKKACiiigAqhrGr6fo1sLjVbuK1gJx5khwv59qv0UAcXcax8O/EEwW51DwnqUz/Ltlmt5mPtgkmqmpeAPBWmwyajFG2gA9bvTr2WyVM8Z+RggHbkYrptS8LeH9UDDU9C0q8Dct9otI5M/mK8Zufhz4c8Y+I7iHwZp8dh4dtcpf3EUsq2l/OrqRCkSuFYLtcNIOAWwMkcAHcWPgCy1C/wBJ1BPGWv6ta6Zei7hhmvIbiPzkDLy+zd0ZgRu713etadDq+j32m3YJt7yCS3lA/uupU/oa8Ri1LXfhx4k1QmG71eK8lLTxTLI32K0jfbDOLg/K6CNtrh8SBhkkqte2aHqlrrek2upae/mWtwm9G9R/Lr3GR6ZoA8x03xJPF+zrql1fOU1TSNNutNucH5luYA0OT7kqrf8AAq9L8PWxsfD2mW0hw0FrFG2fVUAP8q8R+INsunXvjrwuzKkHiO70q/tIx/G09zHBcD65jDEf7de1eK7oWHhbWLskgW9nNKSP9lCf6UAcF4X+I6ReA/D11fRXeq+INZEslpp1ooaedfNbDckBEVduXYgAD8K6LQpPHGoXKz6zBoei2JAYWkLveXA9Q0nyIPwVvrWH8BfB0Xh/wRpOpXcz3ms39hbmS5k5MUIQGOCMfwooPQdWyT14s6h431fWdUu9L+HWk2+pvaMYrnVr6YxWEEo/5ZqVBaVh/EEGFyMmgD0OiuHstM+IUwSTUvEvh+2bA3RWekSOo9cM82f0rtYFdYY1mcSShQGcLtDHucdvpQA+iiigAooooA5Xxl/yMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6PGX/ACMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6APNG8DX/i3wT8IL+zs9G1C10fTIZbmx1SRkjuA9tEAOIpBwRnlfStPTvCV/wCDvh2bLU7m3d7jxRp93FbWrM0FlG+o222CIsASq49B16evcf8ACuPA/wD0Jvhv/wAFcH/xNS2ngHwdZ3UN1Z+E/D8FzA6yRSxadCjxupyGVguQQQCCKAOlooooAKKKKACiiigBsjbI2bDNtBOFGSfpXIX/AMRvD+mSFNW/tWxYf899KuQp99wjK4/GuxooA4b/AIS74deLIkjn1fw1qQbhYLuWJn+mx+R+VJJ8KvBkjGaz0t7Fn5D6deTWowfQROox+GK6fWPD+ja0hTWNJ0/UEP8ADdWySj/x4GuTufhP4bi82Tw8dR8NXb4/faNeSW44ORmMExsPYqaAOv8AD+j2Xh/RbPSdKiMNjaRiKGMuXKqOgySSfxrjYW/sP433ETbUtvE2lrKpJ5a6tW2sB9YpVP8A2zrT+Gut3+p6Xe6dr7o+v6LdNYXzqgQTEANHMFHQSRsjY9SR2rP+L8ZsrLQPEsbGNtB1WC5mcDJFtIfJnH02SFj/ALtADvhtKb/xL8QNRY5B1oWSD0WC3iX/ANCLVT1vxba6F8RtcudUuXTS9N0a1BjQFme4mml2oiD7zsI1AA5NWvgmiSeD7vUkYN/aur6hfbh0YNcyBSPbaq1j+H/DdnrPxz8Ya9qCGdtKNnbWcbcxpJ9nDtLjoXAkwD2yfXgA1rT/AIT/AMTbLl57PwhpjkPHbiAXl+y8/wCsLfuoyRg7QrkdCa7mwt3tbVIpLma6cdZZtu5j77QB+QrlPGXi+6stSi8P+FbBNV8T3EfmCKRykFnGTjzrhxyq56KPmbGB61RtfCfjS7dpdd+IFzEHw32bSNOggjiPcB5Fkdh7kigD0GisvQdKl0m2eKbVdR1NmOfMvWQsPpsRR+lalABRRRQAVyvxY/5JZ4y/7At7/wCiHrqq5X4sf8ks8Zf9gW9/9EPQAeMv+Rj8Cf8AYak/9N15XMaz4VTxtpHxS8PPObf7bqsKpLjOx1sbF1JHcblGR6V0/jL/AJGPwJ/2GpP/AE3XlWtU8FeFdXv5b7VfDWiX17LjzLi5sIpZHwABlmUk4AA+gFAEPhJPFUSQW/iOHRY4Le3EfmWM8srzyDA34ZEEa4B+X5+T1GOY/hP/AMks8G/9gWy/9EJR/wAK48D/APQm+G//AAVwf/E10tpbQWdpDa2cMUFtCixxRRIFSNAMBVA4AAAAAoAlooooAKKKKACua1nxFJpXjfw/pM8a/YtYjuI45QDlLiNQ4Unphk349196k1Dw7cz3MtzY+ItYsZnJIVHjkjXPbZIjDH0xXM+JfCPizWL3w8ZNb0qeDStUh1Hzms3hnITIZPlcqdyswPC9aAOkvteex8eaZotwUFvqlnNJbH+LzoWUuv4pID/wA1peIdXtdB0S91S/Yi2tYjI2Oreij1JOAB6kVxfxdJsNR8C63GgLWWvwwSP/AHIrhHgY/TLpUvxPkOoa74J8NKfl1HVBeXCkZV4LVTMVI9DIIR+NAHY3OopY6HLqepqbaOC3NxcLncYwq7mHHXGDVK68RW+meEP7f10fYYEt1uJUPzMm4DCDuXJIUAdWOBXPfGOZpND0bRgCV1vWbTT5SDgiLf5sn5pEw/GqUT/8J/8AEIsPn8LeF7jC/wB291Id/dYB9PnbvtoA6nRtTvIPDk+teK2i05WVrp4HIC2UIGQrt3YAZY9MkgcAZk8H63P4i0s6m9hLZWU75s1m4llh7SMv8G7qF64wTgnA5LxbF/wm/wAQLbwnJ82gaRFHqWrp2uJWY/Zrdv8AZyjSMOQcIK9KoAKKKKACiiigAooooAK5X4sf8ks8Zf8AYFvf/RD11Vcr8WP+SWeMv+wLe/8Aoh6AOqooooA5Xxl/yMfgT/sNSf8ApuvK6quV8Zf8jH4E/wCw1J/6bryuqoAKKKKACst9ZhXxRFogGbh7N70nPRQ6oPzLH8q1K8505heftAa1IhJGn+H7a2cZ4DSTySfyVaAPRqKKwfH16+m+BfEd9E2yS2025mVvQrExB/SgDT0jULfVtMtr+yYtbXCCSNiMZU9DVuuY+F0Jt/hn4TiZQrJpNoGHXnyVz+tZ3j/U72+1Cz8HeH7h7fVNSjaW7vIjhrCyBw8o9JGPyJ7kt/CaAKerXl14+1W60LRbiW28NWkhh1XUYW2vcuPvWsDDoO0jjp90c5I6XVtW0DwL4etzdvBp2nQ7ba2t4k5duixRRqMsx7KoJpt3Pofw+8FlxGtloulwBEiiGTjoqKOrOzEAd2ZvU1h+CPDd5e6kPGHjKIHxDOp+yWbHfHpMDdIo/wDpoRjzH6k5Awo5AOf8V6Z4t+JmhXVq2l2vhnR5oJFibUJZHvpN0eATHE6pGDkgq7P05XtXXfCDVotc+GHhi+ghECPYxx+WBgKUGwge2VOPbFY3xGv7rxFrdr4A0OeSGS8j+06zdxHBtLHOCgPaSU5UdSBuOOhrp77V9D8IafZ6crQQbEjgstPhZRI4yERI1JGcnAHb3oAg8VeCtN8Sa/4c1i93rd6Hcm4gKYw+R91vbIVh7irXj3TLjWvBet6VZY8++s5bVckD76lTyfYmue1T4j6bo/jqTQdZvtLsoEtPtIla53OxLBRGU/hYZ3d8gjHQ4yND+Ldnd6PrF9cXOjzNpckkbW9vd4nuljcAzRxtztYH5V5yeN3OaANT4p3M2meHNC8OaPctp51q+g0VbpG2tbQlWLlD/f2IVX3YHtXaaJpNjoek2mmaTbR2tjaxiOGGMYCqP5nuSeSSSaxdROgeM9KvtI1i3fy1RZZ7a7RoJIh1WQE4IwQcOp4IPOQa85s/iDqHg3U7zS7u6fxZouns3mXKhv7TsoETc01wgXbJGMqBISjPyQH60Ae3UVFaXMN5aQ3VrKk1vOiyRyIcq6sMgg+hBqWgAooooAKKKKAOV8Zf8jH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+jxl/wAjH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+gDqqKKKACiiigDB8c67/wjPha91YIrtBsVVboWd1Qfqwrerzf48P5nhPSdNz82qa5p9mo9SbhX/khP4V6RQAVn22q29zrd/pkRzPZRRSy+3mb9o/8cP51oV5z8Pw83xR+Jt0xyn2qxtk56bLVSRj6uT+NAHo1FFFABRRXE/FzVb2x8Lw2Gjzm31XW7yHSLW4Az5DSk7pPqsayN9QKAMvwncf2n8Y/E+p6Ggk0P7BBY3t0BhJb+GR/lQ/xbY32sR0IAr0HUrG31PTrqxvolmtLmJoZY26MjDBH5Gq/h/R7Dw5oVlpWlwrb6fZRCKJPRQOpPcnkk9ySTXE+PfiFBpvgaXX9F1LT0AmeKETkSG7VH2yGEK3LAByOCPl5AHNAHb+HtHsvD+h2OkaXEYrKziWGFCckKBjk9z71Q0XSZNE/4SC7Y/ari/vJL0KowSPLRET8AgFcFq/xOig8U6ZFb3epW2jXNnJcXEt1ok/yKjJtkQ7Adr7yCxBAwvTPO7oHxFtr6yvtQuY430K3vntBrFtIptyARh2BbcijIUtyMjPCnNAEPwKS3uvBQ11pkuda1mZ7vVZud63GcGEg8qIxhAvYD3r0WvFfiZqGk+FdbtvEPhvUpdJ1G+uTa3c1tD9ps72YR70hmhDKDK2QFkBUqCdzgcV3Xw+8V3muC+0zxFYR6X4m0wot7aRyiRGV1DJLGe6NyO+CpBJxkgHYUUUUAFFFFABXK/Fj/klnjL/sC3v/AKIeuqrlfix/ySzxl/2Bb3/0Q9AB4y/5GPwJ/wBhqT/03XldVXK+Mv8AkY/An/Yak/8ATdeV1VABRRRQAUUVHJPFHNFE8irJLnYpPLYGTigCSiiigDjtT+G3hm+u5LxLO4sL5wf9J068mtJAT3zGwBP1BrCjOufD/wAR6HbX+v3eueFtUnXTlbUVRrqzuWBMRMqgeYjkFTuGQSvJya7/AErVLfU2vhbbs2ly1rJn++oBP/oQrlfjfbNcfCnxHJHIIprO2+3wyf3ZIGEykfigFAFn4vaLc6/8N9csdODG/EIubUKOWmhdZUA9yyAfjXKfDvXbf4jfEW48W6Ys39i6ZpaadbtKhXNzMwlnxnuirGh9ycZFepaZdC+020u1UoLiJJQp6jcAcfrUlvbw20ZS3ijiQsW2xqFGSck4HcmgDl/iP4SuPF2nabFY6vLo97YXyXkN3FEJGUhHRgATjJWRsHscGtrw1odh4a0Ky0fR4BBY2keyNOp65LE92JJJPckmtOigDifEPgSW616817w14g1Dw9rV3CkVxJAkc8M+zhDJFIpBKgkAgqcGs2U/FPQyXQeG/FVpGv3FD6ddSH2JLxevXFbd34702LxNLpMGJ47SIyaheI48q0YnEcRxndK7ZAQfNx7gHodH1K31fTob6zLmCXO3ehRhgkEEHkHINAHLeF/iNpWsaqNG1GC70HxFgn+zNTTypJAO8TcrKvBwVJOBnArtaw/F/hXR/F2kmw1y0WeMHfFIPllgcdHjccow9R9DkZFcl4N17VfDniSPwV40umu5pUZ9G1dxj7fEo+aOT/psg6/3hz16gHpNFFFABRRRQAVyvxY/5JZ4y/7At7/6Ieuqrlfix/ySzxl/2Bb3/wBEPQB1VFFFAHK+Mv8AkY/An/Yak/8ATdeV1Vcr4y/5GPwJ/wBhqT/03XlSeKNc1/S76KLRvCdzrds0YZ54b6CHY2SNu2RgTwAc9OaAOmorgD438SRjE/w418OOSIrqzkGPYiXmm/8ACwtW/wCid+Lv++Lb/wCPUAeg15j8KyNR+IHxO1ofx6pDpg9hbQhSPzcmry/EDVmYAfDvxbk8crbAf+jq5H4bTeOfDOkarEfh9d3F5qOq3WovJLqlrEuZXyM/MzZwADx2oA9urgfj1qcelfCDxTLJIqGeze0Tccbml/dgD/vqomtviXrnE99oXhW1YA/6GjahdDnkbnCRjjvtauc8Q/DC0kOrST/b9Vnt9Nmc6pq0xuLiaVlfbFFkbIlXGSY1UnKjIwcgHpP22x8LeCku7+dE0/TLBWklXkbEQcjHXOOAOvFZHww0q7j0+78Q67EY9e1+Rbu4jbrbRAYhtx7Ih5/2mc964Tw+f+Es0f4aeEY0zpVto1lrWrjHyuiIot4T2IaVS5HpF716L8UvEM3hb4f61rFoAbqCHbAW+6sjsI0Zv9kMwJ9gaAMBF/4T34iPI+H8M+FbjYi9Vu9SA5b3WEHA/wBtj/druPEesWnh7QNQ1fUX2WljA88hHXCjOB6k9APU18x6lqkmgTav4C1LxlNoMNrFJaWUdqIUSVmjMguLidwWJlbeG2lSjsOMHNQ+CtS8XeOj4TtPEepW99o3im7VpbchtyW+nncwKZ2KJHA3H7zHHbAAB7P4Gh/4RnwpLrniW7trLxP4muEuLiS4GQk0pCwQAZBKxqUXGf7xyM1xcdtfeONV8ReGZtUS10/UJJ5oNVjtsPrJhIQRoxzsjt5AAdpy4GUIG4nofix4ptriCbRntES11Vv7FtdTu4V+zrO8gScbycjbHuIyAGZCASRW98ONCFpPIE1SbUNI0dn0/SRJEqmOPCB8uP8AWbSPLDccKQcnJoAd4P8AAh0q5ivJYdO0yeGxazjj0pBjc+wyzs7LlnJRcZBwM5LE5rL1fwP4d1a2HhH+1LW6ure7/tQ21xGs86oz73WRhh1V3JO7KtzgHAxWv8Vta1KCDSvDfhqcW/iDxBM1vDcYz9lhUbpp8eqrgD/aYVlW/wAEPCmn26SaK+q6ZrafN/bFvfSfaXfOSz5JR9x6grg5PSgDzbxFb3umeJ73TdRE9xfXSrp2i2FzqTNd2sbuGjlimIxNE0oIdJMuqIM7lyK9I+Gvg8ySNq/iCPzdajnnin1KK5J/tcMQN8igAeUAoCRZKLg4A4rznxBHrkHxJttG+IMel6rbTqGt2dfs0d/KwWASxEqyi4VCx8piAGOUIDCvpO1t4rW2it7dFjhjUKiKoAAHoBQB5roLyfDjxVB4bvJCfCerSldEmc5+xTnJNkzf3W5aPPPBXnAr0+sbxh4es/FXhy+0fUQwguUwJE4eJxykinsysAw9xWN8LdfvdZ0Cez13A8QaPcNp2ogDAeRMbZQP7siFXBxj5iB0oA7KiiigAooooA5Xxl/yMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6PGX/ACMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6AOqorn/FbeKlNofCUeiSD5/tA1OSVPTbsMYP8AtZyPSsH7d8ToeZND8JXA6Yi1SdD9fmh6e1AHfUV58db+JCHafBmhyf7Sa4wB/Aw5pP7e+JH/AEJGjf8Ag9/+00AU/iaRqHxL+GejEblN/cam/ovkQHaT/wACcV6dXjl7o/xH1Tx7pHif+xfDdm+n2c9qltPqksgzIRliyw9cAcY/GugOlfEvVQUv/EegaFFkc6VYvcysO43zttH12GgDudT1Gy0qzkvNUvLaytI/vz3Eqxov1ZiAK80+BOr2muXPjzULa6ime51+WRVUnP2fy0SF8HsyoWB6EVavfhZp6ol1vu9c14yKi6nrk/2t7VC4LPHGw8pWUA7dqDBx16Unw70+LSPip8Q7KFWWN0024j3uWZlMLoSWJJPzRtyfWgD0yimTSxwRNJNIkcajLO5AAHua5HUvif4G06Qx3fizRVkBwUS7Ryp9CFJxQB2NedfFJvL8VfDh3OIv7dKk9txtpgtbmi/ELwfrcyw6X4m0i5nb7sS3SCRvopOT+Vc3+0QZbf4dLqlnEX1DS9Ssr2zbjbHKJ1UFv9nDkHH96gDo/iDa6pqOlrY6XHp7RuRNcfbpjHHLGjKxhO0E4cZBbGAOoOcV5X8PdBfxbquq61PBJoN7rlqXuLV7ON4zYzECNrWZT8rsikSFhklgSowpNjxprWt+K9GuxeeC9dW8s4biC3/sXU45fJunjKgybXjlAAOCpXaQxJDcVJ8PPFWj+DxPbatbeLoUS3t4bZ9T0m6kkVVTDRqVQgIGGQB69wBgA6/xbqXgfwJq2l32saiul6jMgsbb98xZoiAoUgkhYlIDZOFDDJOSc8N48+H9holhpN1o0jDTDNukntYTdXV0STJEssQwl3Cr/vG3ZfapwepqLTNX0698deMda1XwP4i8RW+ovbwafIdDZ1+zpEAyATBVQb9xIOM9ay9a8DeMNTtpbDwLoOo+GNCuS7tZ6lqcPkxuwK7okQyPGCHkDx/dYNwAQDQBsfCnTE8WajJr0U+jzWGpQzx3emQh5YrGKQgN5ILDynnKs7qRnBXIyOfQPHHhGaOLTtd8FwQ2viHQ4ilrCoCR3dv1e0fttbGVJ+62CMcmuNubzXdDtJI9f+IXgjwkzMrPHpdoJJHKqqcCeQ4IVFHCHpXPTaz8P9VknjvNf8d+Pnb5Xtbb7SYS3oqQrFHz+NAHqlv8WvBZ8PWmq3+uWdh58e42dxIPtMTg4aNohl9ysCpAB5HFQP8AEe71IOvhDwb4h1g7A8dxcQjT7ZwfSScqx/BDXD2fi5PC0mnReE/g/NpMupTiytpr7yNPMkhUsFdvmbJCnAY84wOa6zzfi/qTAx23g7RIT1E0k91KP++dq0AelWrSvawvcxrFOyAyRq24I2OQDgZwe+KlrmvBWmeJdOiu28V+IYdZmmZWiWGxW2S3AHKjBJcE85bmuloAK5X4sf8AJLPGX/YFvf8A0Q9dVXK/Fj/klnjL/sC3v/oh6ADxl/yMfgT/ALDUn/puvK6quV8Zf8jH4E/7DUn/AKbryuqoAKKKKACuL8W3Pk/ETwJDuA8+W9GPXFuTXaV5x44dj8Y/hnEBkY1OQ8dMW6jP/j/60Aej0UUUAcH8Jbg3K+MZCQceJL6MY/2Sq/0qt8Xgdbl8O+DI+V129D3oH/PlBiWbntuIjT/gdR/A+QyWfjMkAY8VakOP+uoP9am8MZ1v4veLNXYbrfR7eDRLZgeN5Ann/HLRL/wGgD0IAKAAAAOgFcr408c6Z4WmtrJ47rUdbuxm10qwj824mH97b0VBzlmIHB64xT/iT4rXwd4UuNSSD7VfO6W1jajrcXEh2xoPx5PsDVT4b+DB4as5r7VJft/inUiJtT1BxlpHP/LNT/DGvRVGBgdKAMZbH4meJwsl9qmm+DLJiGFpYxC+u9vdXlfEan0KKa8j+JunNp/iaLw54f8AGPjPU9cjH2zUbmfWGEdnEBu2BUCgMw6Z+6CDzkV7V8YvH8XgXw4zWqC6168Vk0+0AyWYDmRh/cTOSfoO9eY/D/wxdaNBY25RtU8XazN/aOrXNzxFHKFEscMjZyVUssrKvLFVBwCMAGxYaBZeFNM0bQ7dn/t26RrlbWzTL2YK5ldB3uGB2LI5GBkjaA2ekMtxpt9psV9eLpdtp6pc3FrbSt9n0+2GVjiYjHnTSt8vORw21c4LNsJBpfiO4jsg2q6pGzQQB2Aa5unCm4uZSB+7jRfLT0AG1RkgHFu9Rj0/Sp9XmuDqevXty81g8u2OGFP9WLx1IxGoVXKl9xCjC5y2QD0zQfFNpqskscsbWMguDbRR3LorzMEDlVAOdwB5XquDnBBxV+JXhb/hLPC81rbv9n1a2YXem3Y4a3uk5jcHtzwfYmuc+E3h6zvLe08WTTxXzSQtHpZXJS2t2JLFQeRJIcl2PzHOD3Fem0Ac38OvEg8W+DNL1ho/JuJ4ytzCRgxToSkiYPPDqw+mK6SvOPAA/sT4k+OfDu3Zb3EsWu2ilskidSs2B2Hmxk/8Cr0egAooooAK5X4sf8ks8Zf9gW9/9EPXVVyvxY/5JZ4y/wCwLe/+iHoA6qiiigDlfGX/ACMfgT/sNSf+m68qLxj4R1HxDqMU9n4u1vRLdIhG1vp5jUOck78spIPIH0FS+Mv+Rj8Cf9hqT/03XldVQB5j/wAKv1b/AKKV4y/8CIv/AIij/hVupKcx/EnxsCfvbruNhn2Hl8V6dXOah4YkuZnktvEOvWJYk7YLhGUZ9BIjYoA5QfDLWkIaH4l+Lg3fzJInGPoUrk9K07xz/wALD1zwq3xI1K0nt4Ir3TpbjT7ecXVuw2uSCByr/KcH3r0W88EX94jJL458Vxq3XyJLaM/gRDkVxHjzwI/g2xs/G3h+91vVtd0CX7RO2pX8lzJc2RBE0IBO1cKSwwB0PXigDdbTPi3pg3WniHwxrgXql9YSWrMPYxsQD+GKwPEPxO8TaVdWdprmijQNUBkQW9w6SWOqZHAhu8YjlGNwR8A52sQSCPYdE1S01vR7LU9OlEtneQrPE47qwyPx9qNZ0qx1vTLjTtWtIbyxuF2SwzLuVh/nkHsaAPk/4W6p4g05PGKeGLV2k0+2kgNrMZYLtZWci2BjxJvMYBRVwiDJBJzmvQ9R8M+MvFt9f+HNYvpLHSr3SIxPKpmvAbguWIDMqLEx2jcNrKF+VcE5rnPGXhy9+GniCxvIrx4beAldE16TJ8rv/Z1+erwMBtSQ8px2Hy/Q/hLXIPEvhjStatUaOG/to7hUY5KblB2n3HT8KAMHSPh1oNhcaROumadEbC1eIW9tbKkLSuFDyle5wpA3ZOGPPNcN4U8O6Nov7QfiO60q0s7Gz03REMywQrEqSTSbs4UYwEj9O5617bXkPh9AfiH8Yr6e7FnBtsbb7SybhCqWmWbHtvz6UAYGvLrOneLoba9s9P8AFGg6bZ3GqiMEW6xi6kKASq25ZFUedtA5Kk5yQM+46Np0Gk6VaafZxJDbW0axRxp91QBwB7V4h4S0TTpfHWs2ek+Kp7jS4r2wgtrCS8W7W5hiiMrIWIaQxqZDgbgoIwcjAr3ugDxG98Q6inxv8QanYeGdS1+30ixh0lGspIwIHf8AfSZV2GScoMjoFx3rpD8V1gYLqPgfxzZ+rnSfNQf8CjZqb8FFMl18Qbx/vzeKbyMH/ZjCIP5GvTKAPJPFXxK+GviLQ7nQ/FV5cWltepseG/0+4gZT2IZo8BgcEHPBFTfBv4h6dqmjy6Nq/iPTLzWNLuWshcC5QG/iGDHOozk7lIB/2g1eqMAwIYAg9QawdY8F+GNa/wCQt4d0i8YAgNPZxuwz6EjI/CgDfrzjVceGfjPpd+gK2Pim2bT7nGAou4AXhdvdo/MT/gK0N8HfDVsHPh241vw3I53M2j6nNCD/AMAJZPw21leKPh540vbayjtPGNvqi6ffwahZpq9iqSxyREkDz4cZBBIJMZOCaAPXKK4D/hOdb0ptvirwRq9sm8qLrSWXUoSB/EQmJVH1jrV8PfEPwj4ilEOk+ILCW5Jx9mkk8mfPp5T4f9KAOqooooA5Xxl/yMfgT/sNSf8ApuvKNN/5Kn4h/wCwLpn/AKPv6PGX/Ix+BP8AsNSf+m68o03/AJKn4h/7Aumf+j7+gCTxp4L03xf9j/tSfUofsm/y/sV5Jb53bc7tpGfujGenPrXL/wDCkfB55Ya0SepOrXGT7/fr06igDzFvgd4JYfvLfVXcfddtVuSV+nz0H4IeDjn5dZ/8G1x/8XXd6zoOm60F/tG280oMK6u0bAezKQaxJfh7oUmQX1lUJztXWbsDnr/y1oA8p+LHw/sfBeiadr2mav4mh061v4V1VU1efcbVzsLLyfmUsp47Zrs4vhjfwxLLoXxJ8Yxo4DIbm7jvEII4xvXp+NaSfB3wJ5sss+gR3c0iMhkvbiW6YAjBIMrNg+45B5FUPgtf3mmLqvgPXJml1Lw44S3mc83Ni/MEnuQPkOOm0CgChrFv8UdA024imu7bxhpskbRyyWSDTtTiUjG+LBMbMo5AxkkDFeQv4itNU8daXqPjG91GXRZo20q81S1mksGhkyDGl3GhBidWDgqSUO5mU4BA+u68z+K3w9OtGXXvDkFt/wAJCkJhntpx/o+qwd7eccA9tr9VIHIwCoBwnjrwt4D8NrqF7F4etdTOlvCtxJqup3EpmkcBxBChZt8pjO7pjkdeSJYri5fxboMHhbwzoej6PqULz2ltdyRIsm1VaOVlt0JUMC2ELncRkgFSDwnw61PQ9N8XPeHUrnRIdJVUP22FS1qjCTzreUlCXuVK+XG4G5o/l5xtHpvhzxZrq+ItTs/DfgCc6fGsc9tbPFb6WzwuzgSOHO7hlcLhRkHLYNAGfY3Oi6rretSfETw9pR8OGZLS31GGOOfT4bgIPNPnlFljBZlAY/IG3Luz1zPEngzwfqHwf8Rat4Wutb0mO2spJm01dRn8k7QWTfFITuRtoKnGCCCKW68Yad4g0Jb3xppk9sqvM9raTKqafqMMcj4topoztkfagISQkNIqleCCMHXvE+v3nhS78G+fbSXV5GlhZ2004MsFmpExubuTAXCxAxMR0KPnJoA+hdN1LQX1b+0HvYodUGlRz3fz7UEBY7XkP3eGWQAk5Hzds1zlx8XLTUbiW08BaHqni25jJVprNBDZqw/ha4kwufpmvCPDMuk+ItWtNL8QanLN4cmWS4e3CyJc6xcgrHC7qMYjLMfKiyAFj55yT9daRYx6ZpVpYwhBHbxLENiBBwMZCjgfQUAeBa/4s+Muq+J7zQtG03R9PntLeG6uI7KVJZ1jlJAAeYhC42t2x79Kq3Gh3M+5/Hfh74ra0pGHhW/hlh98RW8i4H516T4Kb7X8Z/iNcj7lvHp1kp9SInkb/wBGAV6TQB8vWVx4D8JeO9M1e38I3+l6FPbPa6hDq+iTZsmT5orhWdG+8SUbDehI717v4f8AH3g3WEhi0XxHo0zMMJAlyivj/rmSGH5V1VYWueD/AA3rwP8AbWg6XfMRjfcWqOw+jEZH4UAZvxY0KbxB4C1S3sCy6pboL2wkUDclzCRJGVz0JZQPoTWv4O1yHxN4U0jW7cBY7+1juNgOdhZQSv1ByPwrk4fhJoemMjeFdR17w2ytv26dqDmJj/tRS74yPbbVDwz4X8bfD/SINK8O3WieINFtzJIlvfK9lcruYuUWRN6HljjKLjOOgoA9Torz7/hZR0wY8X+FvEOhbE3yXAtvttqn/bWAvj/gQFdJ4c8X+HfEq50DW9P1BsZKQTqzr9VzuH4igDdrlfix/wAks8Zf9gW9/wDRD11Vcr8WP+SWeMv+wLe/+iHoAPGX/Ix+BP8AsNSf+m68rqq5Xxl/yMfgT/sNSf8ApuvK6o0AFFc3e6V4kJY2HiaKLP3RcackuP8AvlkrIvfD/j25CrF47sbRe5g0FSx+heVh+lAHd15f4hvLW/8Aj54Ntba5hln0/T9QlnjjkDNFvESjcP4c1Zm+F39quW8V+L/FGsxuu2S1+1i0tnHvHAqfzrD8N+GNC8N/Hu203w5pVtp9taeGHlfyU5dpLpVUsxyzHCNySTQB7HRRRQB85eB/iba+Cbzxvp+raZeObrxFqEmlSQjcL+czBTbj+64JQ5PGGJ7c+kfAQS3Hw+TWbtFS+1y9utUuFXorySthR7BVUfhXjOpG5tdM8RX8CLvtvEGvJGz/AHRcLJDcRr9WWB1HqcAckV9A/Ci1Sy+GPhOCLO1dLtjyMZJiUk/mTQBx3xE09/GHxd8NeG1v77T4tKsJtckns2VXEhcQxYLKy5B8w8g962/+EF8QRjbb/EbxII+wlhtJG/76MVVvCcn2z45+Pnfk2Njptqh9FdZZCPzOa7karby6rc6XbMXvYIRNJ8pKR7shQzDoTgnHXAz6UAeHah4YjHjiPS9KurzWNVeaOO+1fVZPPdQA0mwYAARMcRrjLN82QK62whe58Q32l+Gbh99oPsUl/uDm2DESXE7Ho08jEKB2KFiMDBZY+E9W0q6tdNgluLjULiKSa71ry9oSWZ/30obJ+cIqRxr1AOTwDkttQhsdH1C20cC2hkElzPLENws9PiBjjA3ceZIIztHPLMxzjBAKhuI7HQNZg0G0jiutRRiZjE7NDbYMMBkz8zyyuCVyed5YnA54a2s18c/FK08HWUrz+HtJiFzrl2BgX8qHZ5SkY/cgqIwoAG1Xx6np9Xjmjg8P+FvD6SpfSyBr+7kYvKlyIQFXd3MakEtgqoVRjJAHZap8J9BubXTn0yS90bWdOtVtLTVNOnaKZEXoGGdrqT1DA5BIyM0AQ/CVk0zXvHXhZCBHpeq/areNVCrFBdIJlRQOAAxkHFekV83aZ4z1nwR8Z9TtfHNnJd6hdaNFBA+k2xd9YkjlbypFjHCOUZwwyFBQ4wMV6ZD4o+Ic1u9yvw8tYkB+W3n16NZ3HY4WMoD7FqAGeKh/Zfxt8E6ikZxqlne6RPJ2G0LPGPxKPXpFeE/EzxTrVwfCNzqHgvxHpUula3b393MsSXcEduodJfngZj9188qM4r1Xw3418M+JlU6Drmn3rsM+VHMPNX/ejPzL9CBQB0NFFFABXK/Fj/klnjL/ALAt7/6Ieuqrlfix/wAks8Zf9gW9/wDRD0AdVRRRQByvjL/kY/An/Yak/wDTdeV1Vcr4y/5GPwJ/2GpP/TdeV1VADZU8yJ03Mm4EblOCPce9eO+N73xFoOriw0nx/eXmpzJvt9Gj0KC9udmcbmKGMIuT9+QqvB5r2Ss/SdHsNJa7ext0jlu5TPczHl5nP8TseTgcDPQAAYFAHnPhPw98T9Siim8a+L4dOiPLWWk2cPmkejTMpCn12g+zV6hDbrHaJbszzIqbCZTvLjGPmJ65rz3Vfiet9fzaV8PNIn8ValE2yWeFxFYWx/6aXB+UkA52rknBHBrNvPA/iTXrSa9+JPjSa2sI0Ms2m6ETaWyIBlg8p/eSLgZOcUAV/hHdP4d8Ta14HScSadpeoTR2sYGTHFKi3EQLZ/hBlXH0r2KvBfgLoVhYg63Y2LaZpV/Pc6rbq5fZDaKBDAHdycsymWQknoa7C7+KQ1Oea2+H2h3XiiSFist6ki22nxEfezcPwxAIOEDZHegDuPEei2PiLQr3R9WgE9jeRGKVD6HuD2IOCD2IBr558K69448OW2oeCEh+0W/ha+t45byzG69WwZ9yyLAVKyr5Y2kD5huHBxXVy+OvG6XG1/EHwlhYni2k1SbzPpuz1/4DWJ4gbx7YeNz4xm0zSfDrzWKaNI6znUjfu0mYzbwoEJkzwA5AwOTgGgDZf4yQadZeIZrrUld7Pf8A2Zb3unTW816pVSkjkgAJuLJkKOF3HFJ4L1TTL+x+KWp3tzHe6XJqUZuJ9MfzEkjEEQfYf4lHzAgZJGQM5Aqu8fxUaDA1nxI0zfeWTQdL8oj0wLjd+ZPenfCu31C4tfidYa1LcHVUvIp5CLRIJQ32dGQ+UjOo+4MAMc/jQAvw+uNJfx/enTPD8+mu2uziO/fTvsqCEWkY+z/MFYMxG8IQOmeuM+614h8PbrV4fHuoWer67pZvZtYea60W1gXK7rONxMGcmQKDtXoMnP0r2a3vrS4kEdvdQSuQWCpIGOAdpOAex4+tAHh3gHx/aeFb3xrYXuieIrr/AIqfUZftNhpz3EA3SA7d6/xDjI7ZFdY3xv8AB8PN+dZsVHVrnSbhQPrhDXAaVr/irw1418f6d4dg017Y6493ILnTr64fdNEjDBt0KgYA4PJ5ra/4Wz4o0tWfWNO8PXKjgRpJeac5PpuuYAgPsXH1oA7Kx+M/w7vceT4r09c/89i0P/oYFddo+v6PrS7tH1awv1Izm1uEl4/4CTXn2k/EbwR4juobLxDp8Wl39wSsUer28ZiuDxnypxuikGSBw2T6Uz4kfCHwjeeE9ZudI8OWVlrUNpNNZzWKG3ZZlQlMbMA844IoA9XorxXwV4G1e68H6JrXhLx94h0t76xgufs16yahbxl0VmUJIMgZJ/irc/tr4leGiTrnh/TvFFgp5udDlMFyqAcs0EvDsf7qNQB2eu+K9B8P3lrba7qtpp0tyCYTdP5SPjqA5wufbOaj1HR/DHjG0Vr+x0jW4ACqvJHHOF/3W5x+FYnhvxn4K+J2mz6fbzWl9uUi50u+iCzJjqGibrg9xkA964HV/gZZ+H72XU/Bdit1CSXOmtfS2dxGcH/j3ukYEc4wkoZevK0AeiWHw80/R5Y28OalrWjxJ0toL1pbcn/rlLvUfQYrsbdXSCNJZPNkVQGfGNxxycDpXlvw8866uXttL8Y+IkuLRs3mi+IoIpbqEHpliquVPGHDMp7E816rQByvjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0eMv+Rj8Cf9hqT/03XlGm/wDJU/EP/YF0z/0ff0AdVRRRQB578UrXSLeGK8vdb8SabezN5dvb6HdSefeOBkIkIDBzgddvA5JArkdB+HvjnV71rjVfGninRdFYYSykvopr5uvzNLGgSPIx8q78ete0m0tzerdmGM3SoYllKjcEJyVB7AkD8q4zxP8AES3sdTl0Twzp1z4m8Rp9+ysSBHbk5x9omPyRDg8HLdOOaAOi8OeHrHw/btHZtdzSSY824u7mS4llI7s7kn8sCvLvitqFlZ/E3wvd6Lq1rHr80VzpV1BDKpn8kxmVCVHKhZIx1/vGtU+CPGHi7954+8TtYWLf8wbw8TBHj0knb53yOCBgZ6Vxw8F6KPiNNpvgfQ4ILTwvYsJ5oQDLNfXS+WitK2WYRxsznngnGKAPfdPuPtdhbXIXb50SybfTIBxWR4Zv5ZtR1/TrmXzZbC8whPXypEWRAfpuZfoorbtYEtraGCIYjiQIufQDArz5bh/DXxluUv5gbDxXaxizZuBFc2ykNF/wNHDAnqVI9KAOR+JPw/sdR+NHh2eC4uLM6zBcS3K28jRg3FqqmCc4IyymQf8AfI65OfVtM8L6fY6h/aDNcXep8g3lzKWkKkY2cYGwdlxgEk9ea5vxi2z4vfDpj0ePU4h9TDG38kNeg0AeWfHfw+158P8AWJFvJrbSbDTprr7LAEVWniXdBj5chQ3JAIztX3ryXxFZXHiL4m+LNNhstklw9kurXEIA8+L7PE0dnGVwQ0824u2RhY8nhTn6J+JVoL/4d+J7UgnzdMuVAHr5TY/WvGdMtLXwd8DdC1O/1eS0vtS/4nVzfRzgXVxO0LPHHHuVtxIKoeDhQx9wAbfhFtb8Qaxe3NzosOmaTqV5HpokiuvtH2aGyyPJjVVACtIs37zOBnGM4r2+vGvhNbaRoWh6VrH/AAkN1c6RHZR28jXN27wQXshzKNpAEfzHB3dC2OD19ds723vLaGe3kDRTDKFgVLfgcHtQB4T4D8ZappmteOb+28G65rVvfa/cBLuw8tl2RBYlXBYHI2n25+tdd/wuK0gONU8HeN9Ox1abR2ZfwZCc1yfwd8PeNb3wLbajo3jWDS7W7urucWUmjRz7GNxIDmQuGOSM9sZx2rsp9Z+IXhYNLrejWXinS1+9PoYaG8RQOWNvISJD6BGz7UALZfG/wBcTmCfXfsFyOsV/bS25H4uoH613Oka1peswiXSNSsr+LGd9rOsox9VJrI8OeIPDHj/S3n06S01KGM7JoJ4h5kDc5WSNxlTweo5xxmvLNF+FPhG/+JXjjTb7SFt/IktL+wks5HtmijmiZWCeWQNoeN+MY5oA96qpq17/AGbptxeG2uroQrvMNrH5kr+yr3PtXnY8A+LNBw/g/wAe6hJGpz9h8QRi+if0XzBtkRfoTVIfFu58M66NC+JWitpt4Lf7V/aGmM13aPEDtMjADzIl3cfMDjuQCKAOg0z4veBNQnNuPElnaXKsUeC/3Wjow6qRKFwa19U8K+FPFSLeXuk6XqLPgrdrGpk47rKvzD8DWT4l8F+E/iLaW+rwtbyXJX/RtXsGjdivTaThkkTqCrhh14FcAPB9h4O1DzvEui/2fbkBF8TeFpZrFEGOt1bRtiLocuA0fPOwUAe06Lo9to0DQWUl0bfgJHPcPMIwOylySPzrG+LH/JLPGX/YFvf/AEQ9bmhwJb6XbpFfT6hCVDR3E0iyM6kZB3AAMMd6w/ix/wAks8Zf9gW9/wDRD0AHjL/kY/An/Yak/wDTdeV01ysj28iwSCKUqQjldwU9jjv9K5nxl/yMfgT/ALDUn/puvK6o+1AHj/jTxd478JzJFcXfgm8mnyLSzVLtby6x2SBPMLH3HA7kCtLwtc/FTX44ptct/D/hi0cZMaxvdXf5bwi599xHpXZeH/C+maHdXd7bxGbVLxt11fznfPN6Av2UYACDCgDgCud8SfE7S9P1SXRfD9pd+JvEScNYaYu8QnJH76X7kQyMHJyPSgDvEBVFDMWIABYjGfevK9E1Dzv2gvEpEJcRWdppgkzwn7uS4b6/eQfjUV9pfxE1+0mvvFPiWy8GaNEjTS2mjr5twsYGT5ly/CsBnlARxWV+zlpUlvayag73cqakZ9UVr599wI5ZBHbmRv4mMcLNnp89AHuFFefav8VtEi1SXSvDltqHijV4jtlt9Gh85ICenmykiNBkYPzZB6iqf/CZ/ERTvf4WSeTnJC6/bNIB67cYz7ZoA8x1Dwdd69q/xP0q9vVXw3pN9c6u9hFuWS8up7cSR+YwI/doQCAOp69Bj3f4Zzm6+HHhSdsFpdJtHOPUwqa8R1jVvE03jDxJqdjpV54S0bXLa0sb6+1m0DypOm9ALeBGY3DsrBVABz+Ar1D9n+8a8+D/AIb8xWSW2ga0kRxhlaJ2jwR2Py9KAPMfGur694Z8d/FTxN4d1q3sl0gaZJc2FzaiWK9DwhVBbIZDngbTz39R7J8MYb5fCkN7q8SxX+pOb6ZQMMGkAOG56gYGOMAKO2T4f8SNCk1b9pez0Sd7hdO1dLO/u0WZlhmgtllLLInRuUABJ+Xt14+m1IYAqQQeQRQAtZN5oFhPpl5YwQrZpdt5kj2qqjF8g7+mCcgdQa1qiu7iKztZrm5cRwQo0kjnoqgZJ/IUActpvhSy0TxDLrk92Db29n9mtln/AOXfc7STytIx+Z5GKkscfd966Wxv7S/iMljcw3MYOC8Thxn6ivnXxt428UeKteOneGdNgm/st/MvJYBDc3UCvhgkNrK4WR1TAZtpO5io24ObnhDSNA8eX76brfxC8Y3eoxf8fGgahN/Z0mcZKtCACwA5+UnHrQBvanf2/iX44WcWkTx3H2CS3hmeFw+zyVnllJx0AM0KZP8AE5HUHHtNeH/FfwRpngrw1pWu+BI4PDN/pV5BA17bJnNvLKsbiVT/AK4AsrYfJ46iul/4TjxX4eBh8YeCr+8CYUah4cAu4pf9rySRJGB3B3dDzQB6XXPeI/BXhnxKWbXtC06+lYbfOlgUyge0mNw/A1j6P8WfBGqXLWq6/bWd6hAe21ENZyKx/h2yhcn6Zq7408IDxPFFcafr2r6JqCJiK7026ZVYc4Dx52SLznkZ9CKAMsfDZdOO7wr4o8R6JtGEgF59st1/7Zzh/wBCKv6db+O9OmSO7v8AQdbtF+9I0EllOf8AvkuhP4CvL5Lz4neBLhx4n8UJcaVGD5Wp3Gki6s254E5iKTQf7xDr/tCvS/C+teLbqC0k1LTNB1CznAZdR0XUi0ToejBHQcfR2oA7SMsyKXXaxAyuc4PpXL/Fj/klnjL/ALAt7/6Ieuqrlfix/wAks8Zf9gW9/wDRD0AdVRRRQByvjL/kY/An/Yak/wDTdeV1Vcr4y/5GPwJ/2GpP/TdeV1VABXOeK/C0XilorbVry5/sVRmbT4HMS3Tekrj5ig/uAgE/e3cAdHRQBX0+ytdNs4bPT7aC1tIV2xwwRhEQegUcAV5L+0P4ktIdOsvCs+oLYwamDcapcbsNDp8ZBkC9y8hxGoHUkivX5pUhieWZ1SNFLMzHAUDkkmvlHRluvHnxAuvHkkC3N1fXh07wpaTjMSiLO67kU/8ALOEfPjvI2ODigDc1271XxZNb6dfaUy2scaHTvCCyNFFbwgZjm1FkyxO1d62yAsQvThjWTr/w/v8AxRFjWfFqXNrb/KtgkJtrS0VeAsUUTlQAOASAxA55r3Wy+HWl2elwW8cszXgYyXd3IFdr6RmDM84Iw7buVPVOApUcVT+JNlYeGPhz4m1O2a5jmt9NnELSXMkm2RkKoRuY87iv07UAeK2/wI02yjiluLK7uYWYAGGBsy55wAXdgMdwg/3h1r0TwdpXiW8tPC3hu/0m8tIfC+omebU7wqElhjEiwRwgMTISkihm4VdpGWPFei/DdLqP4eeGV1CaWa8/sy2M0krFnZzEpbJPJ5z15ra1K/s9Ls5bzUrqC0tIxl5p5BGij3Y8CgCzXzn4k8RT6Z4y+Lh0Jr2TVZktTDHZOqvCYLM+ZPKzDakQ3oB/E7LtUGvfdC1jT9f0qDU9Gu4rywn3eXPEcq+1ipx9CCPwrz/wJpVpefEn4k3siF0bULaBoycxvstYj8yngkMSR6ZoA4bRPhrfR654WvIr+Y6dcE30r6LaqkdrMYVjjm82YO8rtzuLZOSWwvNW9U8OeKdMXx3d6LqviC2NxH59rIdOgmmvJPLEb4Maq0bF1XGMfL8+Dya99ooA8B+Hmqan4Y+OWq6J4jS2jbWrK2Bktp5biH7VFF8qB3G5CyBz5bE4AXBIIr30gMCCAQeCDXl/xG06x0nxL4EuNPtoYLi78So0+xcecWtplLt6sBgZ+leo0AeeeNfhbo2tWtzLpNrZ2GoSDLoYQ1pdkc7biEcNn/nouJF4KsMV574E8YT+ANWTR9bluY/CrTCykiv5PMm0C6IysLyfx2zjmKXptxnG1q+ha4n4j+Bo/FEBurL7NFrCQNb/AOkoXt7yAnJt7hRyUJ5DD5kb5l7ggGr4A0d/D/hKw0p2DLab44iG3fut7eXz/uba6GvnDwvr3if4cah/Y9rYX2qaVENzeHLpt2oWaYOWs5Pu3kAwcbfmAwCqcmvb/BfjDQ/Gmlfb/D18l1Ep2yx/dkhb+66HlT169e2RzQB5v4E8D6D4k0bxHpusWI+0aT4jv47S7hYxXNrmQSoY5Vwy8SKcZweMg1vx6h4o8A/L4hafxN4XTGNUgizfWaZxmeJR++QDGZEG7hiVPWur8P6RJpmt+I7naq2+o3cd0gU/xeRHGxI9cpW9QBjNZaN4jTTNYh+z3RixNZX9u4LKD12OOqsOCOh7itmsvSNCsdHur2XTIzbR3j+dLAhxF5n8TqvRWb+LHU8nnJOpQByvjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0eMv+Rj8Cf9hqT/03XlGm/wDJU/EP/YF0z/0ff0AdVRRRQBT1exGp6fLZtcXNsko2vJbSGOTb3AYcrkcZGCOxB5qPQdF0zw/psWn6JY29jZx/dihQKM9yfUnuTye9aFFAHO/ELxRB4O8H6lrdwvmNbx4hhHWaZjtjjHfliBx2yaz/AITeGJvDHhCGPUm83W7+RtQ1OY9ZLmU7n/LhR7LXNeIyPG3xk0vw+uH0jwsqatfjqHu2yLeM+4GXr1egArm/G3g3TPGVrawauZwtrI00DwPseOUoVWRW6hlzuBHQgV0lNlkSKJ5JXVI0BZmY4CgdST6UAeEan4g1C18S+D9J8WyI3iXQ9chj+1KoRdQs7mOWBbhF7Esyq6jIVvYjHvNeX/Hvwvba74LPiC1VTrPh0f2rYzrzuEeJGQ+qsE/MKfY+j6Xew6lptpfWrB7e6hSeNh3VgCD+RoAmmjSaJ4pVDRupVlPcHqK+ZPh54Xv/ABDrUOhajeTWthpOnXehXMtnmaaTy59hSR3Urbb4wm0LyyqcMOMfT1edaIT4b+MGtaZIdlj4lgXVLPPC/aYlWO4QepK+U/50AcwnwrupPh7qmkyw3x1e5mnWGaXWpzGElkMivKobaWXjcApyy5GetZPjvwjrOlPda/DrV3YQWejF1k1u4F9suvM3LFC2RIrgrkOCcllGCMrX0FTJoo5k2TRpIvo65HTH9TQB5n+z3eXF54R1dr63Nldprl6JtP7WTtJvMIPcDfnI4+avT68G8H/Ezw74Q8U+PtO16S9toj4gnnF2LWSW3TMcSlS6A7TuU8EYwRzXrHh/xt4X8Q7RoniDS72RukcVyhk/FM7h+IoAwvHPw7h1nUF8QeG7ttB8XwD91qMC/LOP+ec6dJEOAOeRgdQMHlNP8avoPjNdQ+J2m3HhzUGsl01r2ONptNuSJSyMky52HlztfGAeTXtNZniC9lsLLzV02bULbkXEcOGdY8HJCH7/APujk9gelAFrTr+01Oziu9Nure7tJRmOaCQSI49QwODXBeK4jB8avAl2qZW6s9RspG+ixyKP/HWp3/CvNBuI11vwFdyeG765RZY7vSuLeYYO3zbc/u5F5zggH3BpdJ1WXVfE2kaZ4ttYdN8V6W8lxD5ZJt7+MxNG8lux5Iw4JQ/MvfI5IAupfDr+y7+bV/h3eJ4d1RzvltAhbT7w8cSwAgKeMb02sMk81seFvFh1K9k0bXbF9H8RwqXezkbek6DH72CTpJHyM9GU8MBxnqqq32n2l81s13Akr20omhcj5o3HdT1HBI9wSOhoAfZWlvY2yW9lDHBbpnbHGu1VycnAHTk1znxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9AB4y/5GPwJ/2GpP/TdeV1Vcr4y/5GPwJ/2GpP8A03XldVQBy3irw7qHiW5FncatNYeHwo86CxYx3F2c5KvL1SPHBCfM2T8wHB1/D2g6V4c0yPTtC0+2sLKPpFAgUE4xk9yTjknJPetKo7meK1t5bi4dY4YkMjuxwFUDJJ/CgDyT4/6/bta2XhCS+Sxg1JTdavdFiPsunRkeYeOcyHEagZySRjmuM8Ua9feJUt7Oewu7HQ5IkFl4Ys5Raz3Vv91JdQnzi2gI+VY85YtgZIBrmtBS98d+NLzxxd24uptXvDZeGdMuCfJcQ5/0mZR1ihHzEfxOccEjPvOnfDiLTTDJa6ncvdSOZdQuZsmW6lIw0oYEFCRxs+aPaFG3gGgDxDUvCvjzULBLK31yx0jR1BVNP0GVrC3iB6hlKB2z1JYsSSaxbL4Kul7bvearexTu4VJkeV5Hf/pmxRBkdeN59q9i+M2nr4K+F+r6ho05Oo7oYbXzIIeZHmQZwECk7S3UYq/48tLy48RxWOpa1qdxb3CK8VjbRyWtqi42N5jQgyzszEnywyjA5wOSActbfEuxuoPAJ1Zrq617S7iVdTtYoS7pMtvNCd2cAOWIO3qN2TgVY+G/iC+t7/xrplq8Gk2ttf3OsTG5X7TNBbTw+YvlpEShKyBiRuP93BPTQsILLw+jRaR4XtJ9aMShDqJjhMEXdjGgYQQDBPzFS3A+Y81na59q8PfEjwl4h1GSzdNWT+yW8+VZdp5kt5I4YgAAG3ouC3+sGWyc0AVodNh8TfGGZ7+9vr5dK0PT7S5kntgS7zSGY+aigLGCq/MGyBn8K9p8L3FvLYzQWsN3CLaZ4mW6Yu24ncSHyQw+bsTjpxjFeYeC449T8ZfEDV7oQtDd6wmnT2l2xKPFBaoSqxgHfKM/dOR97Hv6JpV3qD30H2m4t4bFLfzCrQeS028/LhGbdHs4U7s7i3QYoA6OuD+M2vRaF4NuZpQrKFaZ0LY3rGN23P8AtP5af8DrvK8e+LitrPjTwvoQMbQXOpWscsbjOY4y1zKPxEUI/GgDoPBnw70mPwFpWneJ9KstS1Aobm8kuoFdzcynfKwYjIO4kZGOAK5/4gfCWC6sBNpQutRitlzFp9zclpocYw1ndNmSGQYyEZmiJABVfvD2GigD550jxHea94X1PwF4svRfHV9PnTQdXlj8t7t0BBgmU/duYnC5U8kjnnBb3jQJri40LTp75DHdyW0bzIequVBYfnmvOvil8OY9Yiu7zTrM3Udy6zX2nRyiF5JVGEuraQ8RXKjjJ+WRflfsRyfg74qan4Xg+z+M3n1jw/A4gOvR27Jc2LZwIr+3PzxuOm7HzcEF8k0Ae3a5oela9aG11vTbPULc/wDLO6hWRR7gMDg+9eH/AAU8DapafDzT7/wv4hvNJ1qCa5t7q0uCbmwuXiuJE+eEnKEhFBaNlIHY17vpmoWeq2EF9pl1Dd2c674p4XDo49QRXO/DzT5dLttdtpY3RDrN3PFuXAKSv5oK+2XI/A0AV9E8ZzR6lBonjPTxomtTHZA4k8yzvjyP3E2B8xxny3Cvz0I5qzY+DLXRNZN/4XlbS45pN93p8YzaXGeCwj6RycfeTGf4g1b2s6VYa3pk+n6vaQ3llOu2SGZAysPp6g8g9QRkVS8N6XeaNHLZy38l9p6Y+yPcEtcRr3R3P+sA4wx+bHByRkgG1XK/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9AHVUUUUAcr4y/wCRj8Cf9hqT/wBN15XVVyvjL/kY/An/AGGpP/TdeV1VABRRRQB5p8f9SuovBEehaTJs1XxHdxaRbkZyokP7xuOwQMCe2aT4SaJaR3V9qVmgGm2C/wBg6R3At4DiWQEcEyTByT3Ea81gfF3UHh+Knh+YEMmgaHqWtiM/dLiPYhI9iOK9N8BaUNE8FaHp20q9vZxrID1Mm0FyfcsSfxoA3q8n/aKLal4e0DwpExDeI9YtrKXHUQht7t+G1fzr1ivKPimy2/xd+E13dHFit3fQMe3nSQBYh/31mgDu/GPiLTvBvhS/1vUzssrGLdsQDLHoqKPUkhR9a8z8MfD+/wDH81v4p+LG6fzP3th4eDEW1kh+6ZF43yY65+hz0W78ZIxrfj74aeFpjus7zUZtQuY+zi2j3qrD+6SxHpxXrdAHMar4p8K+DZtP0i/v7HSvNX9xbhdiRpnG47RtjTJxubC54zmvH/BnxFXT9S8dwaFax6zrd54hu541Fwsdvb2kaRp9pnmOVSIbTg9WxgetelaRFDpnxP8AEmm38Ucp1+3j1C3lkXJkSJRDLASeoQlGC46TN715Zonw7udP1y88Oy2lu8l7cz67qKQnZBIpnZLKF9pDeUu2WTC52sUOGC4oAztd+K+sojTz/ESO2aM7Z00Lwu1zbRHqMTTsCwIwQwGCDketavhL4v6xe3MEGi+JvDvi6Zly2n31s+jXsrkgKkLMWhc85xnNdgfAlzrbRTX1oqMDsW4MoE0QJzuUxkAoc5+RkU5P7tTmsXVfhBa/a2jl0661SE48wl1WIj8X3cdeAxyOM0AP17xnpvi7xh8OmtFuLO/s9bkhvdOvU8q4tZDbvgOnoR0YZB9c5A9zr5U8TaZqml6t4evobSS68Q6Jq9lFp018THJdWN15ixwysfmJSWN4w7hThgSozX0n4U8QWXibRo9QsN6fM0U9vKu2W2mU4eKRf4XU5BH4jIINAGxRRRQBmeIdB0vxFYfYtasoruDcHUNkNG46OjDDIw7MpBHY1454w+H+qeHNTXxBo19fSSRYH9r2sYfULePbjFzGMLfQ8DOQJhgHMmK92ooA84+HfxG/tq6t9E8SR21nr0sPn2strJvs9UiA5ltnPX1KH5l/A49HrxHx74QQ63rGj6STAbiwk8Q6UUOGsNRgkUM0R/hWXem4dMhj1NeoeA9cPiXwVoetOqrJfWcU8ir0V2UFgPocigDeooooA5Xxl/yMfgT/ALDUn/puvKNN/wCSp+If+wLpn/o+/o8Zf8jH4E/7DUn/AKbryjTf+Sp+If8AsC6Z/wCj7+gDqqKKKACquq38Gl6XeahdtttrSF55W9ERSxP5CrVecftFX7ad8FvFMyNtaS3W347iSRYyPyY0AV/2fNPuP+EMn8SamoGqeJruTVZiOdqOf3SA+gQAgdt1en1n+HrBNK0DTNPiUJHaW0UCqOwVAoH6VoUAFcp4h/4qDW4fDyHdYQhbrVCOjLn93Af98jcw/urj+IVfbXftGu/2ZpMH2toHAvp922K2GM7c4O6Q8fIOgOSRxnR07TrbTluBaR7DcTNcSsSSXkbqxJ+gA9AABwBQBYmiSeGSKZFeORSrKwyGB4INcF8F55LTw5d+F712a/8ADV0+msX4Z4B81u+PRomT8jWt4l8b6bpF4dLslk1jxEwzFpNjh5jnGDIfuxJyCXcgY6Z6V5DpXiu70v4jyeJZbh9R0+TGn+Jr21VRptgSwFskUhw0rRMzCR+QBJk7eAAD6IrjfiloV9qmh2+o6CoPiHRbgahp4zjzXUEPCT6SIWT6kHtXZUUAZPhTXrLxR4dsNZ0xi1rdxh1B+8h6MjejKwKkeoNa1eZXTf8ACuPGkl42U8H+IbkeecfJp1+3HmH+7FMcAk8B8HIDV6bQB4n8N/DPhvxJqfxCtde06yvL+LxNduVkGJViZY9hyMNtPOO3WtLX/gf4QuPMu1Z7MJGRm4EdxFGo7/vlYgD2YVN4I0GxuvGPxCtNRtA7w6yl3DICUdPNtomJV1IYZxzg849q9BstEtbWKeIvdXUUwAdLy4e4XA7AOTigDxJPAH/CKDTEj1W+XR9Ru4bWPUNA1W4tJYpJTiNjA8kkLpu2glcYznaR07S81Pxf4DDTaxPH4s8Ox5ee4ihEOo2ceT87Rr8kyKAMlQrdTg4qte2djD4+u08xYvDfhtDr13EB8kV08bhFA9AiySkDgMynvS6B4Kl8SaIPFOo3VzpfjHUmF7bX8BzJYRkfubfafleMJjfGwwzFycHBAB0Xg7VLSG+fTre5im06/wB2oaRcIwMc0T/M8aEDGUYk4/usPQ4n+J3h8+IfCN2lo3k6tZg3mm3S/fguYwSjA9sn5T6hiK8cS7vNB1eKybQ45rabUhb6rotrcCL7Ff7TJFd2DsylUmUMyoSvzArkMSK7/XNZ1/x1Zy6D4a0fWNCtblTFfaxqlt9nMERHzLBGTueQjI3YCr1yTigDs/A2uHxL4N0TWmQRvf2cVw6DorMoLAewOa3K8l+Fbt4V8RzeESph0yeGSaxgMjOtvPCwS4iQv8xRg8Uy56eY47V61QAVyvxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9AB4y/5GPwJ/2GpP/TdeV1Vcr4y/5GPwJ/2GpP8A03XldVQAV5d+0Df3Uvhew8K6U+3U/FF4mmow/wCWcJ5mc+wQYPs1eo14L8WNUaP4sXFzEzrL4e8K3N1auvVLu5k8hMeh5XmgDsfhHpFk7XWuWMarpsSf2Poy8HZZQMVL5wMmWVWckjJASvSazPDGkxaD4c0vSbfHlWNtHbggYztUDP44z+NadAHkvxnH9t+M/hz4TX5ku9UOp3K9jFarv2t7MWx+FdN8YPEZ8K+BL3VFu1tjG8a8f62UFgDHEcHEjDIBIIHUjAyOcvSD+1BpoujiNfC0htc95ftPzge+yovG8X/CTfHjwh4eufn07SLGXxBLCfuySb/KiJ/3W5H1NAHm1l4OvvFkBvPGVwYLQybxosE5t7K3kPQ3dyxLTTdcqu5weCVzgb+q2XhdvDM3hew1TUdQubpY7ZryCDy44pkwYQrLHucx4UrChOAozjqe8k+HE9xqTwJeW2k+Hofkt7fToy11IhAJDXEmTGN275YgPdjWX4U8EeHm8V+K9I1zS0vNQgnivLG4uHZpFtHGYxCxO5NjrIrFSMkAknNAHlvwq8YXtik858OXGt+L9Yv727QQXCxDfhYiWjB/dR7hy77e+M44fP431mxktTf+IfhramOOAR2q3NxOYfKYvsZ4VZeXOTgn7oGeppPAPgW8s7CPw9cabcRX8qf2lrVvHhjM7yOLe1dsgbUjQymN2CyF8Eg4rtJvhtBrseI9I+yrMQNxhCwsw4PmRupIIAAy0e7p+8frQBq6B8W9WaEzX+kaZr9hGge4vvCd+LxoMnA32rhZQOpJ5wO1Z76lp3iD41fD3XNH1G3vtM1BtSmgkhJHzLaRJtYEAqw+b5TyM1zX/CobTR9W+0QveWlzblnF1psBha3IU8iXaqj8WC9jxms1Xm0n4geF/GP9nyXWqWuoT6frEVhFtW9L2pkW9ii/vPCWZgo+ZoyF9SAfVlFVtNvrXU9Ptr7T547izuY1liljOVdSMgg1ZoAK5vxP4N0vX7hL1xLZavGnlxalZkJOqZzsY4KyRnvG4ZDnpXSUUAfO9zoviD4V6k99pUljY28zKHKKY9Iv2JxiaPJNjMeAHUmEnaDsztr13wL43sPFi3VssM+na3YkJf6VdjbPbN9P4kPUOOCCOnSumureG7tZra7hjnt5kMcsUqhkdSMFWB4IIOCDXgHi3Q7nwpc6ncaNOx1Lwhax6vpM0jkvJpjM4msJm6vGvlvsJyQCoyMEkA+hKKq6VfQ6npdnf2pJt7qFJ4yeu1lDD9DVqgArlfix/wAks8Zf9gW9/wDRD11Vcr8WP+SWeMv+wLe/+iHoA6qiiigDlfGX/Ix+BP8AsNSf+m68rqq5Xxl/yMfgT/sNSf8ApuvK6qgAooooA+dvi9I7/FDxWedsXg+K3GTwBJeqD+ma+ia+ePi/btH8UPEzHhJ/Bnnqc94bxWIx9BmvocEEAjkGgArjPi54Pbxr4LudPtJfs+q27readcZx5VzHyhz2zypPYNmuzooA+cdI8dR+Kfix8Mbi/i+xa7a/2lpmrWMgw9vcCEYOOu1yDjtwRnivom1uYLqIyWs0c0Yd4y0bBgGVirDI7hgQR2IIr5J/am0bxXovjK18Y2dlZQ2sJ2xatpsTpMhPCrcZZhuA4DgDOcegHr/7Kl0bn4JaKrMGaGa5QnOTkzu3Pv8ANQB0vxQQWUWg+IlIWTR9ThZ3xyYJj5Eq/TEgb/gArN8RCIfEPX7W4lNumo+FsLJu2/6qWUOVJ7qJlPtkVp/GnP8AwrLW2XqixSfTbKhz+lZfxGibxH4osfDkXhvRtcS0tv7SuBqcrRBFZzGixuqthmKvkEYIXB60AQfAG5ZPDVxpWW8m0FrcQJ2ijuLWKbyx9HaTjsCB0q98a7+WHw5bWEE80H22SVpmhkMbmGG3lncBxyufKVcjBwxrd8C6FeaPa6hc6xJbvq2p3Ru7kW2fKi+RY0iQkAlURFGSBk5OBnAp/EzRLrVNPsbrT7JdQuLCZ2ezMgjNzBJE8M0asSAGKSErkgZUZIzmgDyP4k3N/aaPHeJcg6rB4X0y9W5lw2J4L2NhI2eOrsTnsTXR+FtR1HX9Tl1XR4ItD8dwxI2p6XPuWy1mDACyjI3IwyNr43x5CSKwIrKtdGOvaB4k025vNTk1+38Px2lja3mlNZyi3jdnRiCzLK5kVVLKQuVHy85PPWPjvSE1Twlr9lLM720oee3itpXkjhnVkkixty2GaI8ffk3vlvlFAHs0PxO0a12w+KbfUPDd/na0Oo27BCe5SZA0TrnuG/AVsQ+O/CU8Yki8UaGynoRfxf8AxVY8XizxPaRpea34LuV02Yb1/s64F1dW4zwJocKc45PlmTHTHeqcvjD4a3V0/wDaL6XBdg4ddSsDbyA+4lQGgDoJPiD4Oifa/ivQQ3p/aEX/AMVUFz8SvBNvA8r+KtGZV/hiu0kc+wVSWJ9gDS6X4g8C3AWDTNU8Nt3EUM8OR/wEGulhtbVGWWCCBTjKuiAfkRQBx3g+1udc8San4t1K0ms4Li3XT9NtrhCkq2ysWaSRTyrSOQQpwQqLnkkDH+AF6lj4SPg6/l26/wCHZZbW6t3BVvL81jFIoPVGQrgjivUa4H4p+F7y+jtfE3hceX4t0UGW1K8C8i6vayequM49G5BGTQB31FYvgzxHZeLfC+na5ppP2a8iD7G+9G3Rkb3VgVPuK2qAOV8Zf8jH4E/7DUn/AKbryjTf+Sp+If8AsC6Z/wCj7+jxl/yMfgT/ALDUn/puvKNN/wCSp+If+wLpn/o+/oA6qiiigAryr9phl/4VbJC4JWfULOMjPbz1PP5V6rXlf7TgZfg7qtzGu5rSe1uOmek8f+NAHqlYHiy+u1W00rSXMepakzRpNtz9niUZkm9MqCAAerMvUZqfVNcS2uNPtLOBru+vSGjhU7QsQxvlc/wqoI+pIA5NYWoapaaNeeKPFOpkPb6dElnEIxmQgAOyKO7PJIqgdyFoAvajqeg+ANCtYJWeOMny7a2hRprm7lPJCIoLSOxOSfUkkjk1lT6X4k8WXEp1i8m8PeH1YhLGyk23d0oP3ppwf3SkD7keGweX7VRsxa+DtJu/HHj+UN4hukCuF/eG2Vj+7srZfrgHHLtlmOANvH+KNU8QeMr2HR9YtZIEuU8xfCem3B+0SRn+PUboAC3hx/AvzNuwNxGKAJr+80K50u80Pwc0GgeANPy2u6/bEIk2ODbwydZJG4DSAk84BJYCui0rw0/i7T7ewutMk0DwBbR+XbaMuYZ78Y4ecLgxx85EedzH5nI+6ebg1JtUtfhhbR2WlW8ha6kjsoIW+xRXMLCKOQR5BKqS7KCQc4OQea9l0DSk0jTxbiZ7iV3aaaeQANLIxyzEDgZJ6DgDA7UAcf8ADPUbvSry68Da/O82p6TGJLG6lPzX9iTiOT3dP9W/uAed1eg1yHxF8NXWs2dpqWgyR2/ifSHNxps7/dYkYeF/+mcijafTg9q0fBPia18V6EmoW0b28yO1vd2kv+stLhOJInHZlP5jB6EUAamq6faatptzp+pW8dzZXMZimhkGVdSMEGuC8JaneeDtai8G+J7l57OU40HVZjzcx/8APtK3/PZBwD/GoB6gg+j1k+K9E0/xDoN1p2rWMd9bSKT5LttO4cqVbqrA9GHIoAvQWVtBd3NzDCiXFztM0gHL7Rhc/QcVYrxb4c+M/ES63D4RvNO1q7kgmSeK/wBThRJW05g4DTkN/rFdCocD58AkAnNe00AeK+J1aTw38Vbd1kkuRqtvLdLGpaQ2RjtSTgckeUsvHsRXo8B1SWdNR0LUbHUtHvQsyRzMQFUrwYpUByp4OCD7HHFUPFehC+1ldR8Narb6b4ut4gq723x3MQORFcRA5aPk4YYZScqeoPIeH0lgm1I+GbubwtrFmpudS8M3MH2y1b7xMsCKVba5Jw0TBSeqbsigCP4nW1zPqMV9f6Hdp9oj/s+6t7W4Ba8hDiSJ4JBjbcxSAvGrBd2WVSWIFY/hDx38QNfbVLbw7qfgzU4tNlZPP1ITw3UkI5WaSKMYGRwQACGDKVBGKmm+Jd7rmgpa6vpKT2OrRYtbm1imt5XONyPBHMuyZwQGCLLvOOFJ4pPEfhbTtW+yeKLTVHtLqWNZtP8AGOnoI3U4xsvY1AVlPQuVHA2ttx8wBR1jxB4mtrnT/EeqeHLWdNL1KO+vdX0W9+0W625g8qcGJsSJiJkYjBztBOMV9BwyxzQpLC6yROoZHQ5DA8gg9xXkXwb1u8lm1DwZ4jsbC2u7aNpXs4x+6khc/wCtgGNslu5Y+6E7SCCAu18L55PD+rar4AvpWdtJVbrSnkbLS6c5IQdckxMDGTxwFoA9Grlfix/ySzxl/wBgW9/9EPXVVyvxY/5JZ4y/7At7/wCiHoAPGX/Ix+BP+w1J/wCm68rqq5Xxl/yMfgT/ALDUn/puvK6qgAr5/wDFUC3/AMU/HazfdQaBZ8HnZJdxs38q+gK+f/E062fxV8dmbhWPh65467Eu41P86APoCiiigDy3446RqEEei+N/DsLT6x4Zmad4E63NowxNH9dvI/4FjnFYvg7X9N8Q/tAprGkzrPZap4RSaCToRtutrIR2YEcjtivbK+Efivda38OPijqV3ouiP4WkvbeWJPJuTPC4k+/JA+xNuflO3GVb04AAPu4HIyOlcP40/wCJT438Ia4mFWed9FucDl0mUvHn6Sxr/wB9mrPwen+0/CnwfIev9k2yHnOSsSrn9Kj+Ky40DTbjH/HtrOnS57j/AEqNTj3w1AHM+IVnhvvi2IZ5La4bSre7ikjfY20W8q5DDkcxsMjpXSfCTUbi98LyWt5NNcTabctZieZtzyxhVkjZj3by5EBJ5JBPeue+IlvYa74xNinhvV9XmtLFRqE2l6gtsWhkZiltKrOglRijEgngH/aNdd8PNIvtL0a5n1lI4tV1O7l1C5hjfekDOQFiDYGdqKi57kEigDA+NOu6lpmlWtnol5LY3c0V1ePcRBSyxW0JkKjcCMs5jU8dC1cR8Vp73Qde1HXbSK2n1Cwn0S/MUj+XG7sbq3YFjwoKt948AcnpXa/GTTJriPT9QKXL6dHb3lhfPawGeW3iuYggnEY5cIyqWAycEnBwa4PW7mfxR8P/ABnr1xqWiX15DFpoli0zfOkMdrJ5zyskioSW3ysEIxhQMtzQB0fhDWJILSfXvA1nPd6RJJ5mq+GCVW5sZmG5pLYEgfNnf5eQr53IQSQe90Tx34Y1nKWWtWYuVYq9rcP5FxGw6honw6n6ivGtH8Y6LofjvRda/tmzOn3cE1neTRTCXzE2+bCNq/Mzq+VztZmeSTkDatd5qnijw1e+RN8QPB9xpdvKoa3u9a0+OaHaT8od13iFu+2Tbj68UAemghgCpBB5BFNaWNWwzoD6EgV5rZeEfhTqmZNOt/D9whP/AC6XS7R9AjYFbcPw18DGMeX4Y0aRf7xt1cn8Tk0AdNqGq6fptpJdahf2lpaxjLzTzLGij3YnArgdGspfGlv4v1ySB47HWrL+zNMWZCjSWqpJ+9IPIEjyuQCAdoU966G0+Hvg60uEnt/C+ipMhyrizjJU+o44PvXU0AcB8B9Wh1T4VeHkSQG5sLZLC6iPDwywjYUdeqn5QcHsQe9d/XlnxE0mbwbq7/ELwxbsXjAGvWEI4vbUdZQOnmxjLA9xkH0PpWnX1tqWn219YTJPaXMazQyocq6MMgj6g0AWa5X4sf8AJLPGX/YFvf8A0Q9dVXK/Fj/klnjL/sC3v/oh6AOqooooA5Xxl/yMfgT/ALDUn/puvK6quV8Zf8jH4E/7DUn/AKbryuqoAKKKKAPFfjTpzP8AEfwi+9Uh1qw1HQZWbs0sJMQ/F69K+H2pLq/gfQb9XLmayiZyeofYAwPuGBH4Vxv7SEEsfw5Gt2iK15oF/barD2OY5ADg/Rj+VW/hNq9oZ9T0i0lD2Urf21pTYAD2d0S5AAJ+5KZEI7fL0zQB6PRRUd1PFa201xcSLHBEhkkduiqBkk/hQA28tbe9tJrW8giuLaZSkkUqhldT1BB4IrD8DeEdN8FaRNpehq8entcPcRxO27yt+MqCeSMg4zzzXnVj8WvFeoad/wAJDpnw6vb3wm7N5VxDeIbt4gSPMEGMnODwD+OOam8BfG7SPGPxOufD1g5FjJZRyWcksZjdp1y0sZB7gEe37tuuRQB2nxbgNx8MPFKgZZdOmlHOOUUsP1FVPD8yz/FDWpm5aXRdPdD/ALBkuc/rXUeItOGseH9T0wtsF7ay2249t6Fc/rXmHgDVGbxD4O1C6JX+1/D50uVSCNt5aPlkPofmn46/IaAPX6zdI1zTtXn1CDT7pJp9PuDbXUY+9FIOcEe45B7/AJ1pV8H/APCfa34M+PPifXdEikubWbWbi2ntlVtl0nnMFT/fwMqeoPbGQQD65+I6T6TcaV4vs45JTozOt9DEMtLZSACXAHLFCqSAf7BHU1y9/wCFJ9M1K01jQ4bnxJ4LeQahFotpeLGttKx80TQocJOhbDiNmAVuUBzgepaLqC6tpNpfpbXdqLiMSeRdwtDNGT1V0bkEHj+WRzXEnSdX8AXE83hayfVfC0jNLJokRAnsnJyzWhYhWQ5JMJIwfuHnbQBqaf8AEfwtd3H2W41RNMv8DdZ6ojWcyk9tsoXJ+ma62N0ljV42V43GQynIIrmtJ13wx44tZrWF7S/MJ/0jT7uHE0DA4xJBINynPHI+lZ8vwx8NxySS6LHe6BcSHJk0e7ktR/37U+WR9VoA6TUvD+jaoManpOn3n/XxbJJ/MGuVu/h+NI8y8+H142gX65cWe5n064OQdskGcIDjG6PawznnoZ/7A8Z2D50zxlFexLwkOr6akhI95ITGfxwain0rx9qsL2moa/o2lWznDz6TZyNcle4RpXKxkj+LaxHagDofBevL4m8MWOrC3a1edWEsDMGMUiMUdMjrhlYZ74zW1VDQtJstC0e00vS4RDZWsYiiTJOAO5J5JPUk8kkk1foA8v8ACQ/4RD4t674bxs0rXozrenD+FJwQtzGPqdr44ABNeoV5n8c420zStE8Y26sbjwzqEd1JsGWa1kPlTqPqjZ/4DXpUbrJGrxsGRgGVgcgg96AOX8Zf8jH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+jxl/wAjH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+gDqqKKKACuQ+L+kHXfhf4o09F3SS2ErRj1dF3qP8AvpRXX0hAIIIBB4INAHnfwPuJNc8GWPie9UfbdRt44h8xbZFENgUemWDucd39qs634btItT0w6jq0MOnvrMmqG2lUKZ5liLRpuz0Qo0h4/gHTFc/+zkw0/Q/Evhgsc6Brl1aRr6QltyH8SWrM/aQ1mKzhihMhDwaXeuVXOd84W1jx74lmP/ATQBzsniK68e+Nf7Vt/OH2e1lu9Ht/KDGxs0O177y24e5lPywo3Cj5zkAbvXfhf4NHhHR5vtHlvql6wku5hlnkYZx5kh+aR+WJc9STgAYA5T4PeFpP7G0HWLm3Fs9/CNSuvJYqHIAW0hIzkJHFg7RxuGe1egtrb2PiB7DVozDb3MirYXIX93ISozEzdpNwYgHAIxjJyKAPFPC0U9ne6NagRtqmmWd7bQRMc77y2vBLJEMfxPCwI9Q2e1e0+G/FEGvXDC2tbiK2kiFxaXEoAF1FnBdV+8oBIHzAEggjg14re/2r4n8TePdS0uF59O0nVY/Mis0/0kzwxiPzrVycedEq5KEESByhxkV3nhbXbvxVp1rqGnzWcniXRk2TRISsF/byqGSRD1VJFVWUnO1lZCDtNAHp1ed+M9Mv/C+uSeNfC9pJdl1VNb0uAfNewrwJox3njHQfxrlc5xXcaNqMOraTaX9uHWK5jWRVcYZcjofcdDVygCjomrWOu6RaanpFzHdWF1GJIZozwyn+R7EHkEEHmq/inXbPw5olzqV/LHHHEvyh3C727AZIryjxdd6p8MdQ1Oaxilh8NanqUN7HeQwGaHT5JMR3Czxr83lt/rF2j75wcZ5TxF8QLjxBqkGj+GraLUdP1GFLGLVdS02WK2tLti4ct5iAOWThUAwW4JwaAIfCR8QWfxa1G9m1CPWrGyFtoFxO8JVw8heYqjKSG8ougJYZIPXIyfdK4v4YeB18C6RJptveTy2SyEwxOysACBucnaDvZgWIyQM4HTJ7SgDN1XQtM1UH7dZRSSZBEyjZKpHQrIuGU8dQRXB+MNAuI7uxS61CaORJP+JNrxwbjT7k8CGY8CWGThSD1+63JRh6dVbUrG21Kwnsr+FJ7WdCkkb9GBoA8X0CW2kMula3ZJFoPiG7l03UdOzldL1dcs3lHqI5sCRCPuuVYYL8Q+FfEreBo9a0fxjdy2+ntePby38Jw1pdMu7zCvJEcyFZgwBCuZQ2MVDr9nNBHq0Ud5JcXOoaZPcJIfmlF9pk4aLce7+WUUt1bywT1q/8X9AvPFGl6f4n0DRUv5PIhuAqFZTPFjeoeFh87KWO3BOVZ1xyKAJ9U0j+xL7QNZLifT7KcXFte6btCyxuDvULyI96nJVf3UmMgRuV3W/iVMum/EXwH4rspN0RkGn3LKw2yW1wyorH1CyPG341S+HelQWtpZafYB38C+KrI3VrbO5ZtLu8B2iQsM7T8zL1KtGfWpdR8M3OreAvEfhG+CSeINNgkfSnGVZkJEkLrnsZIwp5O0jB6DIB7JXK/Fj/AJJZ4y/7At7/AOiHq/4K1+DxT4T0nXLXHl3tuspUHPlvjDofdWDKfcVQ+LH/ACSzxl/2Bb3/ANEPQAeMv+Rj8Cf9hqT/ANN15XVVyvjL/kY/An/Yak/9N15XVUAFfPfxltHtvibqjxsQdV8JzNCMfentJhcAfiqYr6EryL9oBotFm8F+LplTydH1ZYbpmGcWtwpjl+oxjjvQB6rp93Ff2FteWzboLiJZY29VYAg/kasVxHwmuvK8PzeHp5fMvPD8x08kkZeADdbycdmhKH6g+ldvQAVz3jrwfo3jfQJtI8QWont35RxxJC+OHRuzD8j0ORxWtq2o2mkaXd6jqMywWVpE000rdERRkn8hXltr8dtFC211rGgeJdH0S7I+z6teWOLZwfukspJAPUcGgDvfAPh3/hE/B+maEJ/tK2EZhWXbtLruJBI7HBGfesv4wuIvAN1Kf+Wd3ZPkdsXcRzUXw++JGkeNte8S6bpc0Uh0i5WOOSNwyzxFR+8U9xvDjjjG0960Pilpz6r8O/ENrErPN9jeWJVGSzoN6gf8CUUAU/CIH/CxPHrd/Oshn2+zLx+p/Ou1rzzwbqME3xC1O4hYmHxBo9lq9uexCho3A+gaE/8AAq9CZgqlmICgZJJ4FAENld29/apc2U8c9u+dskbBlODg8j0II/CuG8apDoXjHTtfvEVtE1KD+xNV3jKIGbNvI/bbvZ4yTx+9HYV8ufAH40TeDPEM1hr0kj+GtRnaR8kubORj/rF7lT/EPxHPB+17u2sdb0iW3uUhvdOvYSrrkOksbD26gg9aAPFT4Ui8DeJLKTX7eeTwnp0iT2F7punozIUDbBfOimUiMEBWX5SAC/PX2PQ9e0jX7bz9E1Oy1CHHLW0yyAfXB4+hrjbbU9R+HaCy8Qi61HwrHkW2sIplls4wOI7pR8xUAYEwB4xvwfmOteeEfBfjCKPVDpul3/n/ALxNQsyFeT3E0ZDH86ANG88G+GL2Zpb3w5o1xKxyzy2MTMT7krWXP8MfBssvmx6Fb2sv9+yd7U/nEy1EfBOo2G4+HfGGuWeSMQ3zLfwgegEo3j8HpVl+IVg7eba+GtZhXgGGaaxlb3wwkX8M0AVbvRvEnhFGvfDmqXuvabFl5tG1N/OmZep+z3B+feB0WQuG6ZXrXaaNqdrrOkWWpWEnmWl3Cs8TEYJVhkZHY88jtXH3M/j/AFyBrOLTNM8NJJlJb5r43k0anIzFGqKu70LNgeh6V12haXa6Ho1jpenqVtLOFYIgxydqjAye59TQBckRZEZJFV0YFWVhkEHsRXmXwlZ/DeveI/ANwW8nTJBfaUWP3rGYkhRnkiN9yE+4Fen15j8UgfD/AI18E+MIgVjjuzo2oEADNvc8Izn+6koU/wDAqAPTq5X4sf8AJLPGX/YFvf8A0Q9dVXK/Fj/klnjL/sC3v/oh6AOqooooA5Xxl/yMfgT/ALDUn/puvK6quV8Zf8jH4E/7DUn/AKbryuqoAKKKKAMfxlo6+IPCWs6Q4BF9aS24ycYLIQD+Bwa+YvhhLfaP4Z8J7b427PJJ/YV9djEVvebitzptzjpFMU3IeCDgjJXFfWteF+H9O0W08SfEP4d+K4om0a9nXWbRJThfKuGVW2nquyXaAR0JzxQB6f4Y8Y6frWn3clznS7/T2EWo2N4wSSzkI4DHoVPVXHysOQfRnxBcal8MfEzabMkv2jSLoQSRNuDEwttII6/hXkniTS77wZd2i+J7+6FlaobbSfGUUImltI2Py2+oR4xJHnGHIxnB+VjkUPEvxA8V+DLiK68R6RJd6VMoFte2N60umTK4xlmOW2kHIVufQkUAekeA9HsfF3wK8L6bJcXttazaVbxu9lcNBJlYwrjcvUEhsg5B715RqH7MmpaDrNprPgHxKgu7OZZ4ItRjKlWU5GZEGDnoRtArc+FnxA0zS/DFj4f8Nuy2MMbiAXjhpwXdmLq2ArKCxwpAOABnvXokPjq8EDRtZwXF2GTy9jGMS558oqc+XKyglOWjcjAfmgDurF55bK3ku4RBcvGrSxBtwRyOVz3weM15T4+8PTaPNqM8a339gX1yupLc2EBnuNF1Bf8Al5SIAmSJurqASCX4w7Y9E1Ow0vxl4Ve0vY3uNJ1KBWZQzRMyNhhyCGHb+teYat8LvDnhra2mePde8KOclEOsgRH6pJ94fj2oA7L4XeOYvGWn3ccn2f8AtXTmSO7Noxe2l3LlJYXI5VgD8p+ZCCrDgE377wH4Zv8Aw1d6DdaRbPpt1I88yFfmaVySZd3Xfkn5s5HbivOdN1T4kaOjzaHrXh74kaZD/rEikS2vFHoChKHgHrkn0rsfAfxQ0LxbeyaXtutJ8Qwj99pOpRmGdSOu0Hhh9OcckCgDlrfTPiF8Mx5WiZ8beFY+I7O4lEeoWqDsrkYkA9OvQACtjRvjZ4Qu7wWGszXnhvUuhtdbt2tSD0+8fkH4kV6bWfrei6Zrtk1nrWn2l/at1iuYlkX6gEcH3oAzte8LeHfFiW9zqNlb3UiANb3sLFJo+4McyEOv4Gsb/hHfF2h8+HPEy6nbKMCy8QR+YeufluY8OPTLrJXHax4G1r4Y+frvwtmnn0qIma98MXMjSRSp1ZoCclHxzjnOO/Cn1Hwb4ksPF3hnT9d0hy9neR71DfeQ9GVvcEEH3FAHPn4gNpAx420HUdBUdbxR9ssuuB++jGUHvIiV2OnX1pqdnFeabdQXdpKMxzwSCRHHqGBwas1xeqfD3Tzezal4Zubjw1rEh3PcadhY5m5x50B/dycnkkbvRhQB2lFcLaeLtQ0G8h0/x/a29mJX8u31m0J+w3DZ+VXzzA5yPlclScgOTxXdUAZ3iTSYNe8P6npF2M299bSWz+wdSuf1rlfgfqs2q/DLRhen/T7BG066BOSJYGMRz7kKD+Nd3Xmfw5H9i/Ev4g+HiNsM9zFrlt/tC4TEp/CSM/nQB0XjL/kY/An/AGGpP/TdeUab/wAlT8Q/9gXTP/R9/R4y/wCRj8Cf9hqT/wBN15Rpv/JU/EP/AGBdM/8AR9/QB1VFFFABRRRQB47pN1a+Dv2g/Edne3MVpZ+J7CC/tzKwVGniyjqCf4iMsa4TV5J/H/xR1W5htG8Q6R5ctppsNnMIUmjWMxyTrK4xtjMrhT91pZBg4UtXQftc+FRqnhvRNfTykbSbxUuJZULokErKCzKM5UMEyPQmtn4LSRPr3iW+1gQWGsW0kGk/YomEdvbRAFoY7dRwY23blbgtuPAoAh0X4g6z4ZsDpuq6T9rj021MhjmX+z74W0S/M/lNmGfaF5aGUj/ZXOK07nxdrviG1h1CXwteaJ4YszHqMtzqLp9puPLO+OKOFSdhLhMsxAAz9a6f4qaW994UlvbW3E+oaS41C3jIz5mwHzIvcSRGSPH+3VD4VXMGseBJNGnk+0RWO7T95PMtsUDQP/wKB4zn1zQB03hXw/ZeHLC4t9OjeNLm6mvZFdt2JJWLsAcdATgewFeMaZ4StfEPxa8UaG91qGlw6KGubWfTLg208ZuyshAdf4AQ7BemXY45r3u0gW1tIbdGdliRYwztuYgDGSe5964F/DGp6T8ZR4o0uP7Tpes2YstTj3hWtnjGYpgDjcpC7CByCc8joASeHpNU8J+K7Lw1rGtXGt2Opwyyadc3Uai4haEKXikZQBICG3BiAeGBzxjv64gWs2r/ABUW93B7PRbZ4VZQdqyyhSyHPV9uCcdBtzy3Hb0AY+t+GtH1wyHVbGO582HyJAzMA8ed21gDyAeRnoeRUlvodpF9iMrXN01kzvA9zO8pUt3JJ+YgZAJyQCfU1qUUAFFFFABRRWXrWrDT59Oto1Et3fXCxRxZ52jmR/oqgnPrgdxQBwWt28A8d6ZK6Dyv7eltDjgMJ9MJYf8AfSA1o/CjVo7z4R6Y5kkVrGxFtK6jBUxxgZXPsBWX4gd2uNDu327pPGQUY9FjlhH6JVT4W3sei+D7F9VgC6HeQvBLcFSUhljmljIm4+VWUINx4ypBxkUAdN4BtIPEXw60Se/Rg8xW+XadrQy7ywKkdDnOcerDocV0OrxWSa3ot5dTtBcrJJbwEDiUuhJjJ7A7Aw9SoqTw5pen6RpUVvpHNm37xG8wuGz3B9MYqn4+ATwjqV1wGso/tqMf4TERJkf980AcN8OL2XRfib4k8MXEIt4b5Tq0EKnMccwYLOEJ52vuilA4wXf3rr/ix/ySzxl/2Bb3/wBEPXD/ABBeOz+KPw68U2SiS2up/sTyIfvpOhRCfUZdD+AruPix/wAks8Zf9gW9/wDRD0AHjL/kY/An/Yak/wDTdeV1Vcr4y/5GPwJ/2GpP/TdeV1VABXC/HLRTr/wl8T2SRiSUWbTxrjnfHiQY9/lx+Nd1TZY0lieORQ8bgqynkEHqKAPmn4aa5qmlnRZIke91iHSonjiUgNr2lY3AR5OPtVsS42nBIyO+R9EaDrOn6/pFvqekXKXNlOuUkXI6cFSDyrAggqcEEEEA14n8PPDNjrHhfW/AeqXElnrHhHVZF0y/jfE9qkjGS3lQnnnJG3oQAPTFK4GpWuuy6RrUVlpfiq7PzpOuNJ8S4wPMQ4xDdYx2PJGVYEBQDuv2mGlHwO8UG2PzmODOMfd8+Pd/47mtrx34Tm8YeCE0bQ9en0O0mgEe6CBJBJEVACkHBAxj7pFeL+LPiOxs9W8IeMrbVtLN3ayWkdjPbRfKrDCyrKu1WCYyNuQ2O1eheDfiDbJ4ZstO0yQal9htIbZL1gQZSiqpd4hllBweV3ckYBoA8n8F/B/x/wDCjx/p+vaUltrelo3lXi2cu2R7duGzG+MkcMApPKivrOuLTx/ZpbRyXdpNE2S0nlsJV8pTh5Y2H+sVDjeAA6A5ZRWt4v0N/E2hiztta1PSGLrKt3pkwjkOO2cHKnPI70AeV69Zz+Cb2zszPDYJp1zLc+GtSumK2jRy5M2m3LniPPOxm6gJg7kIPqHhnxDY+MNDuWtTJb3Cbra8tZMebay45Rh0PXIIyGGCCQa4S68BfEOyt3i0n4hR6pbMu1rLXdNjmSQejSD5sde1Z2meLte+HEEkXi34eWtnpeQ02p+Fo1e3GBje8XDKAMck9OlAG9q3wU8MyeGtO0/w+kuh6lpZ8yx1W1OLiOXjLOeN+cDIP4YrMt/iF4p8CD7J8UtEmubGM7U8Q6RF5sDL/emjHMZ9cDr0HevSfCninRPFumDUPDmpW9/a9GaJuUPoynlT7EA1tUAc54V8ceGPFiA+Hdcsb58Z8qOQCUD3jOGH4iqF98PNJ+3S6hoEt54c1KRt8k+kyCJZW55khIMUnXkshPvVfxZ8KPBvidjNe6LBbXwO5L2x/wBHnRuzbkxkj/azXGy6t4r+D88P/CTXs/ibwI8ixf2nIubzTsnCmbH+sTJxu6/ThSAdktx490LAurTTfFVmuB5to32G8x3JjcmJz9Hj+lXNJ+IWgXt7Hp97NPo2rSfdsNXhNrK5zjCbvlk/4AzV1cEsdxBHNBIskUih0dTkMpGQQe4qvqumWGr2T2erWVtfWj/eguYlkRvqrAigC3RXBHwZqvhwiTwBrDW1uv8AzBtUd7iyYekbEmSD/gJZf9itHw34zh1HUho2tWU2h+Igpb7BcsGEygZLwSj5ZlHfHzDHzKtAHWVyvxT8P/8ACU/DvX9HRd09xauYB/02X54z/wB9qtdVRQBznw48QDxT4D0HW9ytJeWkcku3oJcYkH4MGH4VB8WP+SWeMv8AsC3v/oh6534K40qXxh4UYqv9iazK0EajAS2uMTxD/wAff8q6L4sf8ks8Zf8AYFvf/RD0AdVRRRQByvjL/kY/An/Yak/9N15XVVyvjL/kY/An/Yak/wDTdeV1VABRRRQAV5B+0H4evDYWPjHQonl1HRFkW6hjJDXNk4xKnHUqPmHpyeuK9foIyCDyKAOD+HvjnSfGPhnSxI3nTXyNA8cse4SEISdwxgBlDHB4OGHY1jX/AIB1bwk1xdfDaWCTTZizXXhfUGzZzZ5byGOfJY5PHKEkZAAxXF6VoB0Xxf4y8N6askJ024i1vTFgQM4tpiDIiA8fu5FDKvqCP4jXuHhrWG1OGe3vESHVbJxFdwIeA2Mq6Z5Mbj5lPpkHkEAA8KsPA3gTxlqlxDocd34K8XxHfdaJcJhCR/F5JIDp3DxMuAQRtJFdTonh3xT4avbc61o0fiKzgBVZ9NuEEjAnP7yGbaDyEbhz86b+rNnqvEuj6B45u5dH1+zmsdZsnMljcxv5Vyi5+We3lHbOMjnBA3DpnGtfFmtfD66i034kOLzRXcRWniaKPCc8BLtB/q2zgbx8p4zj5jQBrva+MvFbFb+T/hEtGOQYbSZZtQnHPWUApCOn3N7ejLXLaR4Wt9aubtfBejaHpukwzyQPrupWv9oXl5KjbXaLzD90MGXe7Nkg4XHJ9jhljniSWF1kidQyOhyGB5BB7iuF+Hko8P6lqXgu7Aje0kkvdMY9Lizkctwe7RuxRh6bD/FQA3RPhlY2HiGx1y71K8utUtAyxtFFBaRkMMEMsKLvHsxPStH4hfD/AETxzZRrqcTwahb/ADWmo2x2XFswOQUcc4zzjp+PNddRQB86eMviL4/+Fvhyew8TWa6ncwvH/Z2vRRZgvEEi7o7hc5jcpu5HJIHXlj6V8JvitoPxI07dp8n2XVYlzcafMw8xPUqf41/2h+IHSpfip8OYviPa2dhqes6hZaTA/mSW1mFUzv2LMwPAGcDHU554xz/hT9n7wR4a1K11CyXVpL62YPHM986MD65j2fl0oA9crkvhp4P/AOEJ0a/05bsXMM+o3F5EFj2CFJGyIwMnp6+9dbRQAUUUUAQX1nbahZz2l9bxXNrMhjlhlQOjqeoIPBFcP4ce48FeIbbwte3E1zoV8G/sS5mYu8DKNzWbueWwoLRseSqspJKgnv64/wCLVo0/gPU7uDaLzS1GqWrkZ2SwHzRj67Sv0Y0AdhXmfjL/AIknxl8Fa2BiHVILjQrl845I86Ee/wAyuPxr0azuEu7SC5iz5cyLIufQjIrzv9oZDF8NLjVolzc6LeWupwezRzLn/wAdLUAdB4y/5GPwJ/2GpP8A03XlGm/8lT8Q/wDYF0z/ANH39M8XOsmveAnQ5VtYkIPt/Z15T9N/5Kn4h/7Aumf+j7+gDqqKKKACiiigChr2k2mu6LfaVqUfm2d5C0EqeqsMHHofQ9jXzLoEOq+HPEF7oOqae2q6todoLe6swMnXNG35jkiHQzwdVHBK5UHK19U15L8boxoeveCPGkI2vpuppZXTA7c2tx8jZ9QDggH1oA3PD3iWC3s7DULbVv7X8IagFW31F23SWkhOAkzdSpPy7m+ZW+Vs5yOC124uPg94sW6th9o0W9QrDagEtNEjFvs6kA4li3sYy3ytGWRiCitXoHiPwCst7ear4VvF0jVLvP2yCSLzrHUc9RcQZAJIyN6lX+Y8npXHW8zt4i8PaP40afRbvTr4XVgJ5d8czqGUJbXW3EqMrYMUm2Ubhy2KAPR/Bfjnw540sxceHNVt7ttu54A22aL/AH4z8y88Zxj0Jrpc84715f4j8FeDfHRuJNNjj0jxTDiWO9to2s763k7OwG1iO2TkelU9LsPFTab9o+3pqXifSZhb3kDAQNcIjF4STnaxKuw3YUMrnoy4oA7vwbHPaw6jZ3ttJHdR3ksrzlfkuBI7Orq3f5SAR2Ix0wT0NYOm3V/4h0i5F5p+oaAZAI03yxmccfMRtLKvOQDnPfjisjxD4ctdF0s6j4dtprXULU7zcWxMkrJnLmRWP78dyrHccHaQ2DQB2tFcxpfjCzk0SK91P9wwkaGZoEeaFWXkvvVeIyCGDNjgjODkV0kMsc8KSwukkUihkdDlWB5BBHUUAPooooACcAk9K5nwbZNcI3iDUAJNT1Bcqc7hb25OUhT0GMFvViSegA6auN1HT/8AhFrTz9Iu7oqZfLstLeVRb+fK2AM43bAWLbd2AAcDoAAc1q6JJ4l0ezjA+1XHitrryFJ2iOG2YvIB0HJQk92f1NaPw41vTNIgvvDGo3tta31pd3M9uk8qr9rtZZXljmiJOHTDlSVzhlIOK5DVmntn8ST6PdyXk9lZJoKXv3RJqd5cjz3QjjKExZA+7gL/AA8dD4j+EdkNDe28Jtb2uyIhNNv4Rc2Ej7CA+xuYZM4PmRFTnlg9AG/4TurGDxTe6ZoN5BPpElsL1IYnDLbSFyrBMdEb723pnJHBwNH4k3BtvAWvMqs7vZyRKqqWJLqVHA+tVtE8U6dD/ZGmao93aaxcL9nCX0JV5JUXJBkChGJ5IK8NzjuKu+K7/SH0u407ULlmN2GtRDa5knLFc4VVBOQOenHU8UAcP8SrOLw/8MdH1eRDJLoLaY7ZzgRx3EJchegOB19BXXfFj/klnjL/ALAt7/6Ies/WLa68VfCbXdOvXSS/ls7uyaQR7A0qb0VivYkhWx2zWPcawNf/AGZr7U9++S48LTmVv+mgtmD/APjwagDqPGX/ACMfgT/sNSf+m68rqq5Xxl/yMfgT/sNSf+m68rqqACiiigDwf472Nz4S8T2Pj3T1b7BOsdjq4UZ8sq4a3uMZ6q4UZ9MDvXpTyeGPiP4ahstShtr+0v4DP9mkOSu0hWIIwQVLAbhgjI9a6TVNPtNV065sNRgS4s7mNopopBlXUjBBr55+Hltf+HVv9OtZM3vhXWGsm8xsLLbyj/R3c9BuUmNjjgbG/goA6PxN4W1fw/pjafremP8AELwOvIhmUPqmnjpmNuPOA9QVcZ64FcnpHwq0vV7ca58KPFX2qzBIaxvZDugbj5PMwWQgD7kiMp7gjmvorQ9VttZ06O8tN6qSUeKRdskLqcNG69mU5BFcFqvhLTPFGo3OveEb248NeMLVzDNcwoFZ2HRLqHpKpGCCeSNpBIAoA57w419pF+g8ceHdXgYKrSS2tu1/bzyhdoYNCWdcAunzjLJJsbIUV1sV14r8TJHBotk3hHQ1AUXV7Ej3sijHEUHKRDAI3SZPT5B1pvhXx/OusxeGPHlpFovihuIGRibTUQON1vIe/I/dt8wyOvOPQJFDoyEkBhjIODQB4ZH4Yt/FU8h8O6O+uWsEjRN4g8T6pcSRXDqcMIIUPzqDkbgI0yDt3da7DwN8Pbzw3riaiurQ21sYikuladDJHaSMejkSSOdw45Xb0x61e+El2YvDX/CO3Yji1Xw839nXUSjaCq/6qVR/dkj2sD6lh1Brt6APLfGXwtxqjeJvh1dJ4d8UoMt5a4tb4ddk0Y45/vAZzzycEcnrH7QbeGYLO28WeHrjT9fgulg1LTyDzCVb/SLd/uuu5RwTzu4J+9Xv1eP/ABs+E+q/FHUtPjk1y00vR7JSUVbQzTPI33mJ3LgdAAD6k9gAD0nwr4j0nxXosGq6BexXljMOHQ8qe6sDyrD0PNWPEGmQ61oWoaZdIkkF5byQOr9CGUj+teW/Cn4Hw/DvVvt9h4p1iUuMTWyrGkE49HQhvzBBHY17DQByvwr0PUvDXw80LRtbmimv7G3EMjRMWTAJ2gEgdF2jp2rqqKKACsjxR4d03xNphsdWgLoriWGVGKS28o+7LE45Rx2YfyJFa9FAHGeD9Y1G01i48K+J5RNqtvF9os77aFGo22cb8DgSoSFdR6qw4bA7OuH+LKiw0Wx8SRZW60G9iugyjkwswjnQn0MbsfqoPau4oA8zmP8AYX7QVuxZUtvE2jNEFA5e5tX3ZP8A2ykP5V0XxY/5JZ4y/wCwLe/+iHrnvjh/xLrPwt4kRxG+i65bSSP38iVvJlXPbIkH5V0PxY/5JZ4y/wCwLe/+iHoA6qiiigDlfGX/ACMfgT/sNSf+m68rqq5Xxl/yMfgT/sNSf+m68rqqACiiigAooooA8p8UgaT+0P4Lv1yi6xpl3pkjdm8vEyg++TxXp/2S3+3fbPJj+1+X5Pnbfm2Zztz6Z5rzb43xm2u/AWsKOLHxHbJKw/hil3RsfzK16hQBR1fSbHV7dYdRt1mRWDoclWjYfxIwwyn3BBrynxR4xn8F6qdG8WJ/xJr5mhtbjUyLizukOP3bzBd0T4JyJFdTgncBXsleQftPaXFq3gjRbe4XdCdds1k/3XLIf/Q6AAaXqvw3gXWfBAm1rwXKPPudCWUSyWqHkyWT55XnPlk4PODzx1l3baL8SvDGnatomolJEP2nTNVtcebay4weD+KvG3BGQR6cPJ4A8XfDm5kvPhVfrf6IXMknhnU5CUXJyfIlJyp56Ej1JbpXL+H/ABpBpPiq91Lwrpl5YalcN5mveCbpfKnd8ZNzZg4DyYBJQYLqM4BwaAPWdP8AGs+j3cWleP4ItKvXYR2+pIf9AviRxsc/6pzg/u5MH+6X613XXpWJo+qaF428NrdWMlrqmj3qFGV0Dow/iR0YcHsVYfWueXwPf+Hxu8A63JpsC5I0q/Vrux78ICwkhGT0R9o/u0Ad5RXDJ401TSG8vxl4ZvrNVyDf6WG1C0IA5Y7FEqf8CjwPWtfRvG/hfWii6X4g0y4lcZEIuVEo+qEhh+IoA6KigHIyOlFABRRRQAVyfxXvBZ/DjxC20vJPaPaRIOS0k37pAPqzrW/quradpFuZ9W1C0sYByZLmZYlH4sQK4i2uX+IfiLT7y1ikXwfpMwu4biRSn9p3QHyNGDgmGPO7eeHfbjIXJAO8022Flp1rahtwgiSLPrtAH9K4T9oOZYPgz4qZ8/NaiMY7lnVR+pFeh15l8ZH/ALZ1Dwj4NhO6TV9TjubpAMgWlsRLIT6ZYIBnvQBteIImg1L4dQv96PVGQ/UabeCrOm/8lT8Q/wDYF0z/ANH39HjL/kY/An/Yak/9N15Rpv8AyVPxD/2BdM/9H39AHVUUUUAFFFFABXB/HfSv7Y+EPiq1CB3Sya4UEd4sSDHv8ld5VbVLOPUdMu7Kb/VXMLwv9GUg/wA6AM7wTqg1zwdoWqA5+22MNwc+rICf1NXdZ0qw1vTZ9P1ezgvbKYbZIJ0Dq34HuDyD2NcN+zxcyXPwc8OCdds1vHJaOvoYpXj/APZa9GoA8i8T+Dta8NWDT+Hv+Kj0S1XzE0fUZ3F3aAZ/487sZkU4CgKxPA4btWL8PviPaeI5xq2j3zXc9rEqXkM4VLh7XeBtlThTJGX3LKnyspYMFNe7kZBB6Gvmb4WfBnw54u+FVrc3Kz6fry3N3GupWblJF2zOmGHRhgY5GccAigD2zUPGVs+lOmlPGdekdbaLT7j5ZY52OPnTrtXliRwVUkHGDWzZ6VJFo0tld6jd3csysJLmTaHywwSoA2qB2GCB714VdXPjL4eWS2XjhbzVtCgRoovEump57xwt/Bdwt8xQf3gQVHCsSa7vwB47tZbdobq+S904oJrbUIHaeNYzxskbG5cHvINwztc7gC4B1fgMeToktoYreN7O6mtna3iEaylXPz7RwCRgkeue1R+Gdmk65quggeXFu+32aZGPJf76qB0CybuO29abYWwlvjqfhTVYJbK4ut17blhJC5wA7Iw5R+AcZ2k9QCc1f8S6PJqaW1zYzra6tZOZbSdl3KCRhkcd0YcEdehGCAaANqisbTNaaUCLVrOTTLsMse2VgY5HPQRSdHzg4GA3qBWzQAV4x471XVtd8bXGjeFQZtSt0+zpdJkx6WrACWZjjidt21M/dVWbvhvTNe1oWlxDptjC15q1ypaO2STZsjzgyyPg7EHrgkngAmnaLbWvhzw7BDcmzs44QBK6uQm4nGSzckkkZJ5JPvQB5l4rsrnw94ev/CgNnFpkWjSanpEltC0Zgns3SQoxLMXyTG+8nJO/Oc16da67HMuil7a4jXVIfMjcr8sbbA+xu4JGcf7p9s8B4zLeIr/ww9wEtTcPqeh3Cb8hJZIHUANjkEw8cdxXQ+BDZ+KvhvoP2h5DNb28UUxjkaOW3uYl2OMggqysGBH+NAHXX9la6jaSWt/bxXFvJ96ORQynByOD6EA1X03RNL0ty+n6fa28hG1pI4gHYE5OW6nnnk1k6PdXek6ydE1Waa5imBk068lwWkUD54nIAG9cEg/xL6lWrc1O+h03T7i9uiwggQu20ZJA7Adz7UAc1PLb6L4v1BoJdsE+myX95bZyqujKqy4/h3LuBxjdsz1BNcP4fsG079ky4hYAGTwzd3OB0HmwyS/+z1peNmvtK+FvjC/vrSKHWtcDW9vBCd026YLBBEWz8zjd/D8o5x3J3PHOnJo/wP8AEGmREGOy8O3FspHcJbMo/lQBf8Zf8jH4E/7DUn/puvK6quV8Zf8AIx+BP+w1J/6bryuqoAKKKKACvKLNF0j9pHU4DGFt/EGhR3JPaSaCTZyPUIa9Xry34jxtY/F74ZaspxG895p0vv5sOU/VTQB6Na6bbWmoXl7boUmvNhnwx2uyjAbHQNjAJ7gDPQVU1fQbbULlLyOWey1GNdi3lqwWTbnO1sgq65/hYEDqMHmteigDxzWNf03X7qbwV4702O7uWfCW1ygtbiUZIWe3O4xydesbq4ww2cEVai1nW/hbcRWfiu5uNa8GSOI7fXH+a4sCThUu8feTsJR369RjI/aa8NWviW4+H9neB1judcSykkiwJFjlU7tpIOPuZ6HpTZm8e/DO3ltNXtZfH/ggqY2kVA1/bxHgq6HiVcE9c5HUqOKAPRPE+gT6jdWniTwpeW0GvQQ7IpX+a3voD8whl28lCTlXGSpJIyCQZfCvjOz1u6fS72CXSPEcKb7jSbsgSqOheMjiWPIOHTI6ZweK8p8BeONK8KR+doWoHVfhpO4w43NceH5GP+rmQ/MICc7WPTpkjBPsmu6Doni7TrYajbw3sAK3FrcRuVeM8FZIpUIZT0wykUAbdFcENP8AG3hkf8Sm+g8Vaag4tdTcW96oAwAtwq7JP+BqD6vVm0+JGhrOtr4g+1eGr8kgQazH9nVsf3JsmJ/+AuTQB2lFR288VzCk1vLHLE4yrxsGVh6gjrUlABRRRQAUUUjMqKWdgqgZJJwAKAOM+MsjD4ba1BGoaa9RLGJT/E80ixDH4vXZqNqgDoBivPUu4/iB4s0+TTis/hXQpzcm7X5o769AKosRH3kiyzFgcF9oGdpr0OgDzD9pQb/g7rMSpvllmtI41B5LG5ixj1+ldL8WP+SWeMv+wLe/+iHrnPi0x1jxN4F8KQklrzVF1K6XGR9mtR5hDegZ9gHvXR/Fj/klnjL/ALAt7/6IegDqqKKKAOV8Zf8AIx+BP+w1J/6bryuqrlfGX/Ix+BP+w1J/6bryuqoAKKKKACiiigDjPi/o9xrfgG+trGNpLyOW3uYQoyd0UyPx+CkfjXZ0UUAFeffHSAyeAfNAybfUtPm/K7iB/QmvQaz9f0qDW9Jn0+6JEM23JHUYYMP1AoA0K5zxn4K8P+M7NbfxDpsN0Y+YZxlJoTnOUkGGXkA8HBxzmujooA+cb34afEH4beILjxD8OdYbXrOY7rvTL4hZZ1H948LI2M/ONr9sHJz6X8O/ivonjCc6ZcpNoniWL5Z9H1AGOZWxzsyBvHXoAcckCvQ65zxj4J8O+MrZYfEWlwXbJ/q5sbJouc/JIuGXnng4oA6OsvWPD2i61j+2NI0+/I6G6tklI+m4GuDXQviB4OH/ABTWsQ+K9JTpp2tv5d2o/ux3SjDEn/noOAOtSr8XtN00iPxro2t+FpgQpkvbRpbcn/Zmi3KR7nFAGt/wq7wekvmW2j/Y39bK5mtv0jdRUh+Hulr/AMe+peJLf08vW7rj2GZDU2n/ABG8F6gqm08V6HIT0X7dGrf98k5/StmPXtIlG6PVbBx6rcIf60Ac/wD8K/sWI83WvFEi/wB1tbucfo4pJPhp4bmTbeR6pdg9ftGrXb5+oMmDXRnWtKAJOp2IA5z56f41Ru/GXhiyGbzxHotuPWW+iT+bUAVdN+H3hHTZVls/DelLMrBlle2V3UjuGYEj866iuA1D4x/D+yfY3ieyuJCcKlnuuWY+gEYbNUm+JOr6vmPwb4G12/JxtutSQafbYP8AEGk+ZgPQLzQB3HifX9M8MaHdavrl0lrYWy7nkb9AB3YngAck1xfwx0nUNV1jUPHniW3kttR1SNYNPsZR81hYg5VD6O5+dh2OBxyKXRfAOo6prNtr/wASNRt9X1G2bzLPTrVClhYv/eRW5kf0d+RngcA16PQByvjL/kY/An/Yak/9N15Rpv8AyVPxD/2BdM/9H39HjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0AdVRRRQAUUUUAFFFFAHKfDvRbjQbDV7OePy4W1a7uLYDp5UshkGPTliPwrq6KKACuE+DVp/Z/ha/ssYFtrOoxj6fapCP0Iru6q6fYW2nicWqbBPM9xIM5y7HLH8TQBaryTx18F7DUL/+3fA99J4U8TJuZbiyykMxPUSIuMZ7kepyGr1uigDwXSPiX4g8D61Y6T8UbG4sYJ38g6lnzrOQ4OJElxlcnGUbOAc/LjFe62txDd20VxazRzwSqHjkjYMrqehBHBHvUeo2NpqdlNZ6jawXdpMu2SCdA6OPQqeDXBWnwxPhxpG+H/iHUPDsUj72sHUXtlnOSRFIdyk+qOtAHe6lYWup2UtnfwR3FtKMNG4yD6H2IPII5B5FZHhSSWGfVdKnupbr+z51SKWZt0nlvGrqGPViNxG48kDnJyawI9a8f6TL5Wr+F7HXIeSLvRbxYWwP70M5GDj+67Vga347srLVU1S5stc8KaiyCFn1fT2NneKMlY3eEuqsMkq+QRk/eBxQB2ceh6zZ3+qtpt5YQpqE/ntdywtJcIMABMZ2naB8pJwB/Ce9vTfCGjWMiTNardXok897q5w8kkv/AD0Y9N3TGAMYAGAK5rS/jJ4KuYIvt+t2unXTZDRXJZFyDjKuygMp6g9we3St+3+IHg24XdB4s0Bx/s6jD/8AFUAYXirw3e3Vlq2jwwmSHUZXv9Pvozh7G9XEiF/Rd6ghh67SOcnifD2i+HvFHiDX/FWsyXekTXNjYan9psdRltAsUkO1lYowyVlhkGTz0r0XU/in4G04hZ/FGlyyE4EVpN9pkJ9AkW5s/hXjXhfW7fRPEOlJqGheKb+yjhktILVNKnBkSG4kmtbrYVAcFZmXDHKsobHIIAPWRDbavd6Cmgf2reR6c8Ti9uLiXyI1XIYkuczSspZehI3ZJXvs+KZTqGp2OgqwjhlBvLxy23/R42HyDuSzbQcdF3dMjOOfiRK5Edp4I8aTXDYARtOWJcnpl3cKB6nPFZupeGPEXxGEUfjWzs9C0BG3NpttKLi8uBnlJLgALEjYXKx5JGRuFAFixlHxE8Z2Oq2wMnhDQZHktJyPk1G+wU8xAfvRxAuA/RnYkEhc1v8AxY/5JZ4y/wCwLe/+iHrpbW3htLWG2tYkht4UEcccahVRQMBQB0AHGK5r4sf8ks8Zf9gW9/8ARD0AHjL/AJGPwJ/2GpP/AE3XldVXK+Mv+Rj8Cf8AYak/9N15XVUAFFFFABXC/FnS5L608M3kKkvpfiCxu2I6hPM8t/w2yH8q7qkZQwwwBHoRQAtFFFAHnPxmgLnwLOB/x7+KbFj9G3x/zcV6NWbrukw6vBaxz/8ALvdQ3aHGfmjcMP5VpUAefeM/hVofiC+fVtPabQvEJVh/aWn4RpM9RMn3ZVPcMMkcZxXkmmn4j/A29m+16ePEngZnMjDTwR9kBJLMiHJi7sV5jyeCuc19OUUAc54H8a6B440kah4b1CO6jAHmx/dlhJ/hdDyp6+xxwSK37mCG6geG5ijmhcYaORQysPQg9a4PxN8KdA1XUxrGk/aPDviFcldS0lvJdj1PmKPlcE9cjJHGaoLrnxA8Hjy/EejL4u0xOmpaIgju8DvJascMx/6ZtgelAG9P8M/CD3H2i10aPTp8Y8zTZZLI/wDkFlz+NMHgIxSbrPxZ4stx/dOoCcf+RVeotC+K/gvWJzbJrlvZXyna1pqINpMrf3dsgGT9M12sE0VxEssEiSxt0dGDA/iKAOS/4RTXI+bfx1rgxwPNt7STj/vyOfeg+F/EDkeb471faP8AnnZ2anP18o12NFAHFyeB7qcAXXjTxVJ3IjuIYc/98RAj8DQfhp4buGRtXiv9ZKHcBqmoT3SH6xu5Q/itdoTgZPArC1fxj4a0ZS2q+INJs8dpruND+AJyaANm3hitoI4LeJIoY1CJHGoVUUcAADgAVW1vVbHQ9Ju9T1a5jtbG1jMs00h4VR/M9gByTwK4Kb4waJfSNb+DrDVvFV4Dt26baN5Kt23zOFRV6c5PWo9P8Ha74u1W31j4lvbraWziay8OWr+Zbwv2ed/+W0g9MbRg4zk0ASfC2wvdc1nUviBrttJa3WqxLa6ZaSj57SwU7lDejSN85HOOPpXQfFj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD0AdVRRRQByvjL/kY/An/Yak/9N15XVVyvjL/kY/An/Yak/wDTdeV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQQGBBAIPY0UUAYGo+DPC+pMW1Hw3ot03XM1jE5/MrWRJ8KPAMhy3hDRR/u2qr/Ku2ooA4cfCTwB/0KOj/APgOKuW3w38E2rBoPCOgKwOQ39nxEj8StdZRQBVsdOsdPXbYWdtarjGIYlQY/AVaoooAKKKKAOV8Zf8AIx+BP+w1J/6bryjTf+Sp+If+wLpn/o+/o8Zf8jH4E/7DUn/puvKNN/5Kn4h/7Aumf+j7+gDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBssaSxskqK6HqrDIP4Vi3PhHw3cyeZc+HtHmf+9JZRsfzK1uUUAUdM0jTdKQppen2dkh4K20Cxg/8AfIFXqKKACiiigArlfix/ySzxl/2Bb3/0Q9dVXK/Fj/klnjL/ALAt7/6IegA8Zf8AIx+BP+w1J/6bryuqrlfGX/Ix+BP+w1J/6bryuqoAKKKKACiiigAooooAKKKKACiiigAooooAzNc8P6Pr8Ih1zSrDUYh0W6t0lA+m4HFcZcfBP4eyymVfDkVvIf4rW4mg/wDQHFejUUAeb/8ACmfCq8RS69Ev91NZucfX79B+DXhgjDXHiBlPVTrNzg/+P16RRQB5t/wpDwC7BrrRp7xgc5utQuZf0aTH6VuaT8NvBWkur2HhXRopVOVkNojuv0ZgSPzrraKAGxokcapGqoijAVRgAewp1FFABXK/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9AHVUUUUAcr4y/wCRj8Cf9hqT/wBN15XVVyvjL/kY/An/AGGpP/TdeV1VABRRRQAUUUUAFFFFABXJ+LPE2paX4l0HQ9G0uzvrvVYrmYPd3zWyRiHy88rFIST5noOldZXnvxJ8HXXiPxL4b1KLSNB1m002K7jmsdXlKI5l8ray/uZQSPLbqB1FAGcfiXrcvhXTPEFn4a09rK9u47DZNqzpIszXBgyNtuytHuwQ4OSpzt7V38OoT2ehTah4lSy0426PLceRctPFHGuSW3siHoMn5Rj3rhLX4f6pH4Kg0nz7CKYa7Bqq20Tv9ms4UuEkMEJK5IAQ4+VRluiiu98S2UmpeH9SsYYbSaS5t3hEV4GML7lI2vt52nODjmgDj9e+JumW2mw3mmSS7I9QtLe8W8sLiF44ZmPzqjqrNkA7SAQcd66Gw8ZaHf20M0F3KBLe/wBnBJraWKRbnbu8t0dQyHHPzADBHqK4vS/AfiBBCLm6ggtIdRsLqHT21O4v0gWBmMhSWZA4LgqAmNo29eavan4L1g3+qahYSafJcv4gt9ZtYZpXRHRLaOFkdghKE7XIIVu3qcAHRan458P6Y227vZfMN62nrHFazSu1wqeYY1VEJY7eRgHPQZPFZeofEvSLe40D7JDf31pqslxH5tvY3MjwtCDuUxLEX3bgVKkAjBJGAaz9F8G66muabqmqyaYksWu3WqzR20sjKI5bNoFVSyDLBiM5wMZPtTE8G69p15aajpp0u6urbW9Q1AW89xJCkkNzvAHmCNirruBI2kdRnvQB6WDkAjOD6jFLSDOBuAB7gHNLQAUUUUAFFFFABRRRQByvjL/kY/An/Yak/wDTdeUab/yVPxD/ANgXTP8A0ff0eMv+Rj8Cf9hqT/03XlGm/wDJU/EP/YF0z/0ff0AdVRRRQAUUUUAFcp4v8TahpGvaBo+kaZa315qxn2m6vGto4xEgc5KxSE5B9K6uuJ8d+CIPF/iPw3PqdrYXmkWAuhdW10u4v5sYVCowRkEZzkEdRzQBU8M/EcazL4a83Szaw6093bCX7QJFjuLcn5AQoDq4SQq4Izt6c10vhvXv7cu9bWG3CWmn3rWMc/mbvPdFXzDjHyhXLJ1OSh6Vxs/gfxAPA0eiQ3mnve6Jew3OgXsrODsiYFFuAF4OwvGSudynJAOa7HwPobeHPCmnaXLIs1zFGWuZlGBLO5Lyv/wJ2Y/jQBgaJ8TtGvtN1O91CK902KxvZrPM1ncYlKTGJNhMY3SMQP3S5cE4IyDXU6Brun6/ay3GlzPIsMphlSWF4ZIpAASrxuAynBBwQOCD3rgZvBXiJba5trY6SVttfk1/T5pLiTMzPO8hhlQR/IMSMN6s/QHb2rqfBui6hYX2u6rrX2RNQ1e5SZ4LR2kihRIljRQ7Kpc4XJYqOuMYFAHPf8LJvY7+5kudCgTQ7fXP7Ce7S/LTCQuqLIYTEBsLMoOHJGehxWppHjuPUPiFf+GjYNDBCsgtr8y5W6liEfnRquOCnmqM5OcN6VR8O/DqCx1TWdV1WNb2+l1ifVLCM3s5t4y2PLZoifLEg5+YISOxNZemfDTWtMi8MXsfiGW61XTb43tzbzCJbVmnLfa9jLD5pz5jld7HtnHYA9A8Q+ItM8PJbHVJ5Fe5k8qCGCCS4mmbBJCRxqztgAk4HHesif4j+FoBEZNSfa8K3DMtpMywRsxUNMQhEIJBH7zb0PoaPGOhardeIvD2v6D9hmvdKFxE1reytFHNHMqhiJFRyrAxrj5TkEjiuc1Pwj4tuT4i8t9BY+JrGO1vmaSUCzcI0ZaJdh84bG4DFPmHocAA6i+8f+G7HWrnSrm+lW7tpYoLjbaTNHA8oUxh5QhRAwdcEsBk4zkGqHjH4gWWkSGx0x2udUTULKzlX7JNJBF508SMryqNiP5chYKzA528HODn3ngG/bSfGFja3Ftt1aeze0aR2yqQwW8Z8zC8EmFumeo6dm6v4R8Qv9s03Tl0k6Vd65BrEl1PcyLOAtxFM0YjEZXP7vAbf0wMDqADsR4m0gxGQXfyC/8A7MJ8t/8Aj537NnT+9xnp71y0HxIs4ta0jTJPP1MX/wBtJvLDTLkLG0E6xbPLCuTgsQz7gBtBwA61Ul8H+JF1I20B0g6OfEK62bh55BOU8wO0fliPaCDnDbzkY4HWmaL4J1/QrzQr6z/sq7nsbjVfOhluZIlaG8uFlVlcRsd6hFBUrg5PzcZIB6hRRRQAUUUUAFcr8WP+SWeMv+wLe/8Aoh66quV+LH/JLPGX/YFvf/RD0AHjL/kY/An/AGGpP/TdeV1Vcr4y/wCRj8Cf9hqT/wBN15XVUAFFFFABVDxBqP8AY+g6lqfled9itpbny923fsQtjODjOMZwav1meKdPl1bwzq+nWzIs93ZzW8bSEhQzoVBOATjJ9KAMC58biC18Fztp7EeI2VSFlJNvm3abgBcv93bjjOc+1W7zxnpP9i2l5p15HPJqNpNdaePLciYRx7ySMZUDjO7HJA6nFcrZfCuz02fwJdaVpmh2V/o0ivqNxb26xyXAFu8bYZUy2XYN82PXrUHg3wXcJrHji6Kzw2sj3GnaPDdIUEMchMkzKMf6t5nOCOqoMDGMgG74Z+Jmhal4fjvL67a3uodK/tS7VrOeJfLVAZXi3L+8VTkfIW7DvVy28c6Re6pYrb6mILOa3uJ9t3ptxD56RBC0sczhUCKHBJwwbcMEYNcndeAfEWseGobDVf7ItbnT/D13o1m1tdSSrPJPCkfmSFolMajyx8o3/e6/Lzr+OvAV34obTIhdw29vDo2oaZM+WLh7iOFVZRjBA8ts5I7epwAaXh/xvb+IPF407S1lbT/7O+2CWeynt2cmQKpQyKodCDkMoIPrVzxF450Dw9qMlhql1cJdx2wvJEhsp5/LgJZfMYxowVco2SSAMc4yM1NB0rxA/jE6zrlvpFpAmn/YooLG5kmOfMDbiWjQAYHQDj1NYXijTfEt18Rtb/sCxs2t73w9b2bXd9JJHHG3nXOdm2NhIyhwSmV6ryM0AdVJ430BNYGlreSzXnlxzMILWaZEjkGVkeREKKhH8bEKO5FR6X4+8Namk722pbIobZrwyXFvLAjwKcGVGkVRJGOPmQkcjnkVlaD4CfTbXXNOe6VrC90m00qGQEmUCKB4mZgeM/MCME9657Uvhxr3iXRLbS/ENxpVnHp+jzaZazWLPMZnkEaiWRXRdigRL+7BbJJ+bgUAdjH8RPDUllNdfbLlI4mhXZLYXEckplz5XlxtGHl3bWxsDZwfSpT488O/YLa6S8uJRcTSW8dvDZTyXJkj++pgVDKCvfKjGRnGRXO+IfDPinxRZ2D6zDpFvc6XdRXNtBYapdQi4by5Y5d06IrxZEgK7VYjaQSwY1X0PwTrehajBrWnWOk/2mDdxy2s+rXc6FZjbnzTcSo7tIPs4BG1QQe2OQDpfA3jC38QadpYuZI01O+t57uOGOJ1BhjmEZbnOPvR8E556dcPk+IHhxRpuy7uZ31K3+12kdtYXE8ksWcbgiIWA55yBjvXN6R4P8TaG/h+/sTo11qNnY3ljcxTTyxRYnnSUSIwRidpQDaQM5+8OtX/AAH4N1LQLrw/LfTWcn9n6F/Zk3ksx3S+YjZXKj5cKeuD7UAbmm+NdA1LWBpllfNJdO8kcRNvKsUzR/fWKUqEkK4OQjHGD6V0deVeDPhzeaBq2iRzQQXGn6RJI8N3Lrd9NIco6KVtG/cxth8EgsMbsAZ49VoAKKKKACuV+LH/ACSzxl/2Bb3/ANEPXVVyvxY/5JZ4y/7At7/6IegDqqKKKAOV8Zf8jH4E/wCw1J/6bryuqrK8Q6BYeIIbWPUluf8ARZvtED213LbSRybGTIeJlYfLI4xnBDGsr/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6ADxl/yMfgT/sNSf+m68o03/kqfiH/sC6Z/6Pv6lsfBOj2ep2eoK+r3FzZu0kBvNYvLlI3ZGjLBJZWXO13GcfxGpdY8I6Vq+qtqVydShvWhS3aSy1S6tN8aM7KGEMihsGR8EjPzGgDoKK5X/hA9I/5/PEn/AIUeo/8Ax+j/AIQPSP8An88Sf+FHqP8A8foA6qiuV/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6AOqorlf+ED0j/n88Sf8AhR6j/wDH6P8AhA9I/wCfzxJ/4Ueo/wDx+gDqqK5X/hA9I/5/PEn/AIUeo/8Ax+j/AIQPSP8An88Sf+FHqP8A8foA6qiuV/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6AOqorlf+ED0j/n88Sf8AhR6j/wDH6P8AhA9I/wCfzxJ/4Ueo/wDx+gDqqK5X/hA9I/5/PEn/AIUeo/8Ax+j/AIQPSP8An88Sf+FHqP8A8foA6qiuV/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6AOqorlf+ED0j/n88Sf8AhR6j/wDH6P8AhA9I/wCfzxJ/4Ueo/wDx+gDqqK5X/hA9I/5/PEn/AIUeo/8Ax+j/AIQPSP8An88Sf+FHqP8A8foA6qiuV/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6AOqrlfix/wAks8Zf9gW9/wDRD0f8IHpH/P54k/8ACj1H/wCP1Dd/DrQby1mtbyXxBPbTo0csUviHUGSRGGCrAz4IIOCDQBN4y/5GPwJ/2GpP/TdeV1VZXiHQLDxBDax6ktz/AKLN9oge2u5baSOTYyZDxMrD5ZHGM4IY1lf8IHpH/P54k/8ACj1H/wCP0AdVRXK/8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9AHVUVyv/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QB1VFcr/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0AdVRXK/8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9AHVUVyv/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QB1VFcr/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0AdVRXK/8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9AHVUVyv/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QB1VFcr/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0AdVRXK/8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9AHVVyvxY/5JZ4y/wCwLe/+iHo/4QPSP+fzxJ/4Ueo//H6hu/h1oN5azWt5L4gntp0aOWKXxDqDJIjDBVgZ8EEHBBoA7CiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stage I palliation of hypoplastic left heart syndrome.",
"    <br>",
"     (Panel A) Stage I palliation (Norwood procedure) using a modified Blalock-Thomas-Taussig (BT) shunt for provision of pulmonary blood flow. The shunt originates from the innominate artery and inserts into the central pulmonary artery.",
"     <br>",
"      (Panel B) Stage I palliation using a right ventricle (RV)-to-pulmonary artery (PA) conduit (Sano modifcation) for provision of pulmonary blood flow. A larger 5 or 6 mm graft is placed between the right ventricle and the central pulmonary artery.",
"      <br>",
"       (Panel C) Stage I palliation using a hybrid approach. Pulmonary blood flow is restricted with branch pulmonary artery bands, and the ductal patency is maintained by placement of a stent. A stent is placed to create a nonrestrictive atrial septal defect.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7th, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5943=[""].join("\n");
var outline_f5_51_5943=null;
var title_f5_51_5944="Ultrasonography of acute pyelonephritis";
var content_f5_51_5944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62046%7ENEPH%2F69393%7ENEPH%2F51244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62046%7ENEPH%2F69393%7ENEPH%2F51244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasonography of acute pyelonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal ultrasonography in a patient with acute pyelonephritis showing a hypodense mass with internal echoes (outlined by the arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alain Meyrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography scan of acute pyelonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT scan in a patient with acute pyelonephritis showing a large, hypodense region in the right kidney. There is no discrete abscess formation in this setting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alain Meyrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography scan of bilateral acute pyelonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT scan in bilateral acute pyelonephritis showing triangular hypodense streaks spreading from the pelvis to the renal cortex (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alain Meyrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5944=[""].join("\n");
var outline_f5_51_5944=null;
var title_f5_51_5945="Management of Marfan syndrome and related disorders";
var content_f5_51_5945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of Marfan syndrome and related disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5945/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5945/contributors\">",
"     Michael J Wright, MBChB, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5945/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5945/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5945/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/51/5945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Marfan syndrome (MFS, MIM #154700) is an autosomal dominant condition with a reported incidence of 1 in 3000 to 5000 individuals. There is a wide range of clinical severity associated with MFS. Although many clinicians view the disorder in terms of classic ocular, cardiovascular, and musculoskeletal abnormalities, these patients also demonstrate significant involvement of the lung, skin, and central nervous system. A severe and rapidly progressive form of MFS may present at birth, so called neonatal MFS, and carries a poor prognosis.",
"   </p>",
"   <p>",
"    The management and prognosis of MFS and related disorders will be reviewed here. The genetics, pathogenesis, clinical manifestations, and diagnosis of MFS and related disorders and issues related to MFS in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with MFS has improved with the use of beta blockers, restriction of vigorous physical exercise, routine and noninvasive monitoring of aortic size, and elective surgical repair of the aorta. The physiologic changes that occur during pregnancy are associated with an increased risk of aortic dilation and dissection and therefore require more intensive monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2010 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Association for Thoracic Surgery",
"    <span class=\"nowrap\">",
"     (ACC/AHA/AATS)",
"    </span>",
"    guidelines for thoracic aortic disease include recommendations for MFS, Loeys-Dietz Syndrome and other genetic syndromes affecting the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines are similar to the recommendations for MFS published in 2001 by a Task Force of the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AORTIC MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of the aortic diameter is recommended to identify patients at high risk for aortic dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     How to measure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement conventions differ for echocardiography as compared to computed tomography (CT) or magnetic resonance imaging (MRI) and the measurement convention may also differ from one institution to another. The internal aortic diameter or leading-edge-to-leading-edge technique is used to measure the aortic root by echocardiography while CT and MRI measure the external diameter (which is expected to be 2 to 4 mm larger than the internal diameter). The external diameter is the measurement generally used to determine the threshold for surgical repair. The measurement method used should be indicated and used serially for follow-up of aortic disease. Since normal aortic dimensions vary with age and body surface area, these parameters should be taken into account. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Indications in MFS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For MFS, aortic diameter at the sinuses of Valsalva is the key measurement since this is the segment that generally dilates initially. This measurement can usually be monitored by echocardiography. Greater length of aortic dilation (ie, to the aortic arch versus limited to the sinuses of Valsalva) is associated with worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Monitoring MFS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As recommended in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines for thoracic aortic disease, patients with MFS should have echocardiography performed at the time of diagnosis and six months later to determine the aortic root and ascending aortic diameters and their rate of enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, if the aortic diameter is documented as stable over time, then annual imaging is recommended if the aortic dimension is less than 45 mm. If the aortic diameter is &ge;45 mm or shows significant growth over time, then more frequent imaging is suggested (eg, twice yearly) and surgery may be indicated. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Indications in MFS'",
"    </a>",
"    below.) More frequent imaging is also recommended if the aortic diameter shows rapid change (&ge;0.5",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    or if there are concerns regarding heart or valve function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children with MFS, annual imaging is recommended if the aortic dimension is documented as stable over time and not markedly enlarged. There are no age-specific absolute aortic diameters that can be used to determine when more frequent imaging prophylactic aortic surgery is indicated. It is recommended that aortic measurements be compared to the body surface area. Sonographic measurement of aortic diameter should be performed annually as long as the increase in aortic size remains proportional to the increase in body surface area. Twice-yearly measurements are recommended if aortic size (expressed as a percentage increase) diverges from the height when expressed in the same fashion.",
"   </p>",
"   <p>",
"    Individuals under 20 years of age with systemic findings suggestive of MFS, but without cardiovascular involvement, should also have annual echocardiograms due to the potential risk of rapid development of aortic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"     4",
"    </a>",
"    ]. Adults with repeatedly normal aortic root measurements can be seen at two to three year intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring Loeys-Dietz syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As recommended in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines, complete aortic imaging should be performed at the time of diagnosis and 6 months after in patients with Loeys-Dietz syndrome or a confirmed genetic mutation associated with aortic aneurysms and aortic dissections (TGFBR1, TGFBR2, FBN1, ACTA2, or MYH11) to determine if aortic enlargement is occurring.",
"   </p>",
"   <p>",
"    If the aortic dimension is stable, patients with Loeys-Dietz syndrome should have yearly magnetic resonance imaging from the cerebrovascular circulation to the pelvis since they commonly develop aneurysms that are amenable to prophylactic surgical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DRUG THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers decrease myocardial contractility and pulse pressure and may also improve the elastic properties of the aorta, particularly in patients with an aortic root diameter &lt;40 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Prophylactic treatment with beta blockers has been considered the standard of care in adults since the mid-1990s, when the results of an open-label, randomized trial of 70 adults with classic MFS were published; the patients were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or no specific treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/7\">",
"     7",
"    </a>",
"    ]. The following observations were noted at approximately ten years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      (mean dose 212",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      had a significantly slower rate of aortic dilatation as reflected by a lower mean slope of the regression line for aortic root dimensions (0.023 versus 0.084 per year).",
"     </li>",
"     <li>",
"      Survival for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      group was higher during the middle years of the trial and slightly but not significantly better at the end of the trial. However, few patients reached a clinical end point (five in the treatment group and nine in the control group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data supporting the use of beta blockers in children are less clear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study, 44 children and adolescents with MFS were followed for almost four years [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/8\">",
"       8",
"      </a>",
"      ]. The 20 patients who were taking a beta blocker and the six patients taking a calcium channel blocker had a slower absolute aortic growth rate (0.9 versus 1.8",
"      <span class=\"nowrap\">",
"       mm/year",
"      </span>",
"      in untreated patients) and aortic growth rate adjusted for age and body size. Protection was not complete since 5 of the 26 treated patients had a major cardiovascular complication requiring surgery over a four-year follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 63 children was conducted at two sites in which beta blocker therapy versus no therapy was assigned according to local practice [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/9\">",
"       9",
"      </a>",
"      ]. There was no difference in the rate of change in aortic root measurements between the two groups at the end of the study. Only three patients underwent aortic root replacement, one in the treatment group and two in the untreated group. There was a trend toward more side effects in treated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial is needed to determine the efficacy of beta blockers in children with MFS. In the absence of such data, we suggest a beta blocker be given to all children with MFS. The dose should be adjusted to maintain the heart rate at 110",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    after submaximal exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Beta blocker recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    thoracic aorta guidelines, beta blockers should be administered to all patients with MFS and aortic aneurysm to reduce the rate of aortic dilatation unless contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ]. The dose should be adjusted to maintain the heart rate after submaximal exercise (eg, running up and down two flights of stairs) &lt;100",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    in individuals over five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    was the first beta blocker demonstrated to slow aortic dilation, other beta blockers may be used as well. Use of longer acting agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , with daily dosing may improve compliance.",
"   </p>",
"   <p>",
"    Among pregnant women,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    is the preferred beta blocker since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    may impair fetal growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of other drug therapy in MFS has not been established. Limited data suggest that treatment directed at the renin-angiotensin system may be beneficial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 17 patients assigned to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"       perindopril",
"      </a>",
"      or placebo for 24 weeks (in addition to standard beta blocker therapy) found that perindopril reduced both aortic stiffness and aortic root diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       Losartan",
"      </a>",
"      therapy slowed the rate of aortic root dilation in a cohort study of 18 pediatric MFS patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/12\">",
"       12",
"      </a>",
"      ]. The rationale for this study was the observed benefit of losartan therapy in an animal model of FBN1 MFS [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Statins have been demonstrated to attenuate aortic root dilation in a mouse model of Marfan syndrome. They appear to act through reducing the excessive protein manufactured by vascular smooth muscle cells, which occurs in the Marfan aorta. Human studies have not been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not tolerate use of beta blocker may benefit from an angiotensin receptor blocker (preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/12\">",
"     12",
"    </a>",
"    ], an angiotensin converting enzyme inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/11\">",
"     11",
"    </a>",
"    ], or a calcium channel blocker (preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ). The effectiveness of verapamil in preventing aortic dilation and associated complications is supported by scant data [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    include the following recommendations for drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An angiotensin receptor blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      ) is reasonable for patients with MFS to reduce the rate of aortic dilatation unless contraindicated.",
"     </li>",
"     <li>",
"      For a patient with thoracic aortic aneurysm (any cause), it is reasonable to reduce blood pressure with beta blockers and angiotensin receptor blockers or angiotensin converting enzyme inhibitors to the lowest point the patient can tolerate without adverse effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RESTRICTION OF STRENUOUS ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An expert panel of the American Heart Association has made recommendations regarding permissible levels of physical activity for patients with genetic cardiovascular diseases, including MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/15\">",
"     15",
"    </a>",
"    ]. As a general principal, participation in recreational exercise, categorized as low to moderate intensity (approximately four to six metabolic equivalents), can be recommended for many patients with MFS, though these suggestions do not apply to patients who have had aortic root",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    valve replacement.",
"   </p>",
"   <p>",
"    Recreational (noncompetitive) exercises that are of low and moderate intensity that are",
"    <strong>",
"     probably permissible",
"    </strong>",
"    , include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bowling",
"     </li>",
"     <li>",
"      Golf",
"     </li>",
"     <li>",
"      Skating (but not ice hockey)",
"     </li>",
"     <li>",
"      Snorkeling",
"     </li>",
"     <li>",
"      Brisk walking, treadmill, or stationary biking",
"     </li>",
"     <li>",
"      Modest hiking",
"     </li>",
"     <li>",
"      Doubles tennis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, patients with MFS are advised to avoid contact sports, exercise to exhaustion, and especially isometric activities which entail the Valsalva maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"     4",
"    </a>",
"    ]. Activities that are not advised and are strongly discouraged include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/15\">",
"     15",
"    </a>",
"    ]: weight lifting and body building, ice hockey, rock climbing, windsurfing, and surfing. Scuba diving should be avoided due to an increased risk of pneumothorax resulting from barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other activities that are thought to be of",
"    <strong>",
"     intermediate risk",
"    </strong>",
"    , and for which individual assessment is suggested, include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/15\">",
"     15",
"    </a>",
"    ]: basketball (both full and half-court), racquetball, squash, running, skiing (downhill and cross-country), singles tennis, touch (flag) football, soccer, baseball, softball, biking, lap swimming, motorcycling, and horseback riding.",
"   </p>",
"   <p>",
"    Parents of children with MFS face difficult decisions regarding participation in physical education classes. Social pressure may necessitate inclusion of an affected child in a school-structured physical education program. Parents and school officials should agree upon permitted and excluded activities for the affected child. Physical education instructors must agree to abide by the activity restrictions and be able to monitor the child's participation to avoid excessive exertion.",
"   </p>",
"   <p>",
"    Recommendations in competitive athletes with MFS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H20#H20\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Marfan syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     AORTIC ROOT REPLACEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Elective replacement",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective replacement of aortic root disease before critical enlargement is preferable to emergency repair for marked dilatation or dissection. The importance of this approach was illustrated in a series of 675 patients with MFS from Johns Hopkins in which the 30-day mortality for elective repair, urgent repair (within seven days after a surgical consultation), or emergency repair (within 24 hours of consultation) was 1.5, 2.6, and 11.7 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/17\">",
"     17",
"    </a>",
"    ]. In this series, 46 percent of the adults with aortic dissection had an aortic root diameter of &le;65 mm at the time of operation; the authors suggested that prophylactic repair be performed when the aortic diameter is well below this size.",
"   </p>",
"   <p>",
"    Thus, surgical intervention should be considered, regardless of the patient's symptoms, in patients with significant aortic root dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The goal is to improve survival. In a review of 231 patients who underwent elective aortic root replacement at Johns Hopkins, the actuarial survival at five, ten, and twenty years was 88, 81, and 75 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Indications in MFS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aortic root diameter at which elective surgery should be performed is uncertain. The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines recommend elective operation for patients with MFS at an external diameter of &ge;50 mm to avoid acute dissection or rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ]. Indications for repair at an external diameter less than 50 mm include rapid growth (&gt;5",
"    <span class=\"nowrap\">",
"     mm/y),",
"    </span>",
"    family history of aortic dissection at a diameter less than 50 mm or presence of progressive aortic regurgitation.",
"   </p>",
"   <p>",
"    One limitation of recommendations based upon absolute aortic root diameters is that predicted aortic root diameter varies with body size [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/21\">",
"     21",
"    </a>",
"    ] and age and may be smaller in women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/22\">",
"     22",
"    </a>",
"    ]. Smaller patients have dissection at a smaller aortic root size and 15 percent of patients with MFS have dissection at a diameter less than 50 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/23\">",
"     23",
"    </a>",
"    ]. Various strategies have been proposed to identify at risk patients with aortic size less than 50 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    thoracic aorta guidelines include the following recommendation for patients with MFS and other genetic aortic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ]. If the maximal cross-sectional area (&pi;r2) in square centimeters of the ascending aorta or root divided by the patient's height in meters is &gt;10, surgical repair is reasonable. This strategy was supported by a series of 103 patients with MFS who were managed using these criteria without development of aortic dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal timing of elective aortic repair in children is also uncertain and adjustment for body size is particularly relevant in this population. In children younger than 12 years of age, dissection is rare, irrespective of aortic dilation. In these young patients, surgical indications are \"giant aneurysm\" (those that satisfy the adult criterion for intervention), rapid enlargement (&gt;10",
"    <span class=\"nowrap\">",
"     mm/year),",
"    </span>",
"    and progressive aortic insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Indications in Loeys-Dietz syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Loeys-Dietz syndrome tend to have severe vascular disease and nearly all have aortic root aneurysms that lead to aortic dissection. Since aortic dissection has been observed with aortic diameters &lt; 50 mm, repair is recommended at smaller diameters than recommended for MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following recommendations are included in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adult patients with Loeys-Dietz syndrome or a confirmed TGFBR1 or TGFBR2 mutation and an aortic diameter of &ge;4.2 cm by echocardiogram (internal diameter) or &ge;4.4 to 4.6 cm by computed tomographic imaging",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      magnetic resonance imaging (external diameter) it is reasonable to consider surgical repair of the aorta.",
"     </li>",
"     <li>",
"      For young children with prominent craniofacial features of Loeys-Dietz syndrome, prophylactic surgery is indicated if the aortic valve annulus is at least 18 to 20 mm and the aortic diameter exceeds the 99th percentile for age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Symptomatic aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic expansion of a thoracic aortic aneurysm is generally an indication for prompt surgical intervention. An aortic dissection is an indication for emergency surgery when the ascending aorta is involved (type A) or for complications associated with type B dissections. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link\">",
"     \"Management of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two approaches are used for aortic root replacement: a composite valve graft and valve-sparing aortic root replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Composite valve graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total aortic root replacement with a composite valve graft consisting of the aortic root and a prosthetic aortic valve (Bentall procedure) and reimplantation of the coronary arteries was the surgical procedure of choice for older children and adults in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. It has been associated with 5, 10, and 20-year survivals of 88, 81, and 75 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/20\">",
"     20",
"    </a>",
"    ]. Mitral valve replacement may be performed at the same procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of adequate hospital experience as well as early referral for optimizing CVG outcomes was indicated by a study of 1962 composite valve grafts (percent MFS not known) in the United Kingdom Heart Valve Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/26\">",
"     26",
"    </a>",
"    ]. Hospital volume of &le;8 CVG procedures per year and urgent or emergency surgery were among the risk factors for 30-day mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Valve-sparing aortic root replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical procedures that retain the patient's native aortic valve are attractive alternatives to composite grafts. Two such operations are referred to as remodeling and (David) reimplantation techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The former attaches the aortic conduit to a cuff of native aorta just above the aortic valve, while the latter reimplants the native valve into the aortic graft and attaches the vascular graft to the left ventricular outflow tract.",
"   </p>",
"   <p>",
"    While anticoagulation is required for some time after surgery, life-long anticoagulation is not required for patients who undergo a valve-sparing procedure. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Postoperative issues'",
"    </a>",
"    below.) Thus, valve-sparing surgery is a good option for women who desire to become pregnant and for other patients with relative contraindications to long-term anticoagulation. Structurally abnormal valves constitute a contraindication to valve-sparing surgery.",
"   </p>",
"   <p>",
"    Although these valve sparing techniques are more complex than valve replacement, early outcomes are similar. In a report from an international registry of 151 patients undergoing aortic root surgery, those undergoing valve-sparing procedures had longer cardiopulmonary bypass times than those undergoing valve replacement, but there were no in-hospital or 30 day deaths in either group and there were similar complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data on long-term results of valve-sparing surgery are available. Patients who are considering such surgery should be advised that reoperation may be necessary. Reimplantation of the aortic valve appears to provide more stable valve function than the remodeling technique as illustrated by the following series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Johns Hopkins series of 372 patients with MFS undergoing aortic root replacement, five of 40 patients who underwent a remodeling valve-sparing procedure required late aortic valve replacement for aortic insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/31\">",
"       31",
"      </a>",
"      ]. In contrast, all 44 patients who underwent a reimplantation valve-sparing procedure had none or mild (1+) aortic regurgitation on follow-up.",
"     </li>",
"     <li>",
"      In the Toronto series of 103 of patients with MFS undergoing aortic valve sparing procedures, three of 26 patients who underwent the remodeling procedure required subsequent aortic valve replacement (two for aortic regurgitation and one for endocarditis) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/32\">",
"       32",
"      </a>",
"      ]. Of the 77 patients undergoing reimplantation, none required subsequent aortic valve replacement and only two had greater than mild aortic regurgitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Surgical guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;As recommended in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines, patients with Marfan, Loeys-Dietz or Ehlers Danlos syndromes (and others with dilated aortic root and sinuses of Valsalva) should undergo excision of the sinuses together with a modified David reimplantation operation if feasible, or, if not, root replacement with valved graft conduit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Postoperative issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-long anticoagulation is necessary for those receiving mechanical valves. In contrast, only short-term anticoagulation is required in the postoperative period, for those receiving bioprosthetic valves or valve-sparing surgery, regardless of type of repair. Low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is typically given in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/33\">",
"     33",
"    </a>",
"    ]. Most thromboembolic events occur within the first month after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is recommended in association with dental procedures for patients who have had aortic valve replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers or alternate medical therapy should be resumed postoperatively and continued indefinitely due to the recognized vulnerability of the aorta remote from the site of aortic replacement (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Beta blockers'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Coronary ostial aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;One complication of both composite and valve-sparing surgery is the development of coronary ostial aneurysms. These aneurysms develop at the site of reimplantation as a result of stretch of the weakened wall of the coronary ostium and are not likely to progress. In a report of 40 patients, ostial aneurysms were documented in 43 percent at a mean of five years after surgery; aneurysms were more common in those &le;35 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/34\">",
"     34",
"    </a>",
"    ]. Time after operation did not influence the prevalence or size of coronary ostial aneurysms, suggesting that these are not progressive.",
"   </p>",
"   <p>",
"    Rarely, pseudoaneurysms occur at the site of coronary anastomosis; these usually require surgical repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Follow-up imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial surgical repair of the ascending aorta, the arch and descending aorta are vulnerable to development of aneurysms and dissections, indicating that MFS is a disease involving the entire aorta. A significant number of patients require surgeries at other sites throughout the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients who have a dissection at the time of the first aortic surgery are more likely to require subsequent aortic surgery than those who undergo prophylactic composite graft repair.",
"   </p>",
"   <p>",
"    Periodic imaging of the entire aorta is suggested indefinitely following initial aortic repair for aortic dissection or after prophylactic repair. The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines suggest imaging the aorta at one, three, six and 12 months postdissection and then annually thereafter if stable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/2\">",
"     2",
"    </a>",
"    ]. Monitoring can be accomplished with MRI or CT angiography. Use of the same modality at the same institution facilitates comparison of images over time. If a thoracic aortic aneurysm is relatively stable and moderate in size, MRI is suggested over CT to minimize the patient's radiation exposure.",
"   </p>",
"   <p>",
"    Suggested indications for elective prophylactic replacement of the involved segment of aorta include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid increase in size (eg, &gt;5",
"      <span class=\"nowrap\">",
"       mm/year",
"      </span>",
"      or 5 percent for adults, or &gt;10",
"      <span class=\"nowrap\">",
"       mm/year",
"      </span>",
"      for children)",
"     </li>",
"     <li>",
"      Descending thoracic aortic diameter &gt;55 to 60 mm",
"     </li>",
"     <li>",
"      Affected segment diameter two-fold greater than adjacent segment, or symptoms related to aortic dilation develop",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT FOR OTHER COMPLICATIONS OF MFS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications that require attention include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ophthalmologic evaluation is suggested annually due to propensity to lens subluxation (ectopia lentis), cataract, glaucoma, and retinal detachment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Eye care includes vision correction for myopia and photocoagulation for retinal tears and detachment. Early monitoring and aggressive refraction is recommended for children with MFS to prevent amblyopia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link\">",
"       \"Overview of amblyopia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A dislocated lens should not be removed surgically unless more conservative means of correcting vision are ineffective. Indications for surgical lens extraction include lens opacity with poor visual function, refractive error not amenable to optical correction, impending complete luxation, and lens induced glaucoma or uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral valve repair or replacement is recommended for severe mitral regurgitation with associated symptoms or progressive left ventricular dilatation or systolic dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"       \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scoliosis may be initially treated with bracing but surgical correction is usually considered when the curve exceeds 40&ordm;. Surgery may also be necessary for severe pectus deformities and recurrent pneumothoraces. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=see_link\">",
"       \"Pectus carinatum\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=see_link\">",
"       \"Pectus excavatum: Treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"       \"Primary spontaneous pneumothorax in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37065?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The arthropathy associated with joint laxity may require orthopedic correction.",
"     </li>",
"     <li>",
"      Pregnancy in women with MFS is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"       \"Pregnancy and Marfan syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening of family members, genetic counseling, and prenatal genetic testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link&amp;anchor=H21#H21\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\", section on 'Screening relatives'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link&amp;anchor=H5#H5\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\", section on 'Prenatal genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26275021\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF RELATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic follow-up is indicated in patients with the MASS phenotype (",
"    <strong>",
"     m",
"    </strong>",
"    itral valve prolapse, mild",
"    <strong>",
"     a",
"    </strong>",
"    ortic dilatation,",
"    <strong>",
"     s",
"    </strong>",
"    triae atrophica, one or more",
"    <strong>",
"     s",
"    </strong>",
"    keletal features), mitral valve prolapse syndrome (MVPS) or ectopia lentis syndrome (ELS) including annual cardiovascular imaging (to monitor aortic size and mitral regurgitation) and annual ophthalmological evaluation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link&amp;anchor=H1949901#H1949901\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\", section on 'Conditions related to MFS'",
"    </a>",
"    ). Patients with either MASS phenotype or ELS should be counselled regarding the risk of more severe disease (including aortic aneurysm) in their offspring.",
"   </p>",
"   <p>",
"    Careful cardiovascular and ophthalmologic follow-up is also indicated in individuals &lt;20 years old diagnosed with potential MFS or nonspecific connective tissue disorder, since additional clinical features may emerge is such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link&amp;anchor=H3616818#H3616818\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\", section on 'Diagnosis in the young'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life span of untreated patients with the classic MFS was about 32 years in 1972. However, improved therapy has resulted in marked increases in life expectancy to 48 years in 1972 and to 72 years in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/18,35\">",
"     18,35",
"    </a>",
"    ]. Beta blockers, noninvasive aortic imaging and elective aortic root repair have all contributed to this improvement in survival. For reasons that are not well understood, life expectancy is significantly lower in men than in women.",
"   </p>",
"   <p>",
"    A family history of premature death or aortic surgery may identify patients at increased risk. In one study of 108 patients from 33 multigenerational families, those in the highest quartile for aortic size were more likely to have such a family history than those in the lowest quartile (&gt;80 versus &lt;10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5945/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=see_link\">",
"       \"Patient information: Marfan syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with Marfan syndrome (MFS), sonographic measurement of aortic diameter should be performed annually as long as the increase in aortic size remains proportional to the increase in body surface area. Twice-yearly measurements are recommended if aortic size indexed to body surface area exceeds the expected proportion. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Monitoring MFS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adults with MFS, yearly sonographic measurement of aortic root diameter is recommended as long as the diameter is &lt;45 mm; more frequent monitoring is recommend if the aortic root diameter is &ge;45 mm or if the aortic diameter shows rapid change (&ge;0.5",
"      <span class=\"nowrap\">",
"       cm/year)",
"      </span>",
"      or if there are concerns regarding heart or valve function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Monitoring MFS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Loeys-Dietz syndrome with stable aortic size documented by the first six month follow-up should have yearly magnetic resonance imaging from the cerebrovascular circulation to the pelvis since they commonly develop aneurysms that are amenable to prophylactic surgical management. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Monitoring Loeys-Dietz syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-intensity exercise, exercise that involves bursts of activity (eg, sprinting) or are likely to cause marked increases in blood pressure (eg, weight lifting or weight training) should be avoided. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Restriction of strenuous activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low- and moderate-intensity noncompetitive recreational activities may be recommended. The participation of children in school-related physical education programs should be individualized.",
"     </li>",
"     <li>",
"      A beta blocker should be used in children and adults with MFS unless there is an absolute contraindication. The dose should be individually titrated to limit heart rate to less than 100 beats per minute following submaximal exercise. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with MFS, elective aortic repair is associated with reduced mortality when compared to urgent or emergent repair. Elective surgical intervention should be considered when an adult has an aortic root diameter of &ge;50 mm and a child has a disproportionately rapid increase in aortic diameter when compared to the rate of increase in body surface area even if the diameter is &le;50 mm. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications in MFS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adult patients with Loeys-Dietz syndrome or a confirmed TGFBR1 or TGFBR2 mutation and an aortic diameter of &ge;4.2 cm by echocardiogram (internal diameter) or &ge;4.4 to 4.6 cm by computed tomographic imaging",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      magnetic resonance imaging (external diameter) it is reasonable to consider surgical repair of the aorta. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications in Loeys-Dietz syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For young children with prominent craniofacial features of Loeys-Dietz syndrome, prophylactic surgery is indicated if the aortic valve annulus is at least 18 to 20 mm and the aortic diameter exceeds the 99th percentile for age. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications in Loeys-Dietz syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing aortic root replacement, composite aortic root and valve replacement and valve-sparing surgical techniques are considerations, and the choice of operation is dependent upon patient specific considerations. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Elective replacement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/1\">",
"      Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/2\">",
"      Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. Eur Heart J 2001; 22:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/3\">",
"      Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol 1993; 22:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/4\">",
"      Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010; 47:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/5\">",
"      Groenink M, de Roos A, Mulder BJ, et al. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998; 82:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/6\">",
"      Rios AS, Silber EN, Bavishi N, et al. Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J 1999; 137:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/7\">",
"      Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994; 330:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/8\">",
"      Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999; 83:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/9\">",
"      Selamet Tierney ES, Feingold B, Printz BF, et al. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 2007; 150:77.",
"     </a>",
"    </li>",
"    <li>",
"     Wright, MJ, Dietz, HC, III. Connective tissue diseases. In: Oski's Principles and Practice of Pediatrics, McMillan, J, Oski, F (Eds), Lippincott Raven, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/11\">",
"      Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007; 298:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/12\">",
"      Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/13\">",
"      Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/14\">",
"      McLoughlin D, McGuinness J, Byrne J, et al. Pravastatin reduces Marfan aortic dilation. Circulation 2011; 124:S168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/15\">",
"      Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/16\">",
"      Hall JR, Pyeritz RE, Dudgeon DL, Haller JA Jr. Pneumothorax in the Marfan syndrome: prevalence and therapy. Ann Thorac Surg 1984; 37:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/17\">",
"      Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med 1999; 340:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/18\">",
"      Finkbohner R, Johnston D, Crawford ES, et al. Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. Circulation 1995; 91:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/19\">",
"      Gott VL, Pyeritz RE, Magovern GJ Jr, et al. Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients. N Engl J Med 1986; 314:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/20\">",
"      Gott VL. Antoine Marfan and his syndrome: one hundred years later. Md Med J 1998; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/21\">",
"      Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989; 64:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/22\">",
"      Aalberts JJ, Waterbolk TW, van Tintelen JP, et al. Prophylactic aortic root surgery in patients with Marfan syndrome: 10 years' experience with a protocol based on body surface area. Eur J Cardiothorac Surg 2008; 34:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/23\">",
"      Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg 2002; 123:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/24\">",
"      Zanotti G, Vricella L, Cameron D. Thoracic aortic aneurysm syndrome in children. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2008; :11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/25\">",
"      Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/26\">",
"      Kalkat MS, Edwards MB, Taylor KM, Bonser RS. Composite aortic valve graft replacement: mortality outcomes in a national registry. Circulation 2007; 116:I301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/27\">",
"      Karck M, Kallenbach K, Hagl C, et al. Aortic root surgery in Marfan syndrome: Comparison of aortic valve-sparing reimplantation versus composite grafting. J Thorac Cardiovasc Surg 2004; 127:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/28\">",
"      Kallenbach K, Karck M, Pak D, et al. Decade of aortic valve sparing reimplantation: are we pushing the limits too far? Circulation 2005; 112:I253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/29\">",
"      David TE. Surgical treatment of ascending aorta and aortic root aneurysms. Prog Cardiovasc Dis 2010; 52:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/30\">",
"      Volguina IV, Miller DC, LeMaire SA, et al. Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: Analysis of early outcome. J Thorac Cardiovasc Surg 2009; 137:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/31\">",
"      Cameron DE, Alejo DE, Patel ND, et al. Aortic root replacement in 372 Marfan patients: evolution of operative repair over 30 years. Ann Thorac Surg 2009; 87:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/32\">",
"      David TE, Armstrong S, Maganti M, et al. Long-term results of aortic valve-sparing operations in patients with Marfan syndrome. J Thorac Cardiovasc Surg 2009; 138:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/33\">",
"      Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005; 111:e150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/34\">",
"      Meijboom LJ, Nollen GJ, Merchant N, et al. Frequency of coronary ostial aneurysms after aortic root surgery in patients with the Marfan syndrome. Am J Cardiol 2002; 89:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/35\">",
"      Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol 1995; 75:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5945/abstract/36\">",
"      Silverman DI, Gray J, Roman MJ, et al. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol 1995; 26:1062.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8151 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5945=[""].join("\n");
var outline_f5_51_5945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AORTIC MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      How to measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Monitoring MFS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring Loeys-Dietz syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Beta blocker recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other drug therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RESTRICTION OF STRENUOUS ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AORTIC ROOT REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Elective replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Indications in MFS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Indications in Loeys-Dietz syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Symptomatic aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Composite valve graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Valve-sparing aortic root replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Surgical guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Coronary ostial aneurysms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Follow-up imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT FOR OTHER COMPLICATIONS OF MFS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26275021\">",
"      MANAGEMENT OF RELATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=related_link\">",
"      Management of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=related_link\">",
"      Patient information: Marfan syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=related_link\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=related_link\">",
"      Pectus excavatum: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=related_link\">",
"      Pregnancy and Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37065?source=related_link\">",
"      Treatment and prognosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_51_5946="Operative management of anorectal fistulas";
var content_f5_51_5946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Operative management of anorectal fistulas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5946/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5946/contributors\">",
"     Bradley J Champagne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5946/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5946/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/51/5946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/51/5946/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/51/5946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22288661\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anorectal fistula is an inflammatory tract or connection between the epithelialized surface of the anal canal and most frequently, the perianal skin or perineum. It often evolves from a spontaneously draining anorectal abscess. Perianal fistulous disease has significant implications for patient quality of life as sequelae range from minor pain and social hygienic embarrassment to frank sepsis. The management of the anorectal fistula (also called fistula-in-ano) remains one of the most challenging and controversial topics in colorectal surgery. Surgery is the mainstay of therapy with the ultimate goal of draining local infection, eradicating the fistulous tract, and avoiding recurrence while preserving native sphincter function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The surgical approach depends on several factors, such as the etiology, location, type, and duration of the fistula as well as previously performed procedures and preoperative sphincter function.",
"   </p>",
"   <p>",
"    This topic will discuss surgical management of anorectal fistulas. The causes, clinical manifestations, diagnosis, and classification of anal fistulas can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288667\">",
"    <span class=\"h1\">",
"     FISTULA ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most internal openings of the fistula are located around the anal glands surrounding the dentate line [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] since over 90 percent result from a cryptoglandular abscess originating from the crypts of Morgagni, which are located between the two layers of the anal sphincter (",
"    <a class=\"graphic graphic_figure graphicRef63704 \" href=\"UTD.htm?32/32/33284\">",
"     figure 1",
"    </a>",
"    ). Fistulas that occur between the anal orifice and the dentate line are referred to as anal in origin, while fistulas that originate above the dentate line are rectal in origin. Less commonly, fistulas occur between the anal canal or rectum and the vagina or bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The course of an anorectal fistula follows one of four paths: intersphincteric (45 percent), transsphincteric (30 percent), suprasphincteric (20 percent), or extrasphincteric (5 percent), before exiting at the perianal skin (",
"    <a class=\"graphic graphic_figure graphicRef52917 \" href=\"UTD.htm?35/43/36534\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76507 \" href=\"UTD.htm?41/54/42850\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288673\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE ANAL REGION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough knowledge of the anatomy of the anal canal, ischiorectal fossa, perirectal tissues, and the sphincteric muscles is imperative before proceeding with any operative procedure to treat an anorectal fistula (",
"    <a class=\"graphic graphic_figure graphicRef72874 \" href=\"UTD.htm?12/22/12647\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"     figure 5",
"    </a>",
"    ). The following is the anatomical description of the anal region [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288679\">",
"    <span class=\"h2\">",
"     Anal canal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anal canal begins at the anorectal junction and ends at the anal verge. The anal verge is demarcated at the site where the squamous epithelium lining the lower anal canal becomes continuous with the skin of the perineum. Anteriorly, the middle third of the anal canal is attached by dense connective tissue to the perineal body, which separates it from the membranous urethra and penile bulb in males and from the lower vagina in females. Laterally and posteriorly, the anal canal is surrounded by loose adipose tissue within the ischiorectal fossas. Posteriorly, the anal canal is attached to the coccyx by the anococcygeal ligament, a midline fibroelastic structure which may possess some skeletal muscle elements and which runs between the posterior aspect of the middle portion of the external sphincter and the coccyx. Just above this is the raphe of the levator ani muscle, the fusion of the two halves of iliococcygeus, which merges anteriorly with the puborectalis muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288685\">",
"    <span class=\"h2\">",
"     Ischiorectal fossa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ischiorectal fossa is triangular in shape and bounded by the skin inferiorly, the obturator internus muscle laterally, and the inferior surface of the levator ani as its anterior and medial border. Posteriorly, the ischiorectal space is continuous to the sacrotuberous ligament and the gluteus maximus muscle with the potential space in the buttock deep to the muscle. Superiorly, the ischiorectal fossa is sealed off by the origin of the levator ani from the inner surface of the obturator internus and the continuity of the inferior fascia of the pelvic diaphragm with the obturator fascia. Anteriorly, the ischiorectal fossa is separated from the superficial perineal space by the attachment of the perineal fascia to the posterior border of the urogenital diaphragm. The ischiorectal fossa continues forward for a short distance above the urogenital diaphragm and the lower border of the pelvic diaphragm until these two diaphragms join. The left and right ischiorectal fossas communicate posteriorly, above a portion of the external anal sphincter that extends posteriorly to attach to the coccyx (",
"    <a class=\"graphic graphic_figure graphicRef63229 \" href=\"UTD.htm?10/37/10837\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288691\">",
"    <span class=\"h2\">",
"     Internal anal sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal anal sphincter is a well-defined ring of obliquely orientated smooth muscle fibers that is continuous with the circular muscle of the rectum and terminates at the junction of the superficial and subcutaneous components of the external sphincter. The lower portion of the sphincter is crossed by fibers from the conjoint longitudinal tendon that pass into the submucosa of the lower canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288697\">",
"    <span class=\"h2\">",
"     External anal sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external anal sphincter is an oval tube-shaped complex composed mainly of skeletal muscle fibers. The muscle consists of deep, superficial, and subcutaneous parts but should be considered as a single functional and anatomical entity.",
"   </p>",
"   <p>",
"    The uppermost fibers of the external anal sphincter blend with the lowest fibers of puborectalis muscle. The fibers from the upper third attach anteriorly into the superficial transverse perineal muscles and posteriorly the fibers are attached to the anococcygeal raphe. The majority of the fibers of the middle third of the external anal sphincter surround the lower part of the internal sphincter. The middle third is attached anteriorly to the perineal body and posteriorly to the coccyx by the anococcygeal ligament. The fibers of the lower third of the muscle lie below the level of the internal anal sphincter and are separated from the lowest anal epithelium by the submucosa layer.",
"   </p>",
"   <p>",
"    The transverse perinei and bulbospongiosus muscles fuse with the external sphincter in the lower part of the perineum. The perineal body attaches the external anal sphincter muscle to the surrounding structures and is an imbrication of muscle fibers in females in comparison to a central tendinous insertion in men. Also in females, the anterior and lateral portion of the external anal sphincter is significantly shorter and is oriented in a horizontal plane. In males, the external sphincter is more anular and is separate from the central point of the perineum, so that there is a surgical plane of cleavage between the external sphincter and perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288703\">",
"    <span class=\"h2\">",
"     Mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper part of the anal canal is lined by mucosa similar to the rectum, while the lower portion is lined by stratified epithelium similar to the skin of the perianal region. The line around the anal canal that can be traced by following the anal columns is the pectinate line (also called the dentate line or mucocutaneous line). This line represents the change in epithelium as well as lymphatic drainage, blood supply, and venous drainage. The pectinate line is palpated or visualized approximately 2 cm above the anal opening.",
"   </p>",
"   <p>",
"    At the junction of these two types of lining are the anal columns, longitudinal and wider at the distal end, while fading at the proximal end of the canal. They are united distally by thin membranes called anal valves. Between the bases of the longitudinal columns and the anal valves are anal sinuses, rudimentary anal glands (also called crypts or ducts), which open into the anal sinuses. An infection of an anal sinus and gland can develop into an abscess. The abscess develops a fistula that can extend from the anal canal into the perianal musculature, the ischiorectal fossa, and the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288709\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall goal of surgery is to eradicate the fistula, preserve anal sphincteric function, and prevent a recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    .) The tremendous variability of patient factors and heterogeneity of anorectal fistulas requires a greater need for surgical \"judgment\" than in most colorectal diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288715\">",
"    <span class=\"h2\">",
"     Initial office visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate management and long-term success of treating the fistula begins with the first patient encounter in the surgeon's office or emergency room. The internal and external openings of the fistulous tract need to be identified. The external opening may be seen on external examination; the typical appearance is a small dimpled area of granulation tissue that drains pus or blood on manual compression. The internal opening may be identified by anoscopy with manual compression over the external opening. Proctoscopy is also indicated in the presence of rectal disease, such as Crohn's disease or other suppurative conditions.",
"   </p>",
"   <p>",
"    A digital rectal examination is performed on every patient to assess for an indolent or incompletely drained abscess (",
"    <a class=\"graphic graphic_figure graphicRef78125 \" href=\"UTD.htm?5/32/5634\">",
"     figure 7",
"    </a>",
"    ). In contrast, most patients will not tolerate even gentle probing of the fistula track in the office setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288721\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple imaging options for the evaluation of anorectal fistulae. The choice of which modality, if any, to implement is dependent on equipment availability, radiologist expertise, patient tolerance, cost, and the proposed management strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anatomy of most fistulas can be determined in the operating room without preoperative imaging. If the internal openings and extent of sphincter involvement are difficult to identify, intraoperative radiographic studies can be helpful. We commonly use 3-dimensional ultrasound intraoperatively to evaluate recurrent or complicated fistulas. Peroxide can be used with this technique to outline the fistula tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288727\">",
"    <span class=\"h2\">",
"     Surgical planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined medical and surgical therapy is the primary treatment modality if the fistula is secondary to Crohn's disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for surgery is determined 6 to 12 weeks after treatment of the initial anorectal abscess or other septic process. If drainage persists after the initial incision and drainage of an abscess, and a fistula is suspected, surgery is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    .) In our practice, patients are instructed that they will undergo an examination under anesthesia and either a primary fistulotomy or seton placement at that time, depending on both the amount of muscle involved and other characteristics of the fistula. A seton is always placed if there are concerns for incontinence and as the first stage prior to an advancement flap, fistula plug, a \"cutting\" seton, or the ligation of the intersphincteric fistula tract (LIFT). The second operation, if needed, is typically at least six weeks following the first stage and be delayed longer if drainage is still copious. Clinical experience has shown that fistulotomy is an effective procedure for simple submucosal, intersphincteric, and low-sphincteric fistulas, while staged procedures are a better approach for complex fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22288793\">",
"     'Procedures for simple fistulas'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22288835\">",
"     'Procedures for complex fistulas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The major postoperative risks of surgical management of anorectal fistulas include incontinence and recurrences, and should be addressed when discussing treatment options. Fistulas located in the lateral position, complex fistulas, those with horseshoe extensions, and lack of identification of the internal opening have an increased risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/12\">",
"     12",
"    </a>",
"    ]. The risk of postoperative incontinence is higher with anterior fistulas in women, high anal fistulas, previous fistula surgery, and fistulotomy with or without setons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288733\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, patients are advised to maintain a clear liquid diet for 24 hours prior to surgery, and take two enemas the morning of surgery, if tolerated. We also advise patients to discontinue all drugs that can prolong bleeding (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    containing medications, anti-inflammatory drugs). A mechanical bowel preparation is only required for patients undergoing a planned simultaneous sphincter reconstruction or extensive rotational flap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288739\">",
"    <span class=\"h1\">",
"     PROCEDURE SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical management of the anorectal fistula depends on the location of the fistula in relation to the external anal sphincter (Parks' classification) and the amount of the sphincter complex involved with the fistulous tract (",
"    <a class=\"graphic graphic_figure graphicRef52917 \" href=\"UTD.htm?35/43/36534\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=see_link&amp;anchor=H1062220#H1062220\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\", section on 'Classification'",
"    </a>",
"    .) No single operative technique is appropriate for the treatment of all anorectal fistulas; hence, the judgment and experience of the surgeon must guide the treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 63 clinical studies for the treatment of anal fistulous cryptoglandular abscesses identified 35 different treatment methods and a considerable lack of information on morbidity, operative criteria, nine different classifications of fistulas or unclear definitions, lack of information on factors influencing outcomes, and flawed randomization procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure selected for an individual patient is based on a thorough physical examination of the anal region. The key technical component of all operative procedures is the identification and curetting of the internal opening to ensure adequate drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288745\">",
"    <span class=\"h2\">",
"     Simple fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fistulas are simple (minimal involvement of the external sphincter muscle) and classified as low-laying transsphincteric and intersphincteric fistulas (",
"    <a class=\"graphic graphic_picture graphicRef56209 \" href=\"UTD.htm?10/58/11168\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/1\">",
"     1",
"    </a>",
"    ]. The traditional approach to treatment is primary fistulotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/15\">",
"     15",
"    </a>",
"    ]. Fibrin sealant injected into the fistulous tract is another option. No randomized trials or large studies have compared outcomes from these procedures. (See",
"    <a class=\"local\" href=\"#H22288793\">",
"     'Procedures for simple fistulas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288751\">",
"    <span class=\"h2\">",
"     Complex fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complex fistula refers to those fistulas that have a high risk of treatment failure and cannot be safely treated by routine fistulotomy. An anal fistula is defined as complex in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any fistula involving more than 30 percent of the external sphincter",
"     </li>",
"     <li>",
"      Suprasphincteric fistulas",
"     </li>",
"     <li>",
"      Extrasphincteric or high fistulas, proximal to the dentate or pectinate line",
"     </li>",
"     <li>",
"      Women with anterior fistulas",
"     </li>",
"     <li>",
"      Fistulas with multiple tracts",
"     </li>",
"     <li>",
"      Recurrent fistulas",
"     </li>",
"     <li>",
"      Fistulas related to inflammatory bowel disease",
"     </li>",
"     <li>",
"      Fistulas related to infectious diseases including tuberculosis and human immunodeficiency virus",
"     </li>",
"     <li>",
"      Fistulas secondary to local radiation treatments",
"     </li>",
"     <li>",
"      Patients with a history of anal incontinence",
"     </li>",
"     <li>",
"      Rectovaginal fistulas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link\">",
"       \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary fistulotomy alone is inadequate treatment of complex fistulas because of the high risk of postoperative incontinence, so alternative approaches are necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11,15,16\">",
"     11,15,16",
"    </a>",
"    ]. For patients with a complex fistula, including those who fail medical management, draining setons are used at the time of the first operation to preserve the sphincter mechanism and help eradicate the septic focus. The options for second stage management include endoanal advancement flaps, fibrin glue, fistula plugs, modified Hanley procedure, ligation of the intersphincteric fistula tract, or diversion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11,17,18\">",
"     11,17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22288835\">",
"     'Procedures for complex fistulas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288757\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The position of the patient and adequate administration of analgesia are key components for performing the described operative procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288763\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of preoperative antibiotics has not been established for anorectal surgery. In our practice, broad spectrum antibiotics are administered intravenously before the start of the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288769\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of anesthetic is determined by the preference of the patient and surgeon and the general medical condition of the patient. Options include a general anesthetic or locoregional anesthesia, such as a four quadrant pudendal nerve block with 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    . Most patients will do well with a local anesthetic supplemented with intravenous medication for a light sedation. At the conclusion of the procedure, local injection of a long-acting local anesthetic provides several hours of comfort after the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288775\">",
"    <span class=\"h2\">",
"     Position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate positioning facilitates visualization of the internal opening. The lithotomy position is the preferred position for patients with a posterior external opening and when performing advancement flaps, ligation procedures, and diversion. Patients with anterior external openings, Crohn&rsquo;s disease, and most morbidly obese patients are positioned in the prone jackknife position [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288781\">",
"    <span class=\"h2\">",
"     Anal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anal examination is an important component of all fistula procedures. Palpation of the anal canal, the tract, and surrounding structures is performed to determine the amount of sphincter muscle involved (",
"    <a class=\"graphic graphic_figure graphicRef78125 \" href=\"UTD.htm?5/32/5634\">",
"     figure 7",
"    </a>",
"    ). The anal canal is gently dilated digitally, the pectinate line is visualized, and the anal crypts are examined for evidence of inflammation and an internal opening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288787\">",
"    <span class=\"h2\">",
"     Internal opening identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of the internal opening of the fistula is another key element common to all fistula procedures. Lack of identification of the internal opening is one reason for failure of any given technique [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/19\">",
"     19",
"    </a>",
"    ]. Dilute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    or dilute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    is infused via an angiocatheter into the external opening of the fistula while examining the anal canal with an anoscope. Visualization of hydrogen peroxide bubbles or povidone iodine at the internal opening confirms the internal location of the fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288793\">",
"    <span class=\"h1\">",
"     PROCEDURES FOR SIMPLE FISTULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following procedures are used to treat simple fistulas. The key technical component of all operative procedures is the identification and curetting of the internal opening to ensure adequate drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11\">",
"     11",
"    </a>",
"    ]. All procedures include dilatation of the anal canal and anoscopy. Complex fistulas are approached differently. (See",
"    <a class=\"local\" href=\"#H22288841\">",
"     'Fistulotomy and setons'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288799\">",
"    <span class=\"h2\">",
"     Fistulotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistulotomy involves laying open the fistula tract in its entirety. The most critical step in this procedure is to identify and curette the internal opening to reduce the risk of recurrence. In a randomized trial of primary fistulotomy for perianal abscesses in 52 patients, persistent fistulas occurred in seven patients (25 percent) treated with and incision and drainage compared to no recurrences in 24 patients treated with a fistulotomy (",
"    <a class=\"graphic graphic_figure graphicRef69997 \" href=\"UTD.htm?21/14/21729\">",
"     figure 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80548 \" href=\"UTD.htm?25/11/25779\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288805\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;A probe is inserted into the internal opening and gently passed along the fistula tract to the external opening. An incision is made over the entire length of the fistula using the probe as a guide. The tract is gently curetted, and an absorbable stitch is used to marsupialize the tract to promote healing.",
"   </p>",
"   <p>",
"    The wound is gently packed with a petroleum-based gauze and covered with a sterile dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288811\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be observed for a minimum of six months following the procedure before determining a treatment failure or success [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/21\">",
"     21",
"    </a>",
"    ].The most concerning potential complication of a fistulotomy is incontinence from procedure-related damage to the external anal sphincter. The divided muscle fibers retract, and the result is solid fecal, liquid fecal, or gas incontinence. The reported rates of incontinence are highly variable, ranging from 0 to 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence rates for an anorectal fistula treated with a fistulotomy are generally reported to be low, with success rates ranging from 79 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/19,20,22,23,25-28\">",
"     19,20,22,23,25-28",
"    </a>",
"    ]. In an observational study with median 76 months follow-up, the three year recurrence rate for 109 patients with a low-lying simple fistula treated was 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288817\">",
"    <span class=\"h2\">",
"     Fibrin sealant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin sealant is a minimally invasive treatment option for simple fistulas. A mixture of fibrinogen, thrombin, and calcium ions form a clot that is injected into the fistula tract and within 10 to 60 seconds the fistula is potentially sealed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This approach avoids sphincter division but long-term results have not been encouraging (",
"    <a class=\"graphic graphic_picture graphicRef54580 \" href=\"UTD.htm?0/26/431\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288823\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;A catheter is typically inserted through the external opening and advanced to the internal opening. At the internal opening, a seal is created with fibrin, and then 2 to 5 mL of fibrin sealant is injected as the catheter is withdrawn. At the external opening, another plug is created resulting in a dumbbell shaped seal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288829\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence rate for fistulas repaired with fibrin glue alone ranges from 14 to 69 percent, depending on the complexity of the fistula, duration of observation, and technical aspects, such as debridement of the fistulous openings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/17,18,31\">",
"     17,18,31",
"    </a>",
"    ]. In one long-term observational study, 14 of 26 patients (54 percent) with a simple fistula injected with autologous fibrin tissue adhesive had complete closure at one year compared with 34 of 53 patients (64 percent) treated with a commercial preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/21\">",
"     21",
"    </a>",
"    ]. Most of the recurrences were evident at three months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/32\">",
"     32",
"    </a>",
"    ]. Similar fibrin glue experiences have been reported when substituting polymerized bovine serum albumin and glutaraldehyde (eg, BioGlue Surgical Adhesive) for fibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial including only 13 patients compared fistulotomy to fibrin glue for treatment of a simple fistula and reported no recurrences in 7 of 7 patients treated by fistulotomy and 3 of 6 patients treated by fibrin glue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/34\">",
"     34",
"    </a>",
"    ]. There was no change in baseline incontinence score in either group.",
"   </p>",
"   <p>",
"    Fibrin sealant injections are not recommended for patients with complex transsphincteric, suprasphincteric or extrasphincteric fistulas. In a prospective observational study, the success rate of fibrin glue in this population (n = 16) was 14 percent at 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/32\">",
"     32",
"    </a>",
"    ]. In another prospective study, fibrin glue healed 46 percent of complex fistulas (n = 13) with one treatment while the success rate for a fistulotomy was only 13 percent (n = 16). However, these studies are limited by their small numbers of study subjects, the lack of strict comparison of classifications of the fistulas, and a relatively short duration of observation.",
"   </p>",
"   <p>",
"    The main benefit of fibrin glue is sphincter preservation. Fibrin glue extravasation from within the fistula tract and failure to identify and completely fill all branches of the tract with glue are the likely explanations for long-term failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288835\">",
"    <span class=\"h1\">",
"     PROCEDURES FOR COMPLEX FISTULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following procedures are used to treat complex fistulas. All procedures include dilatation of the anal canal, anoscopy, and identification of the internal opening. (See",
"    <a class=\"local\" href=\"#H22288757\">",
"     'Intraoperative preparation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288841\">",
"    <span class=\"h2\">",
"     Fistulotomy and setons",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cutting seton is a reactive suture or elastic that is placed through the fistula tract and tightened at regular intervals. It slowly cuts through the tract, causing scarring, thus preventing the wide disruption of the anal sphincter associated with fistulotomy. A noncutting or draining seton is a seton that is placed primarily for drainage. It does not cut through the sphincter. For complex fistulas, including those that traverse greater than 30 percent of the sphincter, are proximal to the dentate line, or high transsphincteric fistulas, draining setons are used at the time of the first operation to preserve the sphincter mechanism, and help eradicate the septic focus (",
"    <a class=\"graphic graphic_figure graphicRef63341 \" href=\"UTD.htm?22/30/23009\">",
"     figure 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79569 \" href=\"UTD.htm?39/53/40788\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288847\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal opening is identified and a probe inserted between the internal and external openings as previously described. (See",
"    <a class=\"local\" href=\"#H22288757\">",
"     'Intraoperative preparation'",
"    </a>",
"    above.) The skin bridge is opened completely between the internal and external openings, and a small piece of braided silk or an elastic vessel loop is pulled through the fistulous tract. This seton is secured snugly around the sphincter (",
"    <a class=\"graphic graphic_figure graphicRef63341 \" href=\"UTD.htm?22/30/23009\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients are examined at monthly intervals, and the seton is tightened until the deep space is obliterated. The suture promotes granulation tissue formation and allows the edges of the wound to become firm before the sphincter is divided. The seton will slowly divide the fistulous tissue tract on the leading edge of the seton while allowing healing to occur on the trailing edge, and preserving sphincter continuity and theoretically preserving sphincter function. Incontinence occurs not because the sphincter muscle is divided, but when the muscle fibers retract and the space in between is filled with scar tissue.",
"   </p>",
"   <p>",
"    There is a wide variation of times that cutting setons remain in situ. Shortened periods of cutting may result in poor outcomes. From basic biology principles, significant collagen deposition and fibrosis occur over a period of four to six weeks, so setons that cut through more rapidly than this may not provide adequate time for scarring to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288853\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most important complications of a fistulotomy with a cutting seton are recurrence and incontinence. The success rates for cutting setons range from 82 to 100 percent, however, long-term incontinence rates can exceed 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/23,24,26,27\">",
"     23,24,26,27",
"    </a>",
"    ]. Leaving draining setons indefinitely results in low-grade incontinence of gas, mucous, or fluid discharge, and has an adverse impact on quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis (n=35 patients) of the long term results of a cutting seton as a treatment for high transsphincteric, low transsphincteric, extrasphincteric, and suprasphincteric fistulas revealed successful repair in 94 percent of patients and new minor incontinence in 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/37\">",
"     37",
"    </a>",
"    ]. The recurrences were in patients with high transsphincteric fistulas. There was no difference in incontinence between men and women. The mean time to sphincter division was 87 days and the mean time for complete healing was 151 days.",
"   </p>",
"   <p>",
"    A randomized trial compared the risks of incontinence of a modified cutting seton technique, which includes the repair of the internal anal sphincter and directing the seton through the intersphincteric space, with the conventional cutting seton technique in 34 patients with high transsphincteric fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/38\">",
"     38",
"    </a>",
"    ]. There was no significant difference in incontinence rates, resting anal manometric pressures, healing rates or recurrence rates between the two techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288859\">",
"    <span class=\"h2\">",
"     Advancement flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endoanal and endorectal advancement flaps preserve the anal sphincter by closing off the internal opening of the fistula by a mobilized flap of healthy tissue consisting of mucosa and submucosa, with or without the internal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/39\">",
"     39",
"    </a>",
"    ]. The flap provides tissue coverage of tract internal opening and allows the tract to heal and close (",
"    <a class=\"graphic graphic_figure graphicRef79234 \" href=\"UTD.htm?30/27/31155\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Endoanal and endorectal advancement flaps are the preferred approach for complicated anorectal fistulae without coexisting incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/40\">",
"     40",
"    </a>",
"    ]. Not all anorectal fistula patients are candidates for mucosal flap advancement. Very high fistulas, for example, are technically challenging to treat by this technique. Additionally, anal stenosis, active proctitis, and inflammatory bowel disease are relative contraindications due to high complication and failure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288865\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key component of this procedure is to create a flap that includes the mucosa, submucosa, and a portion of the circular muscular fibers that is sufficient to cover the internal opening.",
"    <strong>",
"    </strong>",
"    The base of the flap proximally should measure at last twice its width at the apex. The flap is raised by making a curvilinear incision around the dentate line. The incision should not extend more than one third of the anal canal circumference to prevent stricture formation. If dilute epinephrine is used to control bleeding, care should be taken not to raise a flap that is too thin. A thin flap may result in ischemia and may not provide sufficient integrity to adequately cover the internal opening and prevent recurrence.",
"   </p>",
"   <p>",
"    After the fistulous tract is curetted and debrided, the flap is advanced and sutured in place. We prefer to anchor the center and most cephalad portion of the underside of the flap first, then the lateral portion of the flap is secured with a running or interrupted suture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288871\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of endoanal advancement flap techniques exist, and in experienced hands, have low recurrence rates (0 to 36 percent) and tolerable incontinence rates ranging from 0 to 12.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The wide range in outcomes is due to heterogeneity in patient populations, technique, and experience.",
"   </p>",
"   <p>",
"    A long-term prospective observational study including 70 patients with high transsphincteric fistulas reported that endoanal flap was successful in 79 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective single institution study, 48 of 105 patients had an endorectal advancement flap performed for a cryptoglandular fistula; the percent of fistulas that were complex or simple or recurrent was not described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/43\">",
"     43",
"    </a>",
"    ]. The mean follow-up was 17.1 months, and the mean time to recurrence among patients who recurred was 2.8 months. Thirty-seven of the 48 patients (78 percent) had a successful repair defined by recurrence and incontinence metrics. A prior fistulotomy did not influence outcome. Successful repair was more likely when surgery was performed within three months of the fistula occurrence compared to when the procedure was delayed for greater than six months (success rate 70 versus 62 percent). The rate of a successful repair was significantly lower in patients with Crohn&rsquo;s disease (success rate 50 percent), which was the underlying diagnosis in 44 of the 48 patients. Another large, single institution retrospective study also observed that success rates were higher in patients with cryptoglandular disease than in those with Crohn&rsquo;s disease (success rate 67 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer to use an endoanal advancement flap or a cutting seton for definitive management for patients with recurrences. (See",
"    <a class=\"local\" href=\"#H22288859\">",
"     'Advancement flaps'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22288895\">",
"     'Modified Hanley procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288877\">",
"    <span class=\"h2\">",
"     Advancement flap with fibrin sealant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin glue can be used with an endoanal flap, but may be associated with a higher recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11,17,18\">",
"     11,17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22288817\">",
"     'Fibrin sealant'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288883\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal opening is excised, and the fistulous tract is curetted. The advancement flap is created to sufficiently cover the internal fistula opening.(See",
"    <a class=\"local\" href=\"#H22288859\">",
"     'Advancement flaps'",
"    </a>",
"    above.) Fibrin glue is injected into the external opening retrograde towards the internal opening under direct vision of the advancement flap. Care must be taken to prevent flap dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288889\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective review of 127 patients with high anorectal fistulas treated with an advancement flap found an overall recurrence rate of 26 percent with a mean follow-up of 13 months. Included in this cohort were 26 consecutive patients treated with obliteration of the fistula tract with fibrin glue in addition to the advancement flap. In patients without previous fistula surgery, the advancement flap with glue (n=5) was associated with a significantly higher recurrence rate than an advancement flap alone (n=4, recurrence rate 56 versus 13 percent). There was no significant difference in recurrence rates for patients with a prior fistula procedure, although the trend was for a higher recurrence in the patients treated with an advancement flap and fibrin glue than with advancement flap alone (recurrence rate 41 versus 23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear why the addition of fibrin glue results in a higher recurrence rate; however, this study was limited by the small number of patients treated with the combination of techniques. Given these data, the optimum treatment for patients with a high transsphincteric fistula appears to be an advancement flap without fibrin glue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288895\">",
"    <span class=\"h2\">",
"     Modified Hanley procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified Hanley procedure is a sphincter preserving procedure for the treatment of horseshoe abscesses and fistulas (",
"    <a class=\"graphic graphic_picture graphicRef79569 \" href=\"UTD.htm?39/53/40788\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link&amp;anchor=H88523161#H88523161\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\", section on 'Horseshoe abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modified Hanley procedure is performed in difficult cases of anorectal fistulas including patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Horseshoe fistulas",
"     </li>",
"     <li>",
"      Ischiorectal fistulas",
"     </li>",
"     <li>",
"      Deep post-anal abscesses with fistulas",
"     </li>",
"     <li>",
"      Recurrent fistulas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288901\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key components of this technique are to identify and drain all fistulous tracts. A probe is inserted through the internal opening into the deep space abscess cavity. An incision is made in the posterior midline, initially avoiding the superficial external sphincter. The midline incision is then deepened parallel to and through the fibers of the superficial external sphincter, thereby unroofing the deep space for drainage. A probe is then guided through the internal opening to exit through the midline surgical incision. The walls of the deep space are inspected to identify limbs of the horseshoe abscess fistula.",
"   </p>",
"   <p>",
"    If a deep post-anal abscess or extension into the ischiorectal fossa is identified, we prefer to use a modified Hanley technique for definitive management with draining lateral setons and a cutting seton in the posterior midline.",
"   </p>",
"   <p>",
"    A counter incision is made over the appropriate site with the subsequent incision, drainage, and curettage of all of the fistulous tracts. Next, the seton is attached to the midline probe and retrieved through the internal opening and secured to itself with a 0 silk suture. The underlying perianal skin and anoderm between the primary midline opening and the secondary midline surgical incision is removed to allow subsequent tightening of the seton. A Penrose drain is placed in the tract and removed 24 to 48 hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288907\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective review of 23 patients with high transsphincteric horseshoe fistulas treated by a modified Hanley procedure using cutting setons, 91 percent had complete healing within eight months, and no incontinence was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/46\">",
"     46",
"    </a>",
"    ]. This procedure requires months of postoperative care, but is safe and effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288913\">",
"    <span class=\"h2\">",
"     Fistula plug",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biosynthetic fistula plug is made of lyophilized porcine small intestinal mucosa. It does not generate a foreign body reaction or necessitate disruption of the anal sphincter, and it eliminates the risk of sphincter dysfunction associated with other procedures, such as fistulotomy and setons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/11,48\">",
"     11,48",
"    </a>",
"    ]. The fistula plug was designed to ameliorate postoperative incontinence in high-risk fistula patients, such as fistulas with high internal openings, anterior fistulas, or those that transverse significant portions of sphincter muscle (",
"    <a class=\"graphic graphic_picture graphicRef68400 \" href=\"UTD.htm?43/35/44596\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288919\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;If setons were previously placed in the fistula tract, they are left in place at the start of the operation to aid in visualizing the tract and subsequent fistula plug placement. (See",
"    <a class=\"local\" href=\"#H22288841\">",
"     'Fistulotomy and setons'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once the anatomy of the fistula is confirmed, the fistula plug is prepared by immersion into isotonic saline. A 2-0 silk suture is introduced into the internal opening and pulled through the entire length of the fistula tract with the assistance of the previously placed silastic seton or a lacrimal probe. With the suture coursing through the fistula tract, the tapered end of the fistula plug is attached and the plug is pulled into the fistula from the internal opening toward the external opening until snug.",
"   </p>",
"   <p>",
"    Excess fistula plug material is trimmed from both ends. The fistula tract length is determined by subtracting the length of trimmed excess plug material from the original plug length. The fistula plug is fixed and buried within the internal sphincter at the internal opening by a large figure-of-eight stitch with an absorbable suture. Care is taken to avoid occluding the external opening of the tract, thereby preserving a route for external drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288925\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial reports of the fistula plug were favorable, particularly in high risk fistula patients in whom treatment with fistulotomy, cutting setons, or mucosal advancement flaps were ineffective or caused unacceptably high incontinence rates. Later observational studies had conflicting results. A prospective cohort study comparing the fistula plug technique with fibrin glue found that the fistula plug closure was significantly more successful than fibrin glue closure at three months (success rate 87 versus 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/49\">",
"     49",
"    </a>",
"    ]. A follow-up study that included the original fistula plug cohort found that the success rate of the fistula plug remained high at 83 percent at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the success achieved in these earlier reports has not been replicated in subsequent retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Randomized trials are needed to determine the relative efficacy of these two procedures.",
"   </p>",
"   <p>",
"    A randomized trial of 60 patients with a high perianal fistula (transsphincteric, upper two-thirds of the sphincter complex) compared a fistula plug with an advancement flap [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/53\">",
"     53",
"    </a>",
"    ]. At 11 months, patients treated with a fistula plug had a higher rate of recurrence (71 versus 52 percent) and lower rates of postoperative soilage (29 versus 48 percent). However, these differences were not statistically significant, indicating that the number of patients in the trial was too small to detect significant differences of this magnitude. Larger randomized trials are needed. Technically, insertion of the fistula plug is a minimally invasive procedure and less complicated than an advancement flap, and may serve as an initial treatment option for high perianal fistulas. (See",
"    <a class=\"local\" href=\"#H22288859\">",
"     'Advancement flaps'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288931\">",
"    <span class=\"h2\">",
"     Ligation of the intersphincteric fistula tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ligation of the intersphincteric fistula tract (LIFT) is a sphincter-sparing procedure for complex transsphincteric fistulas first described in 2009 (",
"    <a class=\"graphic graphic_figure graphicRef77076 \" href=\"UTD.htm?9/40/9859\">",
"     figure 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68842 \" href=\"UTD.htm?15/22/15715\">",
"     picture 6",
"    </a>",
"    ).This approach is performed through the intersphincteric plane. The procedure is based on the secure closure of the internal opening and removal of infected cryptoglandular tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/14,54,55\">",
"     14,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288937\">",
"    <span class=\"h3\">",
"     Critical elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intersphincteric tract is identified and isolated by meticulous dissection. Once isolated, the intersphincteric tract is hooked using a small, right-angled clamp. The tract is ligated close to the internal sphincter and then divided distal to the point of ligation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     Hydrogen peroxide",
"    </a>",
"    is injected through the external opening to confirm the division of the correct tract. The external opening and the remnant fistulous tract are curetted to the level of the proximity of the external sphincter complex. Finally, the intersphincteric incision is loosely reapproximated with an absorbable suture. The curettaged wound is left opened for dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288943\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes data are limited. In observational series of mixed patient populations (recurrent, transsphincteric, or high fistulas), primary healing was achieved in approximately 60 to 80 percent of patients over 1 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/14,54,56\">",
"     14,54,56",
"    </a>",
"    ]. In a randomized trial of 39 patients with complex ARF who failed previous fistula operations, patients treated by the LIFT approach had similar probability of recurrence at 19 months compared with patients undergoing an anorectal advancement flap (2 of 25 [8 percent] versus 1 of 14 [7 percent] patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/57\">",
"     57",
"    </a>",
"    ]. However, patients undergoing the LIFT procedure had a statistically shorter time to return to work (1 versus 2 weeks) and no difference in incontinence scores. Data on long-term outcomes and from larger randomized surgical trials will help to determine whether this sphincter-sparing technique will be a viable alternative to the traditional procedures for anorectal fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288949\">",
"    <span class=\"h2\">",
"     Diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we rarely create a diverting stoma to facilitate the treatment of cryptoglandular anorectal fistula disease. Select patients with severe anorectal Crohn's disease, reoperative rectovaginal fistulas, perineal necrotizing fasciitis, and radiation-induced fistulas may require diversion to heal a persistent fistula. Fecal diversion alone is effective in these select patients, but long-term success following reanastomosis is low because of recurrence from the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/51/5946/abstract/58\">",
"     58",
"    </a>",
"    ]. There are no parameters to identify those in whom a successful outcome is likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288955\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are routinely discharged home the same day as the procedure. Pain is managed by nonsteroidal anti-inflammatory medications or opioids, depending on the extent of the procedure.",
"   </p>",
"   <p>",
"    Our general postoperative instructions are as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22290942\">",
"    <span class=\"h2\">",
"     Activity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activity as tolerated.",
"     </li>",
"     <li>",
"      No lifting over 20 pounds for two weeks.",
"     </li>",
"     <li>",
"      No strenuous exercise, running, or aerobics for two weeks.",
"     </li>",
"     <li>",
"      No driving for 48 hours post-surgery and none while taking narcotics.",
"     </li>",
"     <li>",
"      Do not use a doughnut shaped pillow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22290948\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consume a high fiber diet.",
"     </li>",
"     <li>",
"      Add a dietary fiber supplement two to three times a day in juice, coffee, or an noncarbonated beverage.",
"     </li>",
"     <li>",
"      Drink two liters of water or an electrolyte balanced drink daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22290960\">",
"    <span class=\"h2\">",
"     Hygiene",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soak the anal opening in a Sitz bath of warm water, for 15 minutes, three times a day, and after each bowel movement.",
"     </li>",
"     <li>",
"      Use moist cotton pads or moist towelettes rather than toilet tissue",
"     </li>",
"     <li>",
"      Place a cotton ball between buttocks at the anal opening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22290973\">",
"    <span class=\"h2\">",
"     Bowel management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Take two tablespoons of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      for the first five nights, discontinue for loose stools.",
"     </li>",
"     <li>",
"      If no bowel movement for 72 hours, or if severe straining occurs, take Milk of Magnesia one tablespoon every four to six hours until relief.",
"     </li>",
"     <li>",
"      If constipation continues for 48 hours after beginning Milk of Magnesia, then consume 10 ounces of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Slight bleeding with bowel movements is expected. Contact office for excessive (one half cup) of blood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288961\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Office-based anoscopy is performed at three and six months following the procedure. Failure of the procedure is defined as either: (1) patient complaints of persistent drainage, (2) anoscopic identification of persistent abscess or external fistula opening, or (3) development of abscess or infection requiring additional surgery. The risk of these complications is described above with the discussion of specific procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/23/20849?source=see_link\">",
"       \"Patient information: Anal abscess and fistula (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22288967\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anorectal fistulas are a heterogeneous group of disorders that can cause significant pain, social impairment, hygienic disdain, and rarely, sepsis. Surgery is the mainstay of treatment for anorectal fistulas unrelated to Crohn's disease, other infectious processes or malignancy, yet no one procedure is universally efficacious and safe. (See",
"      <a class=\"local\" href=\"#H22288661\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a primary fistulotomy for a well-drained, low-laying transsphincteric and intersphincteric simple fistula (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22288799\">",
"       'Fistulotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest inserting a fistula plug as the initial surgical management of a high, transsphincteric fistula (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the fistula recurs, an advancement flap should be performed. (See",
"      <a class=\"local\" href=\"#H22288913\">",
"       'Fistula plug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest performing an advancement flap to treat a complex fistula (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22288859\">",
"       'Advancement flaps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest performing the modified Hanley procedure, which incorporates a posterior midline incision and unroofing of all fistulous tracts or an advancement flap for patients with horseshoe fistulas, ischiorectal fistulas, deep post-anal abscesses with fistulas, and recurrent fistulas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22288895\">",
"       'Modified Hanley procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/1\">",
"      Williams JG, Farrands PA, Williams AB, et al. The treatment of anal fistula: ACPGBI position statement. Colorectal Dis 2007; 9 Suppl 4:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/2\">",
"      Gurer A, Ozlem N, Gokakin AK, et al. A novel material in seton treatment of fistula-in-ano. Am J Surg 2007; 193:794.",
"     </a>",
"    </li>",
"    <li>",
"     Bastawrous, A, Cintron, J. Anorectal abscess and fistula. In: Current Surgical Therapy, Cameron, J (Eds), Elsevier Mosby, Philadelphia 2004.",
"    </li>",
"    <li>",
"     Lowney, J, Fleshman, J. Benign Disorders of the Anorectum. In: Maingot's Abdominal Operations, 11th edition, Zinner, M, Ashley, S (Eds), McGraw-Hill, New York 2007. p.661.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/5\">",
"      Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     Hollingstead, HW. The perineum. In: Textbook of anatomy, Hollinshead, HW (Eds), Harper and Row, Hagerstown, Maryland 1974.",
"    </li>",
"    <li>",
"     Boileau, Grant, JC. Perineum and pelvis. In: An atlas of anatomy, The Williams and Wilkins Co., Baltimore 1972.",
"    </li>",
"    <li>",
"     Large Intestine. In: Gray's Anatomy: The Anatomical Basis of Clinical Practice, 40th edition, Standring, S (Eds), Elsevier, 2008. p.1137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/9\">",
"      Rociu E, Stoker J, Eijkemans MJ, Lam&eacute;ris JS. Normal anal sphincter anatomy and age- and sex-related variations at high-spatial-resolution endoanal MR imaging. Radiology 2000; 217:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/10\">",
"      Sahni, VA, Burling, D. Imaging of anorectal fistula. Semin Colon Rectal Surg 2009; 20:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/11\">",
"      Rizzo JA, Naig AL, Johnson EK. Anorectal abscess and fistula-in-ano: evidence-based management. Surg Clin North Am 2010; 90:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/12\">",
"      Garcia-Aguilar J, Belmonte C, Wong WD, et al. Anal fistula surgery. Factors associated with recurrence and incontinence. Dis Colon Rectum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/13\">",
"      Holzheimer RG, Siebeck M. Treatment procedures for anal fistulous cryptoglandular abscess--how to get the best results. Eur J Med Res 2006; 11:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/14\">",
"      Shanwani A, Nor AM, Amri N. Ligation of the intersphincteric fistula tract (LIFT): a sphincter-saving technique for fistula-in-ano. Dis Colon Rectum 2010; 53:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/15\">",
"      Whiteford MH, Kilkenny J 3rd, Hyman N, et al. Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised). Dis Colon Rectum 2005; 48:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/16\">",
"      Cavanaugh M, Hyman N, Osler T. Fecal incontinence severity index after fistulotomy: a predictor of quality of life. Dis Colon Rectum 2002; 45:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/17\">",
"      van Koperen PJ, Wind J, Bemelman WA, Slors JF. Fibrin glue and transanal rectal advancement flap for high transsphincteric perianal fistulas; is there any advantage? Int J Colorectal Dis 2008; 23:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/18\">",
"      Loungnarath R, Dietz DW, Mutch MG, et al. Fibrin glue treatment of complex anal fistulas has low success rate. Dis Colon Rectum 2004; 47:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/19\">",
"      Ho YH, Tan M, Chui CH, et al. Randomized controlled trial of primary fistulotomy with drainage alone for perianal abscesses. Dis Colon Rectum 1997; 40:1435.",
"     </a>",
"    </li>",
"    <li>",
"     Zollinger, RM, Zollinger, Jr, RM. Plate CXCVII: Drainage of Ischiorectal Abscess - Excision of Fistula in Ano. In: Atlas of Surgical Operations, 5th ed, Zollinger, RM, Zollinger Jr, RM (Eds), MacMilliam Publishing Company, New York 1983. p.418.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/21\">",
"      Cintron JR, Park JJ, Orsay CP, et al. Repair of fistulas-in-ano using fibrin adhesive: long-term follow-up. Dis Colon Rectum 2000; 43:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/22\">",
"      Christensen A, Nilas L, Christiansen J. Treatment of transsphincteric anal fistulas by the seton technique. Dis Colon Rectum 1986; 29:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/23\">",
"      Hammond TM, Knowles CH, Porrett T, Lunniss PJ. The Snug Seton: short and medium term results of slow fistulotomy for idiopathic anal fistulae. Colorectal Dis 2006; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/24\">",
"      Dziki A, Bartos M. Seton treatment of anal fistula: experience with a new modification. Eur J Surg 1998; 164:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/25\">",
"      Byrne, C, Solomon, M. The use of setons in fistula-in-ano. Semin Colon Rectal Surg 2009; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/26\">",
"      Cox SW, Senagore AJ, Luchtefeld MA, Mazier WP. Outcome after incision and drainage with fistulotomy for ischiorectal abscess. Am Surg 1997; 63:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/27\">",
"      Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut 1999; 44:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/28\">",
"      van Koperen PJ, Wind J, Bemelman WA, et al. Long-term functional outcome and risk factors for recurrence after surgical treatment for low and high perianal fistulas of cryptoglandular origin. Dis Colon Rectum 2008; 51:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/29\">",
"      Spotnitz WD. Fibrin sealant: past, present, and future: a brief review. World J Surg 2010; 34:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/30\">",
"      Saxena, S, Jain, P, Shukla, J. Preparation of two component fibrin glue and its clinical evaluation in skin grafts and flaps. Indian J Plast Surg 2003; 36:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/31\">",
"      de la Portilla F, Rada R, Le&oacute;n E, et al. Evaluation of the use of BioGlue in the treatment of high anal fistulas: preliminary results of a pilot study. Dis Colon Rectum 2007; 50:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/32\">",
"      Buchanan GN, Bartram CI, Phillips RK, et al. Efficacy of fibrin sealant in the management of complex anal fistula: a prospective trial. Dis Colon Rectum 2003; 46:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/33\">",
"      Park JJ, Cintron JR, Orsay CP, et al. Repair of chronic anorectal fistulae using commercial fibrin sealant. Arch Surg 2000; 135:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/34\">",
"      Lindsey I, Smilgin-Humphreys MM, Cunningham C, et al. A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Dis Colon Rectum 2002; 45:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/35\">",
"      Durgun V, Perek A, Kapan M, et al. Partial fistulotomy and modified cutting seton procedure in the treatment of high extrasphincteric perianal fistulae. Dig Surg 2002; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/36\">",
"      Westerterp M, Volkers NA, Poolman RW, van Tets WF. Anal fistulotomy between Skylla and Charybdis. Colorectal Dis 2003; 5:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/37\">",
"      H&auml;m&auml;l&auml;inen KP, Sainio AP. Cutting seton for anal fistulas: high risk of minor control defects. Dis Colon Rectum 1997; 40:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/38\">",
"      Zbar AP, Ramesh J, Beer-Gabel M, et al. Conventional cutting vs. internal anal sphincter-preserving seton for high trans-sphincteric fistula: a prospective randomized manometric and clinical trial. Tech Coloproctol 2003; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/39\">",
"      Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn's fistula-in-ano. Dis Colon Rectum 2010; 53:486.",
"     </a>",
"    </li>",
"    <li>",
"     Bastawrous, A, Cintron, J. Anorectal abscess and fistula. In: Current Surgical Therapy, 8th edition, Cameron, J (Eds), Elsevier Mosby, Philadelphia 2004. p.256.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/41\">",
"      Ozuner G, Hull TL, Cartmill J, Fazio VW. Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. Dis Colon Rectum 1996; 39:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/42\">",
"      Lewis P, Bartolo DC. Treatment of trans-sphincteric fistulae by full thickness anorectal advancement flaps. Br J Surg 1990; 77:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/43\">",
"      Sonoda T, Hull T, Piedmonte MR, Fazio VW. Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum 2002; 45:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/44\">",
"      Miller GV, Finan PJ. Flap advancement and core fistulectomy for complex rectal fistula. Br J Surg 1998; 85:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/45\">",
"      Mizrahi N, Wexner SD, Zmora O, et al. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum 2002; 45:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/46\">",
"      Browder LK, Sweet S, Kaiser AM. Modified Hanley procedure for management of complex horseshoe fistulae. Tech Coloproctol 2009; 13:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/47\">",
"      Ustynoski K, Rosen L, Stasik J, et al. Horseshoe abscess fistula. Seton treatment. Dis Colon Rectum 1990; 33:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/48\">",
"      Ellis CN. Bioprosthetic plugs for complex anal fistulas: an early experience. J Surg Educ 2007; 64:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/49\">",
"      Johnson EK, Gaw JU, Armstrong DN. Efficacy of anal fistula plug vs. fibrin glue in closure of anorectal fistulas. Dis Colon Rectum 2006; 49:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/50\">",
"      Champagne BJ, O'Connor LM, Ferguson M, et al. Efficacy of anal fistula plug in closure of cryptoglandular fistulas: long-term follow-up. Dis Colon Rectum 2006; 49:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/51\">",
"      Safar B, Jobanputra S, Sands D, et al. Anal fistula plug: initial experience and outcomes. Dis Colon Rectum 2009; 52:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/52\">",
"      Christoforidis D, Pieh MC, Madoff RD, Mellgren AF. Treatment of transsphincteric anal fistulas by endorectal advancement flap or collagen fistula plug: a comparative study. Dis Colon Rectum 2009; 52:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/53\">",
"      van Koperen PJ, Bemelman WA, Gerhards MF, et al. The anal fistula plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. Dis Colon Rectum 2011; 54:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/54\">",
"      Bleier JI, Moloo H, Goldberg SM. Ligation of the intersphincteric fistula tract: an effective new technique for complex fistulas. Dis Colon Rectum 2010; 53:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/55\">",
"      Rojanasakul A. LIFT procedure: a simplified technique for fistula-in-ano. Tech Coloproctol 2009; 13:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/56\">",
"      Tan KK, Tan IJ, Lim FS, et al. The anatomy of failures following the ligation of intersphincteric tract technique for anal fistula: a review of 93 patients over 4 years. Dis Colon Rectum 2011; 54:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/57\">",
"      Mushaya C, Bartlett L, Schulze B, Ho YH. Ligation of intersphincteric fistula tract compared with advancement flap for complex anorectal fistulas requiring initial seton drainage. Am J Surg 2012; 204:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/51/5946/abstract/58\">",
"      Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn's disease. World J Surg 2000; 24:1258.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13508 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2143548A13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5946=[""].join("\n");
var outline_f5_51_5946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22288967\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288661\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288667\">",
"      FISTULA ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288673\">",
"      ANATOMY OF THE ANAL REGION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288679\">",
"      Anal canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288685\">",
"      Ischiorectal fossa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288691\">",
"      Internal anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288697\">",
"      External anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288703\">",
"      Mucosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288709\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288715\">",
"      Initial office visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288721\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288727\">",
"      Surgical planning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288733\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288739\">",
"      PROCEDURE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288745\">",
"      Simple fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288751\">",
"      Complex fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288757\">",
"      INTRAOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288763\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288769\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288775\">",
"      Position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288781\">",
"      Anal examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288787\">",
"      Internal opening identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288793\">",
"      PROCEDURES FOR SIMPLE FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288799\">",
"      Fistulotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288805\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288811\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288817\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288823\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288829\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288835\">",
"      PROCEDURES FOR COMPLEX FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288841\">",
"      Fistulotomy and setons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288847\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288853\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288859\">",
"      Advancement flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288865\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288871\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288877\">",
"      Advancement flap with fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288883\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288889\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288895\">",
"      Modified Hanley procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288901\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288907\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288913\">",
"      Fistula plug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288919\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288925\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288931\">",
"      Ligation of the intersphincteric fistula tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288937\">",
"      - Critical elements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22288943\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288949\">",
"      Diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288955\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22290942\">",
"      Activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22290948\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22290960\">",
"      Hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22290973\">",
"      Bowel management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22288961\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22288967\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/13508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/13508|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/32/33284\" title=\"figure 1\">",
"      Location of anorectal abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/43/36534\" title=\"figure 2\">",
"      Anal Rectal Fistulas Parks classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/54/42850\" title=\"figure 3\">",
"      ARF lateral view anal rectal fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/22/12647\" title=\"figure 4\">",
"      Anatomy of the anal canal and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/54/21348\" title=\"figure 5\">",
"      Anal rectal anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/37/10837\" title=\"figure 6\">",
"      Anatomy of the ischiorectal fossa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/32/5634\" title=\"figure 7\">",
"      Submucosal rectal abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/14/21729\" title=\"figure 8\">",
"      ARF fistulotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/30/23009\" title=\"figure 9\">",
"      ARF fistulotomy seton",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/27/31155\" title=\"figure 10\">",
"      ARF Advancement flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/40/9859\" title=\"figure 11\">",
"      ARF LIFT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/13508|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/58/11168\" title=\"picture 1\">",
"      Simple anal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/11/25779\" title=\"picture 2\">",
"      Fistulotomy photograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/26/431\" title=\"picture 3\">",
"      AU fibrin glue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/53/40788\" title=\"picture 4\">",
"      Modified Hadley with cutting setons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/35/44596\" title=\"picture 5\">",
"      Fistula plug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/22/15715\" title=\"picture 6\">",
"      LIFT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12694?source=related_link\">",
"      Anorectal fistula: Clinical manifestations, diagnosis, and management principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/23/20849?source=related_link\">",
"      Patient information: Anal abscess and fistula (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=related_link\">",
"      The role of imaging tests in the evaluation of anal abscesses and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_51_5947="Specimens from bronchoscopy";
var content_f5_51_5947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested studies for specimens obtained at bronchoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Bronchoalveolar lavage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Viral cultures - CMV, herpes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumocystis carinii (P. jiroveci) stain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Legionella*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nocardia*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adenovirus*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AFB culture*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Transbronchial biopsies (5 or more)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pathology",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Denotes when clinically indicated.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5947=[""].join("\n");
var outline_f5_51_5947=null;
var title_f5_51_5948="Infectious causes fever ICU";
var content_f5_51_5948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious causes of fever in the intensive care unit",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Common causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bacteremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intravascular catheter-related infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Surgical site infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ventilator-associated pneumonia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cellulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholangitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diverticulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Empyema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intra-abdominal abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myonecrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Necrotizing fasciitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pseudomembranous colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Septic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sinusitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Suppurative thrombophlebitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5948=[""].join("\n");
var outline_f5_51_5948=null;
var title_f5_51_5949="Clinical features that suggest a diagnosis on intial evaluation";
var content_f5_51_5949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features that suggest a diagnosis on initial evaluation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurally mediated syncope:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long history of recurrent syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After sudden unexpected unpleasant sight, sound, smell or pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged standing or crowded, hot places",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea, vomiting associated with syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        During a meal or post-prandial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With head rotation or pressure on carotid sinus (as in tumours, shaving, tight collars)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Syncope due to OH:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After standing up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temporal relationship with start or changes of dosage of vasodepressive drugs leading to hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged standing especially in crowded, hot places",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of autonomic neuropathy or Parkinsonism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Standing after exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular syncope:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of definite structural heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of unexplained sudden death or channelopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        During exertion, or supine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sudden onset palpitation immediately followed by syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        ECG findings suggesting arrhythmic syncope:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Bifascicular block (defined as either LBBB or RBBB combined with left anterior or left posterior fascicular block)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Other intraventricluar conduction abnormalities (QRS duration &ge;0.12 s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Mobitz I second degree AV block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Asymptomatic inappropriate sinus bradycardia (&lt;50 bpm), sinoatrial block or sinus pause &ge;3 s in the absence of negatively chronotropic medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Non-sustained VT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Pre-excited QRS complexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Long or short QT intervals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Early repolarization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - RBBB pattern with ST-elevation in leads V1-V3 (Brugada syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Negative T waves in right precordial leads, epsilon waves and ventricular late potentials suggestive of ARVC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Q waves suggesting myocardial infarction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARVC: arrhythmogenic right ventricular cardiomyopathy; AV: atrioventricular; LBBB: left bundle branch block; OH: orthostatic hypotension; RBBB: right bundle branch block; VT: ventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5949=[""].join("\n");
var outline_f5_51_5949=null;
var title_f5_51_5950="COX 1 versus COX 2 inhibition";
var content_f5_51_5950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relative cyclooxygenase-1 and cyclooxygenase-2 selectivity of nonsteroidal antiinflammatory drugs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Concentrations of various nonsteroidal antiinflammatory drugs required to inhibit the activity of cyclooxygenase-1 and cyclooxygenase-2 by 50 percent (IC50) in assays of whole blood. The diagonal line indicates equivalence. Drugs plotted below the diagonal line are more potent inhibitors of cyclooxygenase-2 than of cyclooxygenase-1. 6-MNA denotes 6-methoxy-2-naphthylacetic acid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: FitzGerald GA, Patrono C. N Engl J Med 2001; 345:433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5950=[""].join("\n");
var outline_f5_51_5950=null;
var title_f5_51_5951="TCBS agar stool";
var content_f5_51_5951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TCBS agar stool",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_51_5951=[""].join("\n");
var outline_f5_51_5951=null;
